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Abstract 
Owing to their non-selective nature, anti-cancer drugs affect both cancerous and non-
cancerous cells and present a major health risk to healthcare staff working with them. 
This project was conducted at Derriford Hospital, Plymouth, to investigate the extent of 
contamination with anti-cancer drugs on work surfaces and the environmental emissions 
of these drugs.  
In the Isolator study, surface contamination arising from the preparation of five 
anticancer drug infusions (epirubicin, fluorouracil, cisplatin, oxaliplatin and carboplatin) 
in a pharmaceutical isolator and external surfaces of infusion bags and syringes using a 
conventional syringe and needle technique was investigated and compared with that 
obtained using a closed system drug transfer device (Tevadaptor). Wipe samples were 
taken for a period of one week from pre-defined areas in a pharmaceutical isolator and 
from the surface of prepared Intra-Venous (IV) infusion bags and pre-filled syringes to 
obtain baseline data. Gloves and preparation mats used during this period were also 
collected. Following a one-week operator familiarisation period, the Tevadaptor device 
was then introduced for cytotoxic preparation and wipe-sampling of surfaces and 
collection of consumables was continued for a further week (intervention period). The 
samples obtained were then analysed by HPLC and ICP-MS. The baseline 
contamination data from Tevadaptor isolator study was undetected to 0.9 ng cm-2 
(epirubicin), undetected to 3.58 ng cm-2 (5-FU) and 0.05-0.92 ng cm-2 (Pt) in the wipe 
samples from the pharmaceutical isolator surfaces; amounts on glove samples were 
1100-6100 ng/glove (epirubicin), 300-8100 ng/glove (5-FU) and 1-6 ng/glove 
(platinum). During the intervention phase isolator surface contamination was not 
detected in all samples for 5-FU and epirubicin and platinum was detected on the 
isolator surfaces in the range of 0.002-0.09 ng cm-2. The use of Tevadaptor resulted in a 
reduction of contamination on external surfaces by a factor of 10 or more for all marker 
drugs.  
A ward study investigated the surface contamination in the oncology out-patient 
department caused by cisplatin, oxaliplatin, carboplatin and gemcitabine. The study 
compared the effect of using the Tevadaptor to prepare and administer anticancer drugs 
infusions on ward surface contamination to the current UK standard practice. A 
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questionnaire was also distributed to participating staff members to assess the user-
friendliness of Tevadaptor. Wipe samples were taken from pre-defined areas from the 
oncology out-patients department and gloves used by nursing staff for assembly and 
administration of the above drugs were also collected. Sample collection followed a 
similar schedule to the Tevadaptor isolator study. The baseline ward surface 
contamination ranged from undetected to 4.97 ng cm-2 (gemcitabine) and 3.1 ng cm-2 
(platinum). In the case of gloves used by nursing staff the levels of contamination 
ranged from undetected to 1251 ng/glove (gemcitabine) and 405.4 ng/glove (platinum). 
The contamination on ward surfaces during the intervention phase ranged from 
undetected to 3.21 ng cm-2 (gemcitabine) and 2.69 ng cm-2 (platinum) and 
contamination levels on gloves ranged from undetected to 9252 ng/glove (gemcitabine) 
and 1319 ng/glove (platinum). During the intervention phase there was a reduction in 
frequency of contamination, even though the total amount of surface contamination by 
anticancer drugs did not always decrease in comparison to baseline data, presumably 
due to unaccounted spillages.  
A drain study investigated the presence of platinum in hospital wastewater as a measure 
of contamination caused by the excretion of platinum-based anticancer drugs by 
patients. Platinum was measured over a three week period in one of the main drains and 
in the effluent of the oncology ward. The study showed the presence of measurable 
quantity of platinum which ranged from 0.02 to 140 μg L-1 in the oncology effluent and 
0.03 to 100 μg L-1 in the main drain. Data from this study was coupled with published 
measurements on the removal of the drugs by conventional sewage treatment and then 
concentration of platinum arising from each drug was predicted in recipient surface 
waters as a function of water flow rate. Although predicted concentrations were below 
EMEA guidelines warranting further risk assessment, the presence of potentially 
carcinogenic, mutagenic and teratogenic substances in surface waters is cause for 
concern. 
The results showed that a closed system drug transfer device (CSTD) used in 
conjunction with an isolator is highly efficient in reducing surface contamination with 
anti-cancer drugs. However, despite current best practice contamination on ward 
surfaces remained even after the use of a CSTD. Nursing as well as healthcare staff 
should be educated of these results and the risks of occupational exposure to low levels 
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of anti-cancer drugs and the use of PPE should be emphasised. Results of the drain 
study form the basis of preliminary estimates of the likely concentrations of platinum-
based drugs in surface waters and their potential environmental impacts. 
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Chapter 1: Introduction 
1.1 General introduction and rationale 
The risks of occupational exposure to anticancer drugs by healthcare professionals are 
well documented (Connor, 2006). Although all drugs are expected to have some side 
effects, the known carcinogenic, mutagenic and teratogenic (IARC, 1990) effects of 
anti-cancer drugs make them particularly hazardous to healthcare staff involved in 
handling these drugs. Since the hazardous nature of anti-cancer drugs is now well 
established a number of guidelines (ISOPP, 2007, ASHP, 2006, NIOSH, 2004) on safe 
handling of anticancer drugs have been published and use of technologies such as 
pharmaceutical isolators and closed system drug transfer devices has also been 
recommended to reduce the potential of occupational exposure to anticancer drugs. 
During this project the level of contamination by anticancer drugs was monitored in a 
modern day pharmacy aseptic manufacturing unit as well as on the oncology out-
patients ward surfaces, and evaluated the effect of a closed-system device (Tevadaptor) 
on this contamination.  The environmental concentrations of anti-cancer drugs in 
hospital waste-water were also evaluated. 
1.2 Cancer 
Cancer may be described as a disorder of cells where normal cells change their 
behaviour in such a way that they start dividing uncontrollably which may or may not 
result in the formation of tumours, depending on the site of cancer (Chabner and Longo, 
2006). Some of the oldest descriptions of cancer are found in Egyptian writings between 
3000-1500 BC. However, most of our understanding of this disease and its treatment 
through surgery, radiotherapy and chemotherapy has come in the last few decades. 
Cancers may be classified according to their rate or site of growth. See Table 1.1 for a 
general classification of the different types of cancers. 
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Table 1.1: General classification of cancer 
Type Characteristics 
Benign tumours These cancer grow locally and slowly 
Malignant Tumours These cancers grow fast and spread to other organs in the body 
Carcinoma Cancer of the skin and tissues that line organs 
Sarcoma Cancer of the bone, cartilage and muscle 
Leukaemia Cancer of the blood-forming tissue and cells 
Lymphoma and 
Myeloma 
Cancer of the immune system 
There are various factors that increase the risk of cancer in the human population. These 
factors vary from pollution, lifestyle to virus infections (Chabner and Longo, 2006, 
Schellens et al., 2005). Briefly, some of the major factors are tobacco consumption, 
infections such as human pappiloma virus (HPV) and hepatitis B virus, dietary factors 
such as increased alcohol intake, high sun exposure and occupational exposure to 
chemicals and carcinogens including environmental pollutants. For the purpose of this 
thesis the major factor to be considered will be the occupational exposure to 
carcinogens, particularly anti-cancer drugs.   
1.3 Antineoplastic agents 
Surgery and radiotherapy were for many years the main approaches in the management 
of cancer. The aim is the removal of the primary tumour which is usually responsible 
for symptoms in cancer patients. Even though the above approaches improve the 
management of patients by removing the local tumour,  they do not have a great impact 
on the prognosis because most deaths in cancer patients are caused by metastatic spread 
of the disease (Schellens et al., 2005). Antineoplastic agents are therefore used either in 
combination with the above approaches or alone to improve the outcome for patients. 
Most anticancer drugs show their effect by inhibiting the proliferation of cancerous 
cells. Owing to their inherent mechanism and non-selective nature, anticancer drugs are 
toxic to cancerous as well as non-cancerous cells, resulting in the side effects listed 
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earlier. These side effects are suffered by patients as well as healthcare staff, 
particularly nurses, pharmacists, pharmacy technicians and cleaners working in 
oncology units (Clapp et al., 2007, Dabrowski and Dabrowska, 2007, Connor, 2006). 
Such effects may be an acceptable risk for patients suffering from life threatening 
disease. However, this is not acceptable for the healthcare staff. In order to understand 
the risks associated with anticancer drugs a general classification and description of 
anticancer drugs in current use is provided below. The chemical structures of the drugs 
are copied from www.en.wikipedia.org. 
1.3.1 Pyrimidine antimetabolites 
Antimetabolite drugs are structurally similar to intermediate substance of normal 
metabolism and they generally act by inhibiting RNA and DNA precursors. They also 
show their cytotoxic effect by incorporating into nucleic acids; therefore these drugs 
have the potential to affect both cancerous and non-cancerous cells. Examples of this 
class of drugs are 5-fluorouracil (5-FU) and capecitabine. 5-FU (Fig. 1.1) is a uracil 
analogue in which fluorine replaces hydrogen at position 5 and is commonly used either 
alone or in combination for treatment of various malignancies including those in the 
colon and breast. 5-FU either acts by inhibiting thymidylate synthase enzyme which is 
required for generation of thymidine monophosphate necessary for DNA synthesis or by 
incorporating FUTP (fluorouracil triphosphate) into RNA (Schellens et al., 2005, 
Chabner and Longo, 2006). On oral administration, 5-FU shows low and variable 
absorption which may be due to its first pass metabolism in liver. On IV administration 
5-FU is distributed throughout body water and has an elimination half life of about 16 
minutes (www.emc.medicines.org.uk). 
 
Figure 1.1: Chemical structure of 5-FU 
Capecitabine is a fluoropyrimidine carbamate and is used for the treatment of colon, 
metastatic colorectal, advanced gastric and breast cancer. Capecitabine is actually a pro 
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drug of 5-FU and is converted into 5-FU at tumour sites (Schellens et al., 2005). 
Capecitabine shows rapid and extensive absorption on oral administration and is 
extensively bound to plasma proteins especially albumin. It is metabolised in the liver to 
its metabolites which are then converted to 5-FU at the tumour site. Its plasma half-life 
is about 1 hour and is largely eliminated as its metabolites 
(www.emc.medicines.org.uk).  
1.3.2 Purine analogues  
As the name suggests these drugs are structural analogues of purine nucleosides in the 
human cells. Examples include cladribine, fludarabine, 6-mercaptopurine and 
azathioprine. Both cladaribine and fludarabine are deoxyadenosine analogues in which 
hydrogen is substituted by a halogen at position C-2. Cladribine is used in the treatment 
of hairy cell leukaemia (HCL) and B-cell chronic lymphocytic leukaemia (CLL) 
whereas fludarabine is mainly used in the treatment of CLL. Fludarabine (Fig. 1.2) acts 
by inhibiting ribonucleotide reductase. Cladribine (Fig. 1.3) acts by mimicking the 
effects of adenosine deaminase (ADA) which may result in DNA strand break up. Both 
these drugs have the capability to self-potentiate their effect (Schellens et al., 2005, 
Chabner and Longo, 2006). 
 
Figure 1.2: Chemical structure of fludarabine 
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Figure 1.3: Chemical structure of cladribine 
The bioavailability of cladribine on oral administration is between 37% and 51% and it 
shows low plasma binding (20%) with a terminal half-life of 7 to 19 hours. Fludarabine 
shows better oral absorption with a bioavailability of up to 75% and has a half-life of up 
to 10 hours. It is largely excreted through the kidneys (www.emc.medicines.org.uk). 
1.3.3 Antifolates 
Antifolates are of great clinical value and show a wide range of chemotherapeutic 
activity. During DNA synthesis folic acid is reduced to tetrahydrofolic acid by 
dihydrofolate reductase enzyme. Antifolates competitively inhibit the action of 
dihydrofolate reductase therefore inhibiting DNA synthesis during cell replication. The 
most commonly used antifolate is methotrexate (MTX) and is used in treatment of 
various malignant diseases including acute leukaemias, non-Hodgkin's lymphoma, soft-
tissue and osteogenic sarcomas, and solid tumours particularly breast, lung, head and 
neck, bladder, cervical, ovarian and testicular carcinoma. It is also used in treating 
rheumatoid arthritis as well as psoriasis. MTX (Fig. 1.4) acts by inhibiting dihydrofolate 
reductase (DHFR) which is required for DNA synthesis. MTX transforms to 
polyglutamate in the body which is an inhibitor of thymidylate synthase (Schellens et 
al., 2005, Chabner and Longo, 2006). 
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Figure 1.4: Chemical structure of methotrexate (MTX). 
At low doses MTX is readily absorbed via the gastro-intestinal (GI) tract with a peak 
plasma concentration within 1-2 hours and shows up to 50% plasma binding. Excretion 
is mainly via the renal route and is cleared from the body within 24 hours following oral 
administration. On IV administration MTX shows a half-life of up to 2-3 hours in 
human plasma (www.emc.medicines.org.uk). 
1.3.4 Alkylating agents 
Alkylating agents were some of the first chemotherapeutic agents to be used in cancer 
treatment. They include a wide class of drugs and generally act by forming covalent 
adducts with DNA, which leads to single or double strand breaks in the DNA resulting 
in cell death (Chabner and Longo, 2006). The examples of alkylating agents are 
oxazaphosphorines (cyclophosphamide and ifosfamide), melphalan, nitrosoureas, 
busulfan, chlorambucil and thiotepa. Oxazaphosphorines are used in both adult and 
paediatric tumours and both haematological and non-haematological cancers. The 
clinical use of the rest of the alkylating agents is now considerably reduced. Both 
cyclophosphamide (Fig. 1.5) and ifosfamide (Fig. 1.6) may cause haemorrhagic cystitis 
in high doses and must be given with mesna. Oxazaphosphorines are both pro drugs and 
are activated metabolically to form mustard species which form bifunctional DNA 
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adducts (Schellens et al., 2005). Both these drugs are absorbed well orally and show a 
plasma half-life of 4-6 hours (www.emc.medicines.org.uk).  
 
Figure 1.5: Chemical structure of cylophosphamide 
 
Figure 1.6: Chemical structure of ifosfamide. 
1.3.5 Epipodophyllotoxins 
Podophyllotoxin is the active component of the extracts obtained from mayapple and 
mandrake. Etoposide (Fig. 1.7) and teniposide are glycosidic derivatives of 
podophyllotoxin (Chabner and Longo, 2006).  Etoposide is indicated in the management 
of small cell lung cancer and testicular tumours in combination with other 
chemotherapeutic agents. It is also used in monoblastic leukaemia and acute 
myelomonoblastic leukaemia. Both these drugs act by targeting topoisomerase II. 
Topoisomerase II is a nuclear enzyme that breaks the DNA backbone by causing 
transient double-strand breaks and thus allowing intact DNA through the break. This 
process is important for cell proliferation and occurs during the S phase of the cell 
cycle. Etoposide binds to topoisomerase II and prevents it from causing DNA breaks 
and thus preventing cell proliferation (Schellens et al., 2005). These drugs are also 
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important from an occupational hazard aspect as etoposide is known to cause secondary 
leukaemia.  
The bioavailability of etoposide following oral administration is approximately 60% 
and its plasma half-life is 20-30 minutes with a peak concentration between 0.5 to 4 
hours. Etoposide and teniposide show extensive protein binding and the majority of the 
drugs are excreted renally (www.emc.medicines.org.uk). 
   
Figure 1.7: Chemical structure of etoposide 
1.3.6 Anthracyclines 
Anthracyline antibiotics are some of the most widely used anticancer drugs. Examples 
include doxorubicin (Fig. 1.8), epirubicin, daunorubicin and idarubicin. These drugs 
have a wide spectrum of anticancer activity and are used in small cell lung cancer, 
breast cancer, advanced ovarian carcinoma, Hodgkin’s disease, non-Hodgkin’s 
lymphoma and acute myeloblastic leukemia. They are also used in a number of 
combination chemotherapy regimens (Chabner and Longo, 2006). Chemically, 
anthracylines consist of a polyaromatic ring system with a quinine moiety which is 
linked by to an amino sugar by an O-glycosidic bond. The cytotoxic effect of this class 
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of drugs is thought to be due a combination of factors including intercalation into DNA 
structure and generation of reactive oxygen species and inhibition of the topoisomerase 
II enzyme (Schellens et al., 2005). Due to the above effects anthracyclines also show 
mutagenic effects and cause normal tissue damage making these drugs an occupational 
hazard for healthcare staff working with them. 
 
Figure 1.8: Chemical structure of epirubicin hydrochloride 
Anthracyclines are administered via IV injection and are rapidly cleared from blood and 
are widely distributed into tissues such as the lungs, liver, heart, spleen and kidneys. 
The elimination of doxorubicin is tri-phasic with average half-lives of 12 minutes, 3.3 
hours and 30 hours (www.emc.medicines.org.uk). Epirubicin also shows similar 
kinetics to doxorubicin. Anthracylines show high protein binding and are largely 
excreted via the liver (www.emc.medicines.org.uk). 
1.3.7 Taxanes 
Taxanes include paclitaxel and docetaxel and are of natural origin. Paclitaxel (Fig. 1.9) 
was extracted from the bark of the Pacific yew tree (Taxus baccata), whereas docetaxel 
(Fig. 1.10) is a semi-synthetic analogue of paclitaxel. Taxanes have a wide spectrum of 
anti-cancer activity against solid tumours and are licensed to be used in breast cancer, 
ovarian, advanced no-small cell lung cancer, AIDS-related Kaposi’s sarcoma, prostate 
cancer and head and neck cancer. Taxanes are antimicrotubule drugs. Microtubules are 
a normal component of biological cells and are required for mitosis along with various 
other activities such as maintenance of cell structure and cell motility. Microtubules 
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perform their function by depolymerisation into tubulin dimers and further sub-units. 
Taxanes act by stabilizing the microtubule polymer units and thus disrupting normal 
cell function during cell division resulting in its death (Chabner and Longo, 2006, 
Schellens et al., 2005). 
 
Figure 1.9: Chemical structure of paclitaxel 
 
Figure 1.10: Chemical structure of docetaxel 
Both paclitaxel and docetaxel are administered via IV infusion. However, after 
administration paclitaxel shows biphasic elimination whereas docetaxel shows a tri-
phasic elimination. The mean plasma half-lives of both drugs range from 4 minutes to 
52.7 hours and are widely distributed in tissues. Hepatic metabolism is the main route of 
elimination of taxanes (www.emc.medicines.org.uk). 
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1.3.8 Vinca alkaloids  
Vinca alkaloids are another class of anticancer drugs that  are natural in origin. Drugs 
include vincristine (Fig. 1.11), vinblastine (Fig. 1.12), vindesine and vinorelbine. Vinca 
alkaloids are obtained from the periwinkle plant (Cantharatus roseus; Vinca rosea). 
The periwinkle plant was indigenous to Madagascar but is now grown all over the 
world for its medicinal uses. Vinca alkaloids also show a broad activity against various 
types of cancer and are licensed to be used in acute and chronic lymphocytic leukaemia, 
acute myelogenous leukaemia, Hodgkin’s disease, multiple myeloma, breast carcinoma, 
head and neck carcinoma, paediatric solid tumours and Kaposi’s sarcoma. Vinca 
alkaloids are highly toxic and must not be given by any other route than intravenous. 
The primary mechanism of action is binding to microtubules and preventing their 
polymerisation resulting in cell death. However, vinca alkaloids may also exert their 
cytotoxic action by interfering with amino acid metabolism and also have an 
immunosuppressive action (Schellens et al., 2005, Chabner and Longo, 2006). 
 
Figure 1.11: Chemical structure of vincristine 
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Figure 1.12: Chemical structure of vinblastine 
The oral absorption of vinca alkaloids is largely unpredictable. Therefore, intravenous is 
the preferred route of administration. Following IV administration the drugs are rapidly 
cleared from the blood and show significant protein binding. Vinca alkaloids are widely 
distributed in body tissues and are accumulated in the kidney, spleen, liver and lymph 
nodes. They are extensively metabolised in the liver and are excreted via bile 
(www.emc.medicines.org.uk). 
1.3.9 Topoisomerase I targeting agents 
Topotecan and irinotecan are the major topoisomerase I targeting agents in use. Both 
these drugs are semi-synthetic analogues of alkaloid camptothecin, which is extracted 
from a Chinese tree named Camptotheca acuminata. The original alkaloid was found to 
be highly toxic  and therefore is not usable. Topotecan (Fig. 1.13) is indicated in small 
cell lung cancer and ovarian cancer and irinotecan (Fig. 1.14) is licensed to be used in 
colorectal cancer either alone or in combination with 5-FU. As the name suggests these 
drugs act by targeting the topoisomerase I enzyme. The topoisomerase enzyme is 
needed in DNA replication; it binds to double strand DNA and cleaves one strand 
relaxing the supercoiled DNA structure. This class of drugs is a specific inhibitor of the 
topoisomerase I enzyme and acts by binding to topoisomerase I and strand cleaved 
DNA complex, thus resulting in interference in DNA replication and cell death 
(Schellens et al., 2005, Chabner and Longo, 2006).  
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Figure 1.13: Chemical structure of topotecan 
 
Figure 1.14: Chemical structure of irinotecan 
Topotecan is available to be administered either orally or by IV infusion. However, 
irinotecan is only available as IV infusion. The bioavailability of topotecan following 
oral administration is about 40% and peak plasma concentration is reached in 1.5 to 2 
hours.  The mean half-lives following IV infusions is 2-3 hours for topotecan and 14.2 
hours for irinotecan. Both drugs are extensively metabolised in the liver and excreted 
renally (www.emc.medicines.org.uk). 
1.3.10 Platinum agents 
Platinum complexes are a unique class of anti-cancer agents. The drugs include cisplatin 
(Fig. 1.15), carboplatin (Fig. 1.16) and oxaliplatin (Fig. 1.17). They are mainly used 
against solid tumours. Their major uses are in ovarian carcinoma, bladder carcinoma, 
testicular tumours, small cell lung cancer and metastatic colorectal cancer. The major 
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mechanism of action of these drugs is by targeting DNA. All three platinum agents 
inhibit DNA synthesis by forming intra-strand and inter-strand cross links in DNA. 
These drugs form aqua derivatives which are also responsible for their cytotoxic action.  
                     
 Figure 1.15: Chemical structure of cisplatin                 
 
Figure 1.16: Chemical structure of carboplatin 
 
Figure 1.17: Chemical structure of oxaliplatin 
Platinum agents are only available to be administered via IV infusions. The 
pharmacokinetic profile of each drug is largely dependent on the structure of their 
leaving group. All three drugs show extensive protein binding after administration and 
elimination is largely via kidneys. Cisplatin excretion starts within 2-4 hours of 
administration and up to 20-80% of the total administered drug is excreted in the first 24 
hours. Carboplatin is also excreted via urine with up to 65% of dose excreted within 24 
hours of administration. On the other hand oxaliplatin excretion takes longer and up to 
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54% of the dose taking up to 5 days to be excreted via urine. For more details on 
platinum-based drugs see Chapter 2, Section 2.1.2.  
1.3.11 Tyrosine kinase inhibitors  
Tyrosine kinase inhibitors are a new class of anticancer drugs that target cell receptors. 
The examples of this class of drugs are imatinib and gefitinib. Imatinib (Fig. 1.18) is 
licensed for use in conditions such as chronic myeloid leukaemia, acute lymphoblastic 
leukaemia and gastrointestinal stromal tumours while gefitinib (Fig. 1.19) is licensed to 
be used in advanced or metastatic non-small cell lung cancer. Imatinib acts by inhibiting 
Bcr-Abl tyrosine kinase and gefitinib acts by inhibiting the epidermal growth factor 
receptor tyrosine kinase (Schellens et al., 2005, Chabner and Longo, 2006).  
 
Figure 1.18: Chemical structure of imatinib 
 
Figure 1.19: Chemical structure of gefitinib 
These drugs are given orally and imatinib has a bioavailability of up to 98% whereas 
gefitinib shows up to 59% bioavailability. Both the drugs are extensively metabolised in 
the liver and largely excreted through faeces (www.emc.medicines.org.uk). 
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1.3.12 Anti-endocrine drugs 
These drugs are a combination of various classes of drugs and include anti-oestrogens, 
aromatase inhibitors, leuteinizing hormone-releasing hormone analogues, progestins 
and non-steroidal anti androgens. A description of each of these classes is beyond the 
scope of this thesis. A brief description of tamoxifen, one of the most popular anti-
cancer drugs, is provided. Tamoxifen (Fig. 1.20) belongs to anti-oestrogen class of 
drugs and is licensed for use as adjuvant treatment of oestrogen-receptor positive early 
breast cancer. Tamoxifen acts by inhibiting the effect of endogenous oestrogen by 
binding to oestrogen receptors on the cancerous cells. In oestrogen-receptor positive 
breast cancer oestrogen is needed for cell division thus by decreasing presence of 
oestrogen tamoxifen reduces cell division. However, tamoxifen has been known to 
possess adverse side effects, including an increased risk of endometrial cancer 
(Schellens et al., 2005, Chabner and Longo, 2006). 
 
Figure 1.20: Chemical structure of tamoxifen 
Tamoxifen is administered orally and is well absorbed with maximum plasma 
concentration reached within 4-7 hours. It is highly metabolised in the liver resulting in 
conjugates which also have similar pharmacological activity to the parent compound 
and is largely excreted via faeces (www.emc.medicines.org.uk) 
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1.4 Occupational exposure to anti-cancer drugs 
It can be observed from the above description of the various classes of anti-cancer drugs 
that all of them have the potential to cause non-discriminatory DNA damage in the 
human cells, which makes them potentially carcinogenic, mutagenic and teratogenic.  
1.4.1 Hazards of occupational exposure to anti-cancer drugs 
The International Agency for Research on Cancer (IARC) in 1969 initiated a 
programme to evaluate the carcinogenic potential of various chemicals including anti-
cancer drugs and as a result a number of monographs were produced dividing chemicals 
into five groups (1, 2A, 2B, 3 and 4) according to their carcinogenic potential. 
Examples of drugs classified in groups 1, 2A and 2B are provided in Table 1.2 (drugs in 
groups 3 and 4 are not classified as carcinogenic but may be mutagenic and 
teratogenic).     
Table 1.2: Classification of anticancer drugs by the IARC 
Carcinogenic to humans  
(Group 1) 
Probably Carcinogenic to 
humans (Group 2A) 
Possibly Carcinogenic to 
humans (Group 2B) 
busulfan adriamycin amsacrine 
chlorambucil azacitdine bleomycin 
cyclophosphamide bischloroethyl nitrosourea  
(BCNU) 
dacarbazine 
etoposide cisplatin mitomycin 
melphalan carmustine mitoxantrone 
tamoxifen teniposide  
thiotepa   
treosulphan   
azathioprine   
A number of anti-cancer drugs are considered carcinogenic or having the potential to be 
carcinogenic. Some anti-cancer drugs, including MTX, 5-FU, vinblastine and 
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vincristine are also classed into group 3 (not classifiable as to its carcinogenicity to 
humans).  Although there may not be enough data on the carcinogenicity of group 3 
drugs, these are known to be mutagenic and teratogenic in nature. These inferences are 
based on the scientific and qualitative evaluation of data on the particular drug (IARC, 
1990). 
Along with the IARC monographs a number of other studies (Cavallo et al., 2005, 
Martin, 2005, Sasaki et al., 2008) have reported toxic effects of anticancer drugs on 
healthcare workers around the world. One of the earliest reports of this nature was 
published in 1979 showing the mutagenic effects of anticancer drugs in urine samples 
collected from nurses working with anticancer drugs (Falck et al., 1979). These reports 
have generated a body of evidence on the occupational effects of anti-cancer drugs. The 
reported symptoms are acute effects such as headaches, hypersensitivity, hair loss, 
nausea, vomiting and liver damage. Long term effects include increased mutagenic 
activity, increased risk of spontaneous abortions, congenital malformations and 
infertility (NIOSH, 2004). The difficulty in gathering data regarding adverse health 
effects in healthcare staff handling anti-cancer drugs was highlighted by a meta-analysis 
(Dranitsaris et al., 2005). This analysis identified 14 studies from 1966 to 2004 
evaluating health risks in staff following occupational exposure. However, only seven 
studies were suitable for statistical pooling. The analysis concluded that there was no 
significant association between occupational exposure and congenital malformation and 
still birth but there was a small incremental risk of spontaneous abortion in female staff 
handling cytotoxic drugs. This is a significant finding as most pregnancies come to light 
a few weeks after  conception and staff members could handle cytotoxic drugs unaware 
of their pregnancy status. It has been argued that a number of studies reporting adverse 
effects of cytotoxic exposure were carried out prior to the publication of various 
guidelines recommending safe handling of anti-cancer drugs. However, some recent 
studies (Fransman et al., 2007, Ndaw et al. 2010) have reported the presence of anti-
cancer drugs in the urine of healthcare staff as well as detection of measurable quantities 
of anti-cancer drugs on various work surfaces in hospital pharmacy and oncology wards 
proving that risk of exposure to anti-cancer drugs still persist. 
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1.4.2 Conditions and routes of exposure 
In modern healthcare settings, a variety of staff may be involved in caring for a patient 
and potentially all of these staff groups can be at risk of occupational exposure. 
According to NIOSH (National Institute for Occupational Safety and Health) the 
number of workers who come in contact with any hazardous drugs throughout its life 
cycle exceeds 5.5 million. These include stores staff, cleaners, physicians, pharmacists, 
pharmacy technicians and nursing staff. The most common routes of exposure for most 
of the staff members are dermal, inhalation, ingestion and injection. Along with the 
above routes accidental hand-to-mouth contact and needle stick injuries during 
preparation or administration of anticancer IV infusions are also possible. The 
healthcare staff can be exposed to anti-cancer drugs while performing a number of 
routine work life activities (Table 1.3). 
Table 1.3: Conditions of staff exposure to anticancer drugs 
Conditions of Exposure 
Reconstitution of drugs 
Touching contaminated vials without gloves 
Cleaning pharmaceutical isolators/LFC 
Handling contaminated body fluids 
Aerosols generated during drug manipulations 
Administering cytotoxic drugs via parenteral route 
Dispensing loose uncoated tablets 
Crushing tablets to make non-sterile extemporaneous products 
Priming IV sets 
Handling or transporting contaminated clothing material/gowns etc 
Performing regular stock control 
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1.5 Monitoring of exposure to anti-cancer drugs 
In the previous section the risks of occupational exposure to anti-cancer drugs were 
discussed. Therefore, it is important to measure accurately the levels of anti-cancer 
drugs that healthcare staff may be exposed to. These measurements are performed using 
either occupational exposure monitoring (compound selective method or non-selective 
methods) of staff or environmental monitoring of the workplace. A brief description of 
the methods employed for biological and environmental monitoring is given below. 
1.5.1 Environmental monitoring 
Environmental monitoring of the pharmacy aseptic manufacturing units (anticancer drug 
IV infusion are prepared in these units) and drug administration areas provides a 
baseline level of the contamination that  staff are exposed to on a regular basis. The most 
common approach to determine work surface contamination includes wipe and air 
sampling. Wipe samples are taken from various work surfaces using moistened, low 
linting wipe tissues and air sampling involves sucking air in the drug preparation area 
through a filter. The marker drugs are then extracted from wipe tissues and filters and 
then analysed for the particular marker drug. The data obtained from these studies can be 
used to tailor our approach towards reducing work surface contamination with 
anticancer drugs which in turn reduces the risk of exposure to healthcare staff. A number 
of studies (Mason et al., 2005, Turci  et al., 2003, Schmau et al., 2002, Bussieres et al., 
2007, Crauste-Manciet et al., 2005) have been published which have presented data on 
measurable quantities of various anticancer drugs within pharmacy manufacturing units, 
storage shelves, prepared IV bag surfaces,  laminar flow cabinet (LFC) and isolators and 
ward administration areas. A brief review of these studies is provided here. 
Most of the surface contamination data has been provided by European or American 
studies. There is a paucity of data on surface contamination caused by anti-cancer drugs 
in UK hospitals and pharmacy manufacturing units. One such study by Mason et al. 
(2005) reported contamination levels in UK pharmacy manufacturing units. Two units 
were selected for this study, one using negative pressure isolators (NPIU) and the other 
using positive pressure isolators (PPIU). The marker drugs used in the study were 
platinum-based drugs, cyclophosphamide, MTX and ifosfamide. The sampling was 
performed over a period of four days and two wipe samples each day were taken from 
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pre-defined areas on the floor of drug preparation isolator. Along with these samples 
gloves used for preparation of marker drugs were also collected. All marker drugs were 
analysed using published methods. The combined ranges of marker drugs from both 
units in the wipe samples were 5-130 ng m-2 platinum, 20-674 ng m-2 MTX, 22-1596 ng 
m-2 cyclophosphamide and ND (not detected) to  1503 ng m-2 ifosfamide. The ranges of 
marker drug in gloves samples were 3-102 ng/glove platinum, ND to 890 ng/glove 
MTX, ND to 5993 ng/glove cyclophosphamide and ND to 1159 ng/glove ifosfamide.  
These results indicate that despite the use of isolators and best practice UK pharmacy 
workers may be at risk of exposure to anti-cancer drugs.  
A review of analytical methods used to detect surface contamination caused by anti-
cancer drugs provides an overview of levels of contamination reported by researchers 
prior to 2002 and methods adopted to detect the contamination levels (Turci et al., 
2003). The studies reviewed reported environmental monitoring by air samples, wipe 
samples, pads and other matrices such as gloves. The air samples were taken by placing 
PTFE filters or glass fibre filter in cassettes attached to a portable pump. The wipe 
samples were simply taken by using Kleenex wipes or filter paper moistened with pre-
validated desorbing agents such as sodium hydroxide and wiping the surface to be 
studied. In some studies workers were asked to wear cotton gauzes as pads, which were 
collected at the end of the shift. The sample extraction was generally by means of 
shaking sample material with a validated amount of desorbing agent such as distilled 
water or mobile phase for chromatographic analysis. The most common marker drugs 
for the studies were cyclophosphamide, ifosfamide, 5-FU and MTX. Briefly, the main 
findings of the various studies were that in air samples cyclophosphamide was detected 
in the range of 0.1-10.1 μg m-3, 5-FU was detected in the range of 0.05-0.23 μg m-3, 
MTX was detected in one sample at concentration of 7 ng m-3 and ifosfamide was in the 
range of 20-47 ng m-3. The ranges of marker drugs in wipe samples were 
cyclophosphamide 0.1-824 ng cm-2, 5-FU 0.002-4.7 μg cm-2, MTX 0.5-60 μg dm-2 and 
ifosfamide 0.1-1416 ng cm-2. The ranges of the above drugs in pads were 0.001-113.98 
μg dm-2 of cyclophosphamide, 0.11-298.7 μg dm-2 of ifosfamide, and none reported for 
5-FU and MTX.  Finally, the contamination levels in glove samples ranged from 0.1-
63.4 μg/pair of cyclophosphamide, 0.02-60 μg/pair of ifosfamide, 0.023-94 μg/pair of 
MTX and 12-760 μg/pair of 5-FU.   
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Schmau et al. (2002) took wipe samples from 14 different pharmacy units over a period 
of six months. The samples were taken using filters moistened with ethyl acetate or 
hydrochloric acid depending on the marker drug. The drugs used to detect contamination 
levels were cyclophosphamide, ifosfamide, 5-FU and platinum-based drugs. The 
surfaces used for wipe samples were the floor of the biological safety cabinet (BSC) 
used for preparation of IV infusions, the preparation room floor, bench top surfaces used 
to store prepared infusions, storage shelves, transport boxes and waste-bins. 
Cyclophosphamide, ifosfamide and 5-FU were analysed using gas chromatography-
mass spectrometry and platinum was analysed using voltammetry. The median values of 
marker drugs over all surfaces and hospitals ranged from 6-42 pg cm-2 
cyclophosphamide, 9-143 pg cm-2 ifosfamide, 1-9 pg cm-1 platinum and ND to 53 pg 
cm-2 5-FU. These results also showed that floors in front of BSC were most often 
contaminated and drug contamination was spread throughout the preparation area. 
Another study used MTX as a marker drug to monitor surface contamination in a 
satellite pharmacy unit (Bussieres et al., 2007). The monitoring programme was spread 
out over a year and included 40 sampling sessions and a total of 238 wipe samples were 
taken during the whole year. The samples were taken from the BSC surface, prepared IV 
infusion bag surface, phone receiver in the preparation area, infusion packaging and 
labelling area and the floor of preparation room. Samples were taken by using cotton 
swabs soaked in HPLC water. MTX was analysed using validated HPLC-fluorescence 
method. A total of five positive samples were detected which included BSC surface and 
phone receiver. The results of this study may have underestimated contamination due to 
high detection limit of the assay method. These results show the importance of selecting 
an appropriate marker drug and a sensitive method of analysis.  
Crauste-Manciet et al. (2005) detected surface contamination caused by 
cyclophosphamide, ifosfamide, 5-FU and MTX in positive pressure isolators used in a 
hospitals in France. The samples were taken from six locations within the 
pharmaceutical isolators used in two different hospitals. The six locations in the isolator 
were pre-defined and were left and right work surface of the isolator, surface of the 
transfer plate and surfaces of storage boxes. Samples were also taken from desks and 
floors in the drug preparation area. All drugs were analysed using published methods, 
cyclophosphamide and ifosfamide were analysed using GC-MSMS and 5-FU and MTX 
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were analysed using HPLC-UV. The combined ranges of marker drugs from surfaces 
within the isolator from both hospitals were 0.07-6.55 ng cm-2 cyclophosphamide, ND to 
0.85 ng cm-2 ifosfamide, ND to 83.76 ng cm-2 5-FU and ND to 8.61 ng cm-2.   
The surface contamination with BSC and pharmaceutical isolators is generally 
attributed to aerosols generated while preparing IV infusions using needles and 
syringes. However, another important source of contamination in the work place by 
anti-cancer drugs is contaminated vials. A study conducted in the Health and Safety 
Laboratory in the UK investigated surface contamination on the vials of cisplatin, 
carboplatin, cyclophosphamide, ifosfamide and MTX (Mason et al., 2003). Wipe 
samples were taken from the vials and analysed for marker drugs using validated 
methods. The range of contamination on the vials was 76251 ng carboplatin, ND to 9 ng 
cisplatin, ND to 39 ng cyclophosphamide, ND to 344 ng ifosfamide and ND to 18 ng 
MTX. 
1.5.2 Occupational exposure monitoring   
Occupational exposure monitoring of health care staff is based on compound specific or 
non-specific methods. Compound specific methods rely on detection of a specific drug 
or its metabolites in the urine samples of the healthcare staff, whereas non-specific 
methods are based measuring mutagenicity or DNA damage caused by anti-cancer 
drugs. A brief description of the occupational exposure monitoring methods is provided 
below. 
1.5.2.1 Urinary mutagenicity assay  
A test of urinary mutagenicity is commonly used as an indicator of exposure to 
cytotoxic drugs. As noticed previously a major mechanism of action of anti-cancer 
drugs is by either binding directly to DNA or inhibiting enzymes required for the 
production of DNA. These effects have the potential to cause mutagenicity which could 
be determined by using techniques such as Ames-test and thioether assay. The Ames-
assay was initially described by B.N. Ames in the early 1970s and is commonly used to 
determine the mutagenic potential of various pharmaceutical agents (Mortelmans and 
Zeiger, 2000). This test uses strains of Salmonella typhimurium which cannot synthesise 
histidine and is unable to grow in histidine-free media. On exposure to the mutagenic 
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chemical the salmonella strains mutate to start producing histidine. Urine extracts from 
healthcare staff exposed to anticancer drugs are subjected to the Ames-test to determine 
a measure of exposure to cytotoxic agents. The thioether assay is a non-selective 
method for determination of exposure to hazardous chemicals in healthcare staff as well 
as the general public (Sorsa  and Anderson, 1996). This method is based on detection of 
thioether in the urine of staff. Anticancer agents such as alkylating agents are 
neutralised by conjugation with glutathione which is the excreted in urine as thioether, 
therefore the presence of thioether in the urine of healthcare staff members may indicate 
exposure to anticancer drugs. 
One of the earliest reports to raise concerns about the occupational exposure to anti-
cancer drugs by healthcare staff was by Falck et al. (1979). This study used the Ames 
assay to measure an increase in mutagenicity in the urine of nurse handling anticancer 
drugs as compared to control samples taken from office staff as well as patients 
undergoing cancer treatment. Newman et al. (1994) used the Ames assay as well as 
thioether assay as a biomarker of anticancer drug exposure in nurses. In this study the 
urine samples from 24 oncology nurses was compared to 24 control nurses. The results 
indicated that there was no statistical difference between the thioether concentrations in 
the urine of both groups of nurses regardless of smoking status. However, there was a 
slight increase in the mutagenicity in the urine of oncology nurses. Sorsa and Anderson, 
(1996), provide a review of biological monitoring studies prior to 1996. Among the 
studies reviewed Jagun et al. (1982), reported elevated levels of urinary mutagenicity in 
nurses handling anti-cancer drugs as compared to the control group but no safety 
measure such as use of gloves and gowns were taken in this study. Even though urinary 
mutagenicity has been used to indicate exposure to anticancer drugs some researchers 
have questioned their reliability. A study among Swiss nurses measured urinary 
mutagenicity using the Ames test after working with cisplatin, cyclophosphamide, 
adriamycin and 5-FU without using gloves, masks and a BSC (Friederich et al., 1986). 
Mutagenicity was observed in the urine of patients undergoing cancer treatment and 
nurses who were smokers but no mutagenic activity was detected in the urine of the 
nurses working with anti-cancer drugs. 
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1.5.2.2 Cytogenetic monitoring 
Exposure to anticancer drugs such as alkylating agents may cause DNA interstrand 
crosslinks and sister chromatid exchange (SCE) (Cornetta et al., 2008). The extent of 
DNA damage could be assessed by using techniques such as COMET assay and 
micronucleus test. The COMET test is a highly sensitive test and is used to detect DNA 
strand breaks, which may be due to exposure to anticancer drugs (Fairbairn et al., 1995). 
This test was first introduced by Osteling and Johanson as technique to visualize direct 
damage to DNA (Fairbairn et al., 1995). In this technique the cell containing damaged 
DNA are stained with a DNA binding fluorescent dye and suspended in thin agarose 
gel, then an electric current is passed through the gel and broken and charged DNA 
segments migrate leaving a comet shape. In the micronucleus test the numbers of 
micronuclei are used as a measure of extent of DNA damage. Micronuclei are 
cytoplasmic bodies formed during anaphase of mitosis or meiosis. In cells exposed to 
hazardous chemicals such as anticancer drugs there is an increased likelihood of 
presence of more than one micronucleus. A number of studies on nurses and healthcare 
staff handling anticancer drugs have proved a direct relationship between exposure to 
anticancer drugs and DNA damage (Sasaki et al., 2008, Cornetta  et al., 2008, Undegar 
et al., 1999, Ursini et al., 2006).  
In a study among Japanese nurses working with anticancer drugs the COMET test was 
used to assess DNA damage (Sasaki et al., 2008). The study included 121 female nurses 
(57 were involved in handling anti-cancer drugs in past six months and the others had 
not handled any anticancer drugs in past six months) and 46 female clerks as control 
subjects. The nurses were selected from three different general hospitals using anti-
cancer drugs. A detailed medical history of the participating staff was taken and seven 
members were then excluded from the study as they were recently exposed to radiation. 
The blood samples were taken from the staff on the morning of the shift. The results 
were analysed using student’s t test and showed that the tail length in COMET test in 
test subjects was significantly longer than 46 control subjects indicating that there was 
more DNA damage in nurses involved in handling anticancer drugs than the rest of the 
nurses and control group.     
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In an oncology hospital in Italy, early DNA damage was assessed in healthcare workers 
by COMET assay in lymphocytes and exfoliated buccal cells as compared to healthy 
volunteers as controls (Ursini et al., 2006). A total of 30 healthcare workers regularly 
handling anti-cancer drugs were selected for this study which included pharmacy 
technicians (n = 5), day hospital nurses (n = 12) and ward nurses (n = 13). The day 
hospital nurses performed 300 drug administrations whereas ward nurses performed 35 
drug administrations during the study. All members of staff used recommended level of 
personal protections equipment such as gloves, gowns and masks. The results showed 
that there was slight increase in DNA damage of buccal cells of day nurses as compared 
to all other groups whereas no difference was observed in DNA damage in 
lymphocytes. 
In another Italian study DNA damage in oncology nurses was assessed using the 
COMET test as well as the micronucleus test (Cornetta et al., 2008). In this study blood 
samples were taken from a total of 83 nurses and compared to 73 office workers used as 
control subjects. A health questionnaire was completed by all subjects to account for 
lifestyle effects such as drinking, smoking and ageing. The results of the study showed 
that exposed nurses had significantly higher DNA damage. 
Undegar et al. (1999) studied the blood samples from 30 Turkish nurses who had 
worked with anticancer drugs in the past six months were compared to 30 control 
subjects. The DNA damage was assessed using the COMET test. The results showed 
the nursing group had significantly higher DNA damage as compared to the control 
group. However, in this study although the nurses had access to protective gloves and 
gowns and also the use of a ventilation device for the preparation of IV infusions, a 
number of nurses in the study reported a lack of adherence to the safety precautions.         
1.5.2.3 Urinary monitoring 
Another approach using the direct measurement of anticancer drugs in urine samples of 
healthcare staff has also been employed to study the impact of exposure to anticancer 
drugs. In such studies urine samples from the healthcare staff handling anticancer drugs 
on a regular basis are collected and analysed for either the marker drugs or its 
metabolites providing evidence of occupational exposure. In a study conducted in an 
Italian hospital urine samples were collected from 17 subjects working in oncology 
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units of the hospital at the start and end of their shifts (Turci et al., 2002). The marker 
drugs used in this study were cyclophosphamide, ifosfamide, MTX and platinum-based 
drugs. The above drugs were tested using validated methods, cyclophosphamide, 
ifosfamide and MTX were tested using HPLC-MS/MS and urinary platinum was tested 
using ICP-MS. Cyclophosphamide was most frequently detected in eight samples in the 
range of 50-10031 ng L-1, ifosfamide was detected in one sample at 153 ng L-1 and 
platinum was detected in three samples in the range of 920-1300 ng L-1. MTX was not 
detected in any of the samples. During this study all infusions were prepared in a 
vertical flow BSC and workers wore protective gloves, gowns and masks.  
Turci et al. (2003) also reviewed various biological monitoring studies. According to 
this review cyclophosphamide was the most frequently used biomarker. Other drugs 
used were, ifosfamide, MTX, platinum-based drugs, doxorubicin and epirubicin. The 
detected ranges reported in the review were ND to 38.23 μg L-1, ND to 12.74 μg L-1, 
ND to 2348 μg L-1 of MTX, 0.6-34.4 μg L-1 of platinum, 0.005-0.127 μg L-1 and 0.01-
0.182 μg L-1 of epirubicin. All of the above results were from urine samples collected 
from pharmacy technicians or nurses handling anti-cancer drugs. 
Fransman et al. (2007) examined the trend of exposure levels to anticancer drugs among 
nurses in the Netherlands by comparing the results of two biological monitoring studies 
conducted in 1997 and 2000. The biomarker for both studies was urinary 
cyclophosphamide. The results of the trend analysis showed a marked reduction in 
exposure levels among nurses in 2000. The total number of positive urine samples 
decreased by four fold and median contamination value decreased by three fold. The 
reduction was attributed to changes in practice and adherence to safety precautions. 
Even though cyclophosphamide is commonly used biomarker it is not the most suitable 
drug for monitoring studies. Cyclophosphamide in itself is an inactive pro-drug and is 
extensively metabolised in the liver into active metabolites. The urinary excretion of the 
unchanged drug is 5-25% of the administered dose. Hence, by using cyclophosphamide 
studies are prone to underreporting the risk of occupational exposure.   
Ndaw et al. (2010) used detection of α-fluoro-β-alanine (FBAL), a major metabolite of 
5-FU, in the urine samples of workers as a marker as exposure to 5-FU. In this study 
post shift urine samples were taken from pharmacy technicians (n = 6) and oncology 
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nurses (n = 13) over a period of five days. The samples were analysed using HPLC-
MS/MS.  The total number of urine samples positive for FBAL was 35 out of a total of 
121 collected with a concentration range of <1-22.7 μg L-1.    
Most of the studies discussed above have been undertaken in hospitals where open 
fronted vertical flow BSC were being used for the preparation of anticancer drug 
infusions. This may result in increased exposure to pharmacy workers as opposed to the 
UK pharmacy staff who generally compound chemotherapy infusions in pharmaceutical 
isolators. There is however a distinct lack of data regarding surface contamination and 
biological monitoring of staff in the UK. Just two studies reporting contamination levels 
in UK hospitals appear to have been published. The first study established ward surface 
contamination levels by anticancer drugs and also attempted to monitor urinary levels of 
cyclophosphamide, ifosfamide, MTX and platinum (Ziegler et al., 2002). The results 
showed none of the urine samples collected during the study were contaminated with 
the above drugs. In the second study by Mason et al. (2005), daily pre-and post-shift 
urine samples were collected from pharmacy workers over a period of four days from 
two pharmacy units. The marker drugs for the study were cyclophosphamide, 
ifosfamide, MTX and platinum-based drugs. The results did not show the presence of 
any cyclophosphamide, ifosfamide and MTX in the urine samples. However, platinum 
in the range of 6-82.4 nmol mol-1 creatinine was detected in post shift samples. 
Assuming the staff had average creatinine clearance of 1.8-50 mmol L-1 (average 
creatinine clearance of healthy humans) the above value of platinum would equate to 
2.1-803 μg L-1. 
The occupational exposure monitoring studies discussed above are an important tool in 
the understanding of occupational risks to the healthcare professionals working with 
anti-cancer drugs. Such studies not only provide an actual measurement of drugs the 
healthcare workers are exposed to but also the type and extent of DNA damage the 
exposure to anticancer drugs may cause. However, non-selective bio-monitoring has 
certain limitations that may produce false positives as they do not account for DNA 
damage caused by external factors such as vehicular exhaust, smoking and ageing.  On 
the other hand compound selective bio-monitoring provides an accurate measure of the 
occupational exposure but the detection levels depend on factors such as the extent of 
drug metabolism, drug assay, sensitivity and selectivity of the assay and the equipment 
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used to test the samples. As there are no safe exposure levels of anticancer drugs 
measures must be taken to reduce the work surface contamination to ALARA (as low as 
reasonably achievable) (Weir et al., 2012).  
1.6 Measures to reduce occupational exposure to anti-cancer drugs 
1.6.1 Guidelines on safe handling of cytotoxic drugs 
Both the causes and effects of occupational exposure to anticancer drugs are now well 
established, as a result a number of organisations and government agencies around the 
world have published guidelines on safe handling of anticancer drugs. The major 
guidelines are included in the following or documented in the following:  
 NIOSH (The National Institute for Occupational Safety and Health) Alert 2004 
(NIOSH, 2004) 
 ASHP (American Society of Health-System Pharmacists) Handling Cytotoxic 
Drugs in Hospitals; and Technical Assistance Bulletins on Handling of Cytotoxic 
and Hazardous Drugs (ASHP, 2006) 
 ISOPP (International Society of Oncology Pharmacy Practitioners) Standards of 
Practice. Safe Handling of Cytotoxics (ISOPP, 2007) 
 Safe handling of cytotoxic drugs 2003 (HSE, 2003) 
 SHPA (Society of Hospital Pharmacists of Australia) Standards of Practice for 
the Safe Handling of Cytotoxic Drugs in Pharmacy Departments (SHPA, 2005) 
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Table 1.4: Recommendations on safe handling of injectable chemotherapy as adapted 
from NIOSH and ISOPP guidelines   
Recommendations on safe handling of injectable chemotherapy 
Packaging should specify hazardous/cytotoxic drugs 
Drugs should be transported in closed containers to minimize risk of breakage 
Spill training must be provided to all staff according to written policies and procedures 
IV infusions must be prepared in ventilated cabinets 
Appropriate PPE such as chemo resistant gloves, gowns and masks must be worn while 
preparing chemotherapy infusions  
Gloves must be changed every 30 minutes or when torn, punctured or contaminated 
After preparation final container should be sealed in a plastic bag in the ventilated 
cabinet 
All waste containers must be sealed and wiped within the ventilated cabinet  
Closed system drug transfer devices (CSTD) may be considered for the preparation of 
infusions 
Needle free, closed systems should be used while performing drug administrations 
Use PPE while administration of IV cytotoxic drugs 
Use specified chemotherapy waste bins for disposal of contaminated gowns, gloves and 
IV bags 
Wash hand with soap and water after preparation and administration of 
chemotherapeutic agents 
These guidelines and recommendations tend to target injectable anticancer drugs. The 
handling of oral chemotherapy also present the same risks and hazards, therefore the 
safe handling of oral chemotherapy is just as important. In a recent publication a team of 
international pharmacists from North America and Europe reviewed existing guidelines 
on handling chemotherapy and recommended measures to fill existing gaps (Goodin et 
al., 2011). The recommendations, represented in Table 1.5, were made to 
manufacturers, health care providers, patients and care givers.  
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Table 1.5: Recommendation on safe handling of oral chemotherapy as adapted from 
Goodin et al. (2011). 
Recommendations on safe handling of oral chemotherapy 
Packaging to state if segregation technique used 
Packaging material to be durable, tamper-proof and be able to contain accidental 
leakage 
Oral anti-cancer drugs to be stored and transported separately from non toxic drugs 
Tablets or Capsules to be packed based on amount needed per cycle 
Cytotoxic drugs to be stored separately from other drugs in pharmacies 
Appropriate PPE to be used while dispensing chemotherapy 
Tablets or capsules not to be dispensed using automated counting machines 
Separate equipment must be used for cytotoxic and non cytotoxic agents 
All non disposable equipment to be cleaned after each use 
All healthcare workers dealing with oral chemotherapy must be trained and competency 
assessed 
1.6.2 Central intravenous additive service (CIVAS)  
In the UK and most European countries the preparation of cytotoxic IV infusions as 
well as general IV injections used to be a ward based activity. In most cases nursing 
staff would prepare these infusions without any safety equipment. However, due to a 
number of patient safety incidents a government commissioned report “Breckenridge 
Report 1976”; (Breckenridge, 1976) recommended the setting up of CIVAS 
(Centralized intravenous additive services) units and preparation of IVs away from 
wards under the supervision of pharmacists. This report coupled with increased 
concerns about the safety of staff working with anticancer drugs gave rise to setting up 
of pharmacy aseptic units in UK hospitals. The major advantages of preparing IV 
infusions in CIVAS units are that products are made under controlled conditions by 
competent and skilled staff using written procedures resulting in safe and accurate 
products, IV products are provided free of contamination and are properly labelled and 
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packaged. The preparation of infusions in CIVAS units save valuable nursing time and 
expensive drugs are used efficiently. 
In recent times the preparation of IV infusions in UK hospitals has been undertaken in 
specialised aseptic manufacturing units using pharmaceutical isolators or BSCs by 
trained pharmacy technicians and assistant technical staff. All CIVAS units prepare 
products either under Section 10 Exemption of the Medicines Act 1968 (Applebe and 
Wingfield, 1997) or hold “specials” manufacturing license granted by the Medicines 
and Healthcare products Regulatory Agency (MHRA). Due to the above regulations the 
CIVAS units are regularly inspected by regional QA officers or MHRA inspectors thus 
ensuring the staff are aware of the current good manufacturing procedures (GMP) which 
helps in providing not only a safe product to the patient but also decreases the risk of 
occupational exposure to the staff handling anticancer drugs.   
1.6.3 Biological safety cabinets 
Biological safety cabinets (BSCs) were initially used in the 1980s to compound 
cytotoxic IV infusions. They gained popularity in the USA and parts of Europe. 
However, in the UK and France pharmaceutical isolators are more commonly used. 
BSCs are of three different types, class I, class II and class III. Class I cabinets do not 
provide any product protection and are therefore not used for compounding of 
chemotherapy infusions whereas class III cabinets are enclosed units (isolators) and are 
described in Section 1.6.4. A class II BSC may be defined as a ventilated cabinet 
equipped with a HEPA filter and have laminar flow and is designed to protect 
personnel, products or the background environment (Kruse et al., 1991). The 
appropriate level of protection in a BSC is maintained by its air flow. The air enters the 
cabinet through its front opening and is passed through a front air intake grill. The 
blower fan located in the bottom of the BSC pushes the air though a air flow plenum to 
the upper air flow plenum. A certain percentage of the air is then forced through the 
HEPA filters in a unidirectional downward flow capable of maintaining EU GMP Grade 
A environment and the rest of the air exits through the exhaust HEPA filter.  Figure 
1.21 illustrates the air flow in a BSC. 
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Figure 1.21: Airflow diagram of a class II cabinet, copied from                           
http://www.phac-aspc.gc.ca/publicat/lbg-ldmbl-04/ch9-eng.php  
1.6.4 Pharmaceutical isolators 
A pharmaceutical isolator (Fig. 1.22) may be defined as “an arrangement of physical 
barriers that are integrated to the extent that the isolator can be sealed in order to carry 
out a routine leak test based on pressure to meet specified limits. Internally it provides a 
workspace, which is separated from the surrounding environment. Manipulations can be 
carried out within the space from the outside without compromising its integrity” 
(PIC/S, 2007). Isolators may be constructed using either rigid or flexible material and 
provide an enclosed work area. The common construction materials are flexible film, 
stainless steel, coated steel, glass and plastics. The general design is of an enclosed 
workspace, interlocking transfer chambers on each side of the isolator and access 
devices such as gauntlets or sleeves and gloves (Midcalf et al., 2004; Sewell, 1999). The 
isolators are maintained at either a negative or positive pressure to the surrounding 
environment depending on the type of protection needed. Negative pressure isolators are 
used to manipulate hazardous drugs such as anticancer drugs whereas positive pressure 
isolators are used to protect products such as TPN (Total Parenteral Nutrition). The 
work zone is maintained at EU GMP Grade A environment and full laminar air flow 
over the work zone is provided via an inlet HEPA filter. The air leaving the work zone 
is returned to the downflow fan system via the main HEPA filter located underneath the 
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work tray. The exhaust fan is mounted on the top of the isolator which in most cases is 
vented outside of the clean-room.  
Pharmaceutical isolators have been in use for aseptic processing since the 1980s in 
hospital pharmacies and pharmaceutical industry for various purposes (Midcalf et al., 
2004; Sewell, 1999). Some of their applications in the pharmaceutical industry include 
raw material sampling, weighing and dispensing of active pharmaceutical ingredients 
(APIs), and mixing and blending of APIs. In hospital pharmacies isolators are primarily 
used for the compounding of cytotoxic IV infusions as well as other hazardous 
injectable drugs. Some other applications include sterility testing, research and radio-
pharmacy. The major advantage of using an isolator is that it provides a physical barrier 
between the operator and the cytotoxic drug, hence reducing the risk of exposure to 
staff. Isolators also provide an aseptic environment for the product, thus reducing the 
risk of microbial contamination of the IV infusions. On the other hand technicians may 
find it uncomfortable to work in an isolator. Pharmaceutical isolators used for 
compounding cytotoxic drugs may get contaminated with the cytotoxic drugs which 
may be difficult to clean. Studies have demonstrated that contamination of isolator 
surfaces with anticancer drugs, which may get transferred to infusion bags and syringes 
prepared for patient use result in exposure of healthcare staff to cytotoxic drugs 
(Crauste-Manciet et al., 2005, Mason et al., 2005). In most aseptic manufacturing units 
in the UK pharmaceutical isolators are cleaned at the start of each working day and then 
at the end of each session. Common cleaning agents used for this purpose involve sterile 
neutral detergents followed by 70% denatured ethanol. This cleaning regimen, although 
effective against viable organisms, does not effectively remove traces of cytotoxic 
contamination (Roberts et al., 2006). This contamination may be a source of exposure 
of anticancer drugs to pharmacy staff.  The contamination of pharmaceutical isolators 
with hazardous drugs is mainly due to contaminated vials, aerosols generated during 
compounding process or spills. To reduce the risk of aerosols and spills to some extent 
closed system transfer devices have been introduced to be used during the compounding 
process. 
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Figure 1.22: Construction of a typical pharmaceutical isolator 
1.6.5 Personal protection equipment  
Despite the use of pharmaceutical isolators and LFCs the risk of occupational exposure 
to anticancer drugs still remains, especially for pharmacy staff engaged in manipulation 
of anticancer IV infusions and injections. For these members of staff personal protection 
equipment (PPE) remains the last line of defence against exposure to anticancer drugs. 
The PPE used in pharmacy aseptic units include chemo resistant gloves, disposable 
chemo resistant gowns and masks. A brief description of gloves and gowns is provided 
below. Even though masks are commonly used there is limited evidence to show that 
surgical masks used in the UK pharmacy aseptic units can prevent inhalation of anti-
cancer drugs.    
1.6.5.1 Gloves  
Gloves such as those illustrated in Fig. 1.23 are the most important part of PPE as 
dermal contact is the most common route of exposure to anti-cancer drugs. Protective 
gloves are subject to European as well as American standards and guidelines on the 
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recommended use during operation. According to NIOSH and ASHP guidelines 
operators must use double gloves and change them every thirty minutes (Crauste-
Manciet, 2007). Special attention must be paid to the gloves and their material and 
permeability characteristics. A number of factors may increase the permeation of drugs 
through the gloves such as the concentration, hydrophobicity and molecular weight of 
the chemicals, working temperature and exposure to alcohol during the infusion 
preparation stage (Crauste-Manciet, 2007). In the UK protective gloves are regulated by 
European PPE Directive, 89/686/EEC. According to the European Standards EN 374-1: 
2003 the permeation rate of gloves must not exceed 1 μg cm-2 min-1 and must be tested 
against 3 out of 12 predefined chemicals (methanol, acetone, acetonitrile, 
dichloromethane, carbon disulphide, toluene, diethylamine, tetrahydofurnae, 
ethylacetate, n-heptane, 40% sodium hydroxide and 96% sulphuric acid). Note that 
these chemicals do not include anti-cancer drugs. On the other hand standards published 
by American Society for Testing and Materials ASTM D6978-05 specify a permeation 
rate of no more than 0.01 μg cm-2 min-1 and gloves must be tested against a minimum of 
nine cytotoxic drugs out of which seven are predefined (carmustine, cyclophosphamide, 
doxorubicin, etoposide, 5-FU, paclitaxel and thiotepa) by the standard and two more to 
be selected from the predefined list. 
 
Figure 1.23: Illustration of chemo-resistant gloves 
Studies have evaluated gloves made of different materials and have concluded that the 
protection provided against anti-cancer drugs shows a large variation depending on the 
material, thickness and physico-chemical properties of the drugs. Singleton and Connor 
(1999) evaluated 14 different brands of gloves, 11 of which were made of latex and 
three of nitrile. The drugs used for the study were carmustine, etoposide and paclitaxel. 
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The permeability of the above drugs was tested through the gloves after a contact period 
of two hours. All of the gloves were impermeable to carmustine, 13 types of gloves 
were impermeable to paclitaxel and only two types were impermeable to etoposide. The 
results of this study were surprising as carmustine is demonstrated to be permeable 
through a wide variety of materials. Even though latex does provide resistant to anti-
cancer drugs, latex gloves are no longer used in the NHS owing to their allergenic 
nature.  
Klein et al. (2003) investigated the permeation of 14 different cytotoxic drugs through 
the swatches of selected medical gloves. Gloves were either made of latex or neoprene 
and four glove systems were single layer and two were double layer. The drugs used 
were bleomycin, carmustine, dacarbazine, daunorubicin, etoposide, idarubicin, 
irinotecan, mitomycin, mitoxantrone, oxaliplatin, topetecan, vinorelbine, ifosfamide and 
teniposide. A stock solution of each drug was made at the highest clinical concentration 
of the particular drug and the permeability of each glove material was tested using an 
apparatus where the test drug was added to a glass tube which was sealed with a section 
of glove material and dipped in water (acceptor medium). A sample was taken from 
water every 30 minutes and assayed for the drug. The results showed that all gloves 
exhibited low permeation for most drugs except carmustine which clearly permeated 
through single layer gloves. According to this study even though most gloves met the 
EN 374 standard for permeation they did not reflect actual practice as gloves are 
subjected to higher temperatures as well as stretching and rubbing. 
Wallemacq et al. (2006) simulated real use conditions of protective gloves to evaluate 
13 different gloves against the same number of anti-cancer drugs. The gloves used in 
the study were made of natural latex, neoprene, nitrile and vinyl. The drugs used were 
carmustine, 5-FU, cisplatin, cyclophosphamide, ifosfamide, cytarabine, docetaxel, 
doxorubicin, etoposide, irinotecan, MTX, thiotepa and vinorelbine.  Each drug was 
tested at its highest concentration prepared in pharmacy units. A special apparatus was 
designed to subject test gloves to rubbing, stretching and tension simulating in-use 
conditions. The samples were taken at 15, 30 and 60 minutes. The results showed most 
glove materials were permeable to cytotoxic drugs at rates below ASTM D6978-05 
except vinyl gloves which were permeable at rates higher than the standard. Carmustine 
was widely permeable through all materials and 5-FU, cisplatin and etoposide also 
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showed permeation more than 10 ng cm-2  min-1  after 60 minutes. The results from the 
glove evaluation studies have concluded vinyl gloves are most permeable to anticancer 
drugs and nitrile, latex and neoprene gloves present a better barrier against anti-cancer 
drugs.  
1.6.5.2 Chemo-gowns 
 
Figure 1.24: Chemo-resistant gown used for the compounding of anti-cancer drugs 
Disposable chemo resistant gowns (Fig. 1.24) must be worn at all times while 
preparing, handling and administering anticancer drug infusions. The chemo gowns 
should be lint free, of low permeability, closed front, tight cuffs, comfortable, tear and 
cut resistant and inexpensive. According to ASHP guidelines washable gowns such as 
lab coats, scrubs and cloth gowns do not provide any barrier against hazardous drugs. 
There is limited data available on the evaluation of chemo gowns. One study evaluated 
six commercially available gowns for splash protection against fifteen anticancer drugs 
(Harrison and Kloos, 1999). The gowns were laminated with polypropylene, 
polyethylene or vinyl acetate polymer. A sample from each gown was taken and placed 
on an absorbent mat in a class II BSC. A drop of each test drug was dropped on the 
gown material and was observed visually after 1 minute for signs of penetration. The 
authors concluded that gowns laminated with polyethylene or vinyl provided adequate 
protection, whereas polypropylene based gowns were not sufficiently splash resistant. 
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1.6.6 Disposal of cytotoxic waste 
All cytotoxic waste generated within pharmacy or clinical areas must be disposed of 
safely following a formal risk assessment. Most NHS hospitals use waste management 
agencies to dispose of clinical waste. Hospitals must make sure that the waste 
management agency used by them is authorised to deal with cytotoxic and hazardous 
waste. It is recommended that all hazardous waste must be segregated from all other 
waste and contained in thick, leak proof, sealable plastic bags or containers. These bags 
or containers must be readily available and solely used for disposal of cytotoxic waste. 
According to department of health guidelines for management of cytotoxic waste all 
containers must be colour coded (DOH, 2013). The bags used for disposal of cytotoxic 
waste must be UN approved orange coloured (Fig 1.25) and plastic containers must be 
yellow body with purple lid (Fig 1.26).  The above bags and containers must have 
European Waste Catalogue (EWC) code 180108. It is recommended that all cytotoxic 
waste is incinerated (DOH, 2013).      
 
Figure 1.25: UN approved bag used for cytotoxic waste 
 
Figure 1.26: UN approved purple lid plastic bin for cytotoxic sharps waste 
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1.6.7 Closed system drug transfer devices 
The major source of contamination with anti-cancer drugs in the workplace is from the 
generation of aerosols during the preparation of IV infusions. Closed system drug 
transfer devices (CSTD) have the potential to eliminate the aerosol generation and thus 
can drastically reduce workplace contamination. CSTDs have been in use in North 
America and Europe since the late 1990s and there is a limited number of FDA 
approved CSTDs available in the market which include PhaSeal, Chemoclave, Texium 
IV and Onguard with Tevadaptor. According to the National Institute of Occupational 
Health and Safety (NIOSH) alert a closed system is defined as “a device that does not 
exchange unfiltered air or contaminants with the adjacent environment” and a closed 
system drug-transfer device as “a drug transfer device that mechanically prohibits the 
transfer of environmental contaminants into the system and the escape of hazardous 
drug or vapour concentrations outside the system” (NIOSH, 2004).    Although all 
CSTDs are designed differently they all act by maintaining a “closed” connection 
between the vial and the transfer device (syringe). In the case of most devices (except 
PhaSeal) the “closed” connection is maintained with the use of 0.22 μm filters. 
However, this filter does not contain the escape of anti-cancer drug vapours therefore 
such devices may also be considered “semi-closed”. In some devices such as 
Tevadaptor an active carbon filter is used to absorb the anti-cancer drug vapours which 
may get saturated with use and therefore data on the maximum loading capacity of the 
filter must be provided by the manufacturer.   
The major advantages of CSTDs are they reduce the production of aerosols during the 
compounding process which are generally considered to be a major cause of 
occupational exposure to hazardous drugs. CSTDs are also needle free systems (except 
PhaSeal which is a needle safe system) and therefore they reduce the risk of needle stick 
injuries to staff manipulating cytotoxic drugs. One of the most commonly used CSTDs 
is the PhaSeal system (Fig. 1.27). The basic components of the PhaSeal system are the 
PhaSeal protector, PhaSeal injector and PhaSeal connector. The protector is a vial 
adaptor used to attach to the drug vials, the injector is the drug transfer device that 
attaches to the disposable syringe and the protector and the connector attach the 
patient’s IV line to the injector. This system works by creating a dry, leakproof 
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connection between the drug vial and transfer device and thus reducing the formation of 
aerosols.  
 
 
Figure 1.27: PhaSeal system and its components  
A large number of studies have been published presenting the effectiveness of this 
device in reducing workplace contamination with anticancer drugs while preparation 
and administration of IV infusions. Below is a brief review of studies documenting the 
efficacy of CSTDs. 
Connor et al. (2002) evaluated a CSTD (PhaSeal) using cyclophosphamide and 
ifosfamide as marker drugs and 5-FU as a control in a renovated pharmacy unit with 
new biological safety cabinets. The marker drugs were prepared using the CSTD and   
5-FU was prepared following the standard practice of using needles and syringes to 
prepare IV infusions. The samples were collected from various locations before the 
commencement of drug preparation after the renovation work and then continued over a 
period of 168 days. The results showed the contamination with 5-FU increased over 
time in all locations and ranged from 1 to 10 ng cm-2. On the other hand the 
contamination with cyclophosphamide was generally less than 3 ng cm-2 and 
contamination with ifosfamide was less than 1 ng cm-2. The authors therefore concluded 
that a CSTD was generally effective in reducing contamination with marker drugs. 
PhaSeal 
protector 
PhaSeal 
injector 
PhaSeal 
connector 
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Wick et al. (2003) also evaluated the efficacy of CSTD (PhaSeal) in reducing surface 
contamination and personnel exposure by anticancer drugs. Surface wipe samples were 
collected before and six months after the use of CSTD. Twenty four hour urine samples 
from the healthcare staff involved in preparation or administration of anticancer drugs 
were also taken. Cyclophosphamide and ifosfamide were used as marker drugs for this 
study. Before the use of CSTD cyclophosphamide was detected in all 17 surface 
samples in the range of ND to > 0.33 ng cm-2 and 11 samples had ifosfamide in the 
range of ND to 0.076 ng cm-2 with one sample above linear range of assay. However, 
after the use of CSTD 7 out of 21 samples had detectable levels of cyclophosphamide in 
the range of ND to 0.037 ng cm-2, and 16 out of 21 samples showed ifosfamide in the 
range of ND to 0.001 ng cm-2 with five samples above the linear range of the assay. 
Urine samples from eight members of staff were collected during both phases of study 
and before CSTD six samples were positive for cyclophosphamide and two were 
positive for ifosfamide whereas, after the use of CSTD no contamination was detected 
in urine samples. 
Spivey and Connor (2003) used fluorescein to determine the source of surface 
contamination in the work place and the effectiveness of a CSTD in reducing the 
contamination. The results indicated that when the CSTD (PhaSeal) was used for 
reconstitution of fluorescein no leakage was observed as compared to standard practice 
(using a needle and syringe) which showed leakage in each step of reconstitution. A 
study by Harrison et al. (2006) evaluated the use of CSTD (PhaSeal) within and outside 
a biological safety cabinet. The marker drugs used for the study were cyclophosphamide 
and ifosfamide. During this study baseline samples from workplace surfaces were taken 
for twelve weeks and then the CSTD was introduced. Cyclophosphamide was prepared 
using the CSTD within a BSC and 5-FU was prepared using the CSTD outside the BSC 
on a counter top. The results indicated the use of CSTD in BSC showed marked 
reduction in surface contamination by cyclophosphamide. However, the use of the 
CSTD outside the BSC did not reduce contamination by 5-FU. 
Two recent studies conducted in Japan and Australia also confirm the efficacy of 
PhaSeal in reducing workplace contamination. The Japanese study used 
cyclophosphamide to detect work surface contamination and exposure to healthcare 
staff by comparing results from samples taken before and after the use of a CSTD 
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(Yoshida et al., 2009). The samples were collected for five days during the conventional 
drug preparation phase and then operators were trained in the use of the CSTD for two 
weeks and samples were taken again while IV infusions were prepared using the CSTD. 
Twenty four-hour urine samples from healthcare workers were also collected during 
both phases. The results showed that during the baseline phase the range of 
cyclophosphamide was 0.0095-27 ng cm-2 and during the CSTD phase the range was 
ND to 4.4 ng cm-2, thereby illustrating that the use of CSTD over standard working 
practices significantly reduced work surface contamination as well as the presence of 
cyclophosphamide in urine samples of pharmacists preparing chemotherapy infusions. 
Siderov et al. (2010) also used a similar approach by adopting cyclophosphamide as a 
marker drug and taking wipe samples pre and post introduction of PhaSeal. After one 
year of the study the authors concluded that there was a reduction of 75% in positive 
samples of cyclophosphamide and a reduction of 68% in total contamination. 
A study of 22 US hospital pharmacies reported the effect of introducing a CSTD 
(PhaSeal) on work surface contamination (Sessink et al., 2010). The study was 
conducted over a period of five years from 2000 to 2005. Cyclophosphamide, 
ifosfamide and 5-FU were used as marker drugs for the study. Wipe samples were 
collected from BSC surfaces and showed that prior to introduction of CSTD the 
percentage of samples found to be positive for cyclophosphamide, ifosfamide and 5-FU 
was 78%, 54% and 33%, respectively. In contrast the percentage of positive sample 
after the introduction of the CSTD was 68% for cyclophosphamide, 45% for ifosfamide 
and 20% for 5-FU. The reduction in the median values of cyclophosphamide, 
ifosfamide and 5-FU were 95%, 90% and 65%, respectively, showing that the use of 
CSTD results in large reduction in surface contamination by anticancer drugs as 
compared to the conventional method of preparing IV infusions using needles and 
syringes.  
Although the product literature of each CSTD claims that microbiological sterility is 
maintained during the compounding process as well as during the storage of prepared 
infusions, there is a paucity of published data confirming these assertions. In a study 
comparing four CSTDs (PhaSeal, Chemoprotect Spike, Clave connector and Securmix) 
in maintaining sterility during manipulations, the rubber stoppers of vials containing 
saline were contaminated with Pseudomonas aeruginosa and the devices were then 
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connected to the artificially contaminated vials. The cells transferred during the 
manipulations were counted using solid-phase cytometry. The results showed that 
PhaSeal was the most effective device in preventing microbial contamination of the 
contents of the vial (De Prijck et al., 2008). In a second study PhaSeal devices were 
connected to vials containing sterile culture media and stored at room temperature; at 
day 7 there was a 98% probability that the vials were not contaminated (McMicheal et 
al., 2011). In an extension of this study, sterile test culture media were transferred from 
vials into IV bags using PhaSeal devices and the bags were then incubated for 14 days. 
The results showed that at day 7 the probability of uncontaminated samples was 99.7% 
(Thomas et al., 2011).  
It is clear from above examples that CSTDs are effective in reducing the surface 
contamination within pharmacy aseptic manufacturing areas. However, it should also be 
noted that even though pharmaceutical isolators provide a high level of protection to 
pharmacy operators, the exterior surfaces of infusion bags and syringes prepared in the 
isolators are likely to be contaminated with anti-cancer drugs, which in turn results in 
contamination of ward surfaces and poses an exposure risk to nurses. The use of CSTDs 
along with pharmaceutical isolators would provide a higher level of protection to 
nursing staff as the outer surfaces of IV infusion bags prepared using CSTDs are less 
likely to be contaminated with anti-cancer drugs. NIOSH also recommends the use of 
CSTDs in conjunction with BSCs or pharmaceutical isolators in order to reduce the risk 
of occupational exposure to anti-cancer drugs. Despite this recommendation and clear 
evidence that CSTDs reduce contamination, such devices are not used regularly in the 
UK National Health Service (NHS) hospital pharmacy aseptic manufacturing units, 
perhaps, at least partly, due to the added costs involved. There is also a lack of data on 
the effectiveness of CSTDs when used within pharmaceutical isolators which are 
generally preferred in the UK hospital pharmacies as compared to open fronted LFCs 
used in parts of Europe and USA. The studies undertaken during the course of this 
project seek to fulfil that gap and provide evidence of the efficacy of the Tevadaptor 
(CSTD) device when used in conjunction with negative pressure pharmaceutical 
isolators. 
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1.7 Aims and objectives of the present study 
1.7.1 Aims 
During the first phase of this project (Tevadaptor isolator study) 7 the baseline 
contamination levels of anti-cancer drugs within the pharmaceutical isolators used at 
Derriford Hospital pharmacy manufacturing unit was examined. The levels of various 
marker drugs on the outer surface of IV infusions bags and syringes prepared within 
these isolators for administration to patients are also examined. The contamination 
levels are then compared against the contamination detected in the same isolators after 
the use of Tevadaptor (a closed system drug transfer device) to compound the IV 
infusions of the selected marker drugs. The aerosols generated during the compounding 
of IV infusions of anti-cancer drugs with standard practice of using needles and syringes 
are the major source of contamination caused by the anti-cancer drugs on work surfaces, 
which results in occupational exposure of staff to the anti-cancer drugs. The Tevadaptor 
device, manufactured and marketed by Teva Medical Ltd, works by inhibiting the 
formation of aerosols generated during the compounding of IV infusions (see Chapter 2, 
Section 2.1.2 for details of Tevadaptor), thereby reducing the work surface 
contamination with hazardous anti-cancer drugs. This is the first UK study on the 
effectiveness of any CSTD. The majority of the data on the effectiveness of the CSTDs 
is based on studies conducted in the USA or continental Europe. However, these data 
may not be extrapolated to the UK as it is standard practice to compound anti-cancer 
drugs in enclosed pharmaceutical isolators in the UK as opposed to the use of open 
fronted LFCs in the USA and Europe. The handling of CSTDs is likely to present a 
challenge in the isolators. Therefore, the effectiveness of Tevadaptor under actual 
working conditions in a UK hospital pharmacy aseptic unit using isolators and the user 
friendliness of the device in working conditions will be reported.  
The second phase (Tevadaptor ward study) of the project examines the contamination 
on the work surfaces of oncology out-patients wards. It is assumed that the 
contamination from the surface of IV bags and syringes could be transferred to work 
surfaces on the wards/clinics where the infusions are assembled prior to administration 
to the patients. The contamination on the out-patients ward surfaces is then compared to 
the levels detected on the same surfaces after the marker drugs are prepared using 
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Tevadaptor for compounding of the marker drug infusions in the pharmacy and 
administration to the patients in oncology out patients department.  The user friendliness 
of Tevadaptor for pharmacy technicians as well as nurses is also examined. 
The final phase (Drain study) of the project detected the levels of platinum-based anti-
cancer drugs in the waste water of Derriford Hospital. These measurements were then 
used to further estimate the levels of platinum-based drugs disposed in the city drains 
and the levels of platinum (from platinum based drugs) in the river water where the 
treated water from sewage treatment plants is disposed.  
1.7.2 Objectives 
The above aims were achieved by the following objectives: 
a) The development  and validation of, sensitive and selective analytical methods 
(HPLC and ICP-MS) to detect the marker drugs for the study; 
b) Taking wipe samples from predefined surfaces of the pharmaceutical isolator, 
outer surfaces of prepared infusion bags and syringes and the selected surfaces 
from oncology out-patients ward;  
c) The collection of baseline data by taking wipe samples from pre-defined 
surfaces while marker drug infusions are prepared using conventional methods 
of using needles and syringes; 
d) The collection of intervention data by taking wipe samples from same surfaces 
as baseline phase (marker drug infusions were to be prepared using the 
Tevadaptor device); 
e) The comparison of the surface contamination in baseline and intervention 
samples to ascertain the efficacy of the Tevadaptor device in reducing work 
surface contamination with anti-cancer drugs as claimed by the manufacturer of 
the  device; 
f)  The development of a questionnaire and collection of responses from staff 
members who used the Tevadaptor device to assess its user friendliness; 
g) The collection of waste-water samples from hospital drains to detect the 
environmental concentrations of platinum-based drugs as excreted by the 
patients. 
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Chapter 2: Materials and methods  
2.1 Study setting 
Derriford Hospital is a university hospital serving 450,000 people in southwest UK, and 
includes a major cancer centre. The hospital pharmacy provides dispensary, clinical and 
aseptic manufacturing services to the hospital and has two purpose-built aseptic suites 
with five pharmaceutical isolators dedicated to chemotherapy preparation. There are 
two specialist in-patient wards one each for oncology and haematology and a 
chemotherapy outpatients department. All aseptic production in the pharmacy is 
undertaken according to written standard procedures (SOP) and all staff members are 
required to read and understand these procedures before undertaking any activity. The 
pharmacy is audited annually by the regional QA Manager for  southwest England to 
ensure compliance with national guidelines for the preparation of aseptic infusions. To 
gain approval for each part of the project a research protocol was submitted to the 
regional research and ethics (REC) committee based at Bristol, UK, which decided that 
this was an evaluation study and did not need a full ethics review. 
2.2 Materials 
2.2.1 Drug selection for the project 
Healthcare staff members are at a risk of being exposed to a cocktail of cytotoxic drugs 
in the course of their daily activities. Therefore marker drugs for this study reflect a 
wide range of drugs. The marker drugs were selected according to their frequency of 
usage, special handling requirements and physico-chemical properties.  Consideration 
was also given to the availability of analytical techniques and methods with a low LOD 
(limit of detection) and LOQ (limit of quantification). MTX, epirubicin, cisplatin, 
carboplatin, oxaliplatin, 5-FU and gemcitabine were used in this study. An estimate of 
the average amount of the above drugs used in a six month period (first half of 2009) in 
Derriford Hospital is provided in Figure 2.1 and a brief chemical description of each 
marker drug is provided below.  
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Figure 2.1: Total amounts of marker drugs (in grams) procured at Derriford Hospital 
pharmacy over a period of six months (from Jan 2009 to June 2009). 
2.2.1.1 Methotrexate (CAS No. 59-05-2) 
Methotrexate (MTX) is a 2,4-diamino-substituted pteridine ring linked to a                   
p-aminobenzoyl moiety, amine bonded to a glutamic acid unit (Fig 1.4, Chapter 1). It 
has a molecular weight of 454.4 and its molecular formula is C20H22N8O5 and its 
IUPAC name is (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-
ethylamino]benzoyl]amino]pentanedioicacid). MTX is practically insoluble in water 
and alcohol but soluble in alkali hydroxides and carbonates. It absorbs UV radiation 
with maxima at 224 and 307 nm in 0.1 N HCl (http://pubchem.ncbi.nlm.nih.gov). IARC 
has classified MTX under Group 3 (not carcinogenic to humans but mutagenic and 
tertatogenic) therefore it should be handled and disposed of as cytotoxic agent. In case 
of accidental spills, the area must be isolated and may be cleaned using hypochlorite 
solution which has been proved to degrade MTX. The ecological effects of MTX can be 
noticed as it has EC50 of 260 mg L-1 in algae, LC50 of more than 1000 mg L-1 in 
daphnia and EC50 of 85 mg L-1 in fish embryo assay. It is estimated that in the case of 
release to the environment MTX is likely to exist as particulate matter. However, it is 
likely to degrade quickly as it absorbs UV radiation. Moreover, if released into soil 
MTX is expected to degrade to 7-hydroxymethotrexate which is persistent and toxic 
(Methotrexate, MSDS). Methotrexate is supplied either as a clear yellow solution for 
injection or deep yellow tablets. The injection may be diluted with normal saline or 5% 
Gemcitabine, 
112g
Carboplatin, 
290g
Cisplatin, 40g
Oxaliplatin, 30g
Epirubicin, 4g5-FU, 840g
MTX, 110g
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dextrose before administration. MTX can be administered via the IV, IM and intrathecal 
routes and is formulated as its sodium salt to improve its solubility. The recommended 
storage conditions for MTX are at a temperature below 25oC and protected from light. 
MTX is used under a wide range of clinical conditions which include, cancer 
chemotherapy, psoriasis, and polyarticular-course juvenile rheumatoid arthritis 
(www.emc.medicines.org.uk), hence it is likely to be present in the workplace 
environment as well as the general environment. It has been commonly studied for work 
place contamination and measurable levels have been detected on vials, gloves, the 
handles and doors of storage fridges, shelves, on the floor, telephone hand-sets, bench 
areas, trays and areas inside BSCs (Turci et al., 2003).  
2.2.1.2 Epirubicin (CAS No. 56390-09-1) 
Epirubicin belongs to the anthracycline class of anticancer drugs and consists of a 
polyaromatic ring system with a quinine moiety which is linked to an amino sugar by an 
O-glycosidic bond (Fig 1.8, Chapter 1). It has a molecular weight of 543.5 and can be 
represented by its molecular formula C27H29NO11. The IUPAC name of epirubicin is 
(8R,10S)-10-((2S,4S,5R,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)-
6,8,11-trihydrpxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahyrotetracene-5,12-
dione. It is soluble in water and methyl alcohol. Epirubicin exists as red-orange crystals 
with a melting point of 185oC, however it is supplied as its hydrochloride salt as a clear 
red solution with a pKa of 7.7 or a freeze dried powder 
(http://pubchem.ncbi.nlm.nih.gov). It undergoes extensive photolysis under fluorescent 
light hence, must be protected from light and is known to adsorb to glass and certain 
plastics (Allwood et al., 2002). The IARC has classified epirubicin in group 2A 
(probably carcinogenic to humans) therefore it must be handled as for cytotoxic agents. 
Accidental spills must be cleaned up using procedures for handling cytotoxic agents. 
Epirubicin may emit toxic fumes of carbon monoxide, nitrogen dioxide and other 
chlorine-containing compounds, hence appropriate masks must be used during clean-up 
processes. There is limited data available on the ecological effects of the epirubicin 
therefore any release to general environment should be avoided (Epirubicin, MSDS). 
Epirubicin is normally administered as a bolus injection but can be diluted in 5% 
glucose or normal saline to be administered as an IV infusion. The undiluted drug vials 
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are recommended to be stored between 2 and 8oC. Epirubicin is used in various cancer 
conditions which include, breast, ovarian, gastric, lung, malignant lymphomas, 
leukaemias and multiple myeloma (www.emc.medicines.org.uk). Its wide use makes it 
a likely contaminant in the general work place environment. 
2.2.1.3 5-Fluorouracil (CAS No. 51-21-8) 
5-Fluorouracil (5-FU) is an anti-metabolite. It is essentially a uracil in which hydrogen 
at position 5 is replaced by fluorine (Fig 1.1, Chapter 1). Its molecular weight is 130.7 
and the molecular formula is C4H3FN2O2. It is partially soluble in water and is soluble 
in ethanol. 5-FU is stable at acidic pH and degrades to barbituric acid and uracil at pH 
above 9.0. The IUPAC name of 5-FU is 5-fluoro-1H,3H-pyrimidine-2,4-dione 
(http://pubchem.ncbi.nlm.nih.gov). 5-FU is supplied in the form of solution which also 
contains sodium hydroxide to adjust pH to 8.9. It has maximum stability between pH 
8.6 to 9.0 and is prone to precipitation at low temperatures which can be re-dissolved by 
heating up to 60oC. IARC has classified 5-FU under Group 3 (not classified as 
carcinogenic to humans) and it is a known mutagenic. Accidental spills must be handled 
according to the procedures for cytotoxic drugs. On release to the environment 5-FU 
may exist both as vapour or particulate phase. In vapour phase it is likely to be degraded 
photo-chemically by the production of hydroxyl radicals and in the particulate phase it 
is likely to be removed from the atmosphere by deposition. On release to soil 100% 
biodegradation is likely to be noticed within five days (Fluorouracil, MSDS). 
5-FU is also generally administered as a bolus injection or could be diluted with 5% 
glucose or normal saline. It can be stored at room temperature and is unaffected by 
light. It is commonly used in the treatment of cancer of colon and breast 
(www.emc.medicines.org.uk) and has been proved to contaminate work surfaces (Turci 
et al., 2003).  
2.2.1.4 Cisplatin (CAS No. 15663-27-1) 
Cisplatin was the first platinum derivative introduced in the market. It contains two 
chlorine atoms and two amino groups arranged in a cis configuration (Fig 1.15, Chapter 
1).  Its molecular weight is 298.03 and its molecular formula is Cl2H4N2Pt. The IUPAC 
name of cisplatin is cis-diamminedichloroplatinum(II). It is partially soluble in water    
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(1 mg mL-1). It is unstable in aqueous media and undergoes hydrolytic reaction unless 
chloride ions are present. It is stable at a pH of 3.5 to 5.5 and is sensitive to daylight and 
any contact with aluminium should be avoided (http://pubchem.ncbi.nlm.nih.gov). 
Cisplatin forms aqua species in the presence of water which are responsible for its 
cytotoxic action. Equations 2.1 and 2.2 demonstrate the aquation reaction of cisplatin 
(Allwood et al., 2002). 
cis-PtCl2(NH3)2 + H2O ⇌ cis-PtCl(OH2)(NH3)2+ + Cl-  Eqn 2.1 
 cis-PtCl(OH2)(NH3)2
+ + H2O ⇌ cis-Pt(OH2)2(NH3)22+ + Cl- Eqn 2.2 
Cisplatin is a known carcinogen and classified by IARC under Group 2A (probably 
carcinogenic to humans). All accidental spills must be contained and breathing of drug 
vapour or dust must be avoided. There is no ecological data available (Cisplatin, 
MSDS). However, up to 75% of cisplatin in drain water is converted into mono-aqua 
form which is also considered cytotoxic (Hann et al., 2003).  
It is generally supplied as a yellowish-white freeze dried powder or a pale yellow clear 
solution free of particles. It is administered via IV infusions after dilution into normal 
saline. Cisplatin should be stored at room temperature, protected from light and is 
supplied in amber colour glass vials. Platinum based drugs are commonly used in the 
treatment of solid tumours and cisplatin in particular has wide applications in testicular 
cancer, ovarian cancer, bladder carcinoma, squamous cell carcinoma of the head and 
neck, small cell lung carcinoma and cervical cancer (www.emc.medicines.org.uk). Due 
to its widespread use there is also an increased risk of contamination of work place 
surfaces with cisplatin. 
2.2.1.5 Carboplatin (CAS No. 41575-94-4)  
Carboplatin contains two amino groups and a 1,1-dicyclobutanedicarboxylate group 
(Fig 1.16, Chapter 1). It has molecular weight of 373.3 and can be represented with the 
molecular formula C6H14N2O4Pt. The IUPAC name of carboplatin is                           
cis-diammine(cyclobutane-1,1-dicarboxylate-O,O’)platinum(II) 
(http://pubchem.ncbi.nlm.nih.gov). There is no monograph available for carboplatin 
from IARC although it is considered as mutagenic and teratogenic. Carboplatin is stable 
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in aqueous solution but converts to cisplatin in the presence of chloride and hydroxyl 
ions. It is stable at a pH of 4 to 6.5. Carboplatin is also incompatible with aluminium as 
is cisplatin and on interaction with aluminium result in precipitation and loss of 
potency. Accidental spills may result is formation of toxic gases therefore protective 
masks must be worn during the clean-up and area should be isolated (Carboplatin, 
MSDS). Carboplatin is known to convert to cisplatin in the presence of water and 
chloride ions (Allwood et al., 2002) (see Equations 2.3 and 2.4) therefore on release into 
environment it is likely to exist as cisplatin or highly active mono-aqua form of cisplatin 
(equations 2.1 and 2.2):  
C6H12N2O4Pt (carboplatin) + H2O                 Pt(OH2)2(NH3)2
2+                          Eqn 2.3 
Pt(OH2)2(NH3)2
2+ + Cl-                     PtCl2(NH3)2                                                 Eqn 2.4 
Carboplatin is supplied in the form of clear solution for infusion and is soluble in water. 
It can be stored at room temperature away from light. It is administered via IV infusion 
after dilution into 5% glucose. It may be diluted in saline but the shelf life is limited to 
24 hours. It is used in the treatment of ovarian carcinoma of epithelial origin and small 
cell lung carcinoma (www.emc.medicines.org.uk). Due to the favourable toxicity profile 
of carboplatin as compared to cisplatin, it is one of the most common anti-cancer drugs 
in use and also more likely to be present in work place environments. 
2.2.1.6 Oxaliplatin (CAS No. 61825-94-3) 
Oxaliplatin is the newest of the platinum derived chemotherapy agents. It contains a 
1,2-dicyclohexane and an oxalato group (Fig 1.17, Chapter 1) and has a molecular 
weight of 399.3. Its molecular formula is C8H16N2O4Pt and the IUPAC name of 
oxaliplatin is [(1R,2R)-cycloheaxe-1,2-diamine](ethanedioato-O,O’)platinum(II) 
(http://pubchem.ncbi.nlm.nih.gov). Oxaliplatin is also not classified by IARC as 
carcinogenic but is known to be teratogenic and mutagenic. It is slightly soluble in 
water (6 mg mL-1) and practically insoluble in dehydrated alcohol. A 0.2% aqueous 
solution of oxaliplatin has pH range of 4.0 to 7.0. It is also incompatible with 
aluminium and other oxidising agents such as sodium bicarbonate and sodium 
metabisulfite (http://pubchem.ncbi.nlm.nih.gov). All spills must be isolated and cleaned 
as per procedures for cytotoxic agents, soaking the area of spill with hypochlorite 
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solution or household bleach for ten minutes can degrade oxaliplatin. It may also release 
toxic fumes of carbon oxides and nitrogen oxides on thermal decomposition therefore 
appropriate masks must be used in case of cleaning up spills. Even though ecological 
data is limited, it is suggested that on release to the environment oxaliplatin may not 
readily hydrolyse and has a half-life of 27.4 days at pH 7.0 and 25oC (oxaliplatin, 
MSDS). Oxaliplatin forms dichloro, monoaqua-monochloro and diaqua species in the 
presence of water and chloride ions (see equation 2.5) and these complexes are shown 
to be more cytotoxic than oxaliplatin (Jerremalm et al., 2004):   
Pt(dach)oxalato + H2O + Cl
-                          Pt(dach)Cl2 + [Pt(dach)(H2O)Cl]
+ + 
                                                                         [Pt(dach)(H2O)2]
2+                              
     (dach = cyclohexanediamine)                                                      Eqn 2.5 
Oxaliplatin is supplied either in the form of white freeze-dried powder or solution in 
water for injection and is stable under normal condition of use. It can be stored at room 
temperature and is unaffected by light. Oxaliplatin in combination with 5-FU and folinic 
acid (FA) is indicated (www.emc.medicines.org.uk) for adjuvant treatment of stage III 
(Duke's C) colon cancer and treatment of metastatic colorectal cancer.  
 2.2.1.7 Gemcitabine (CAS No. 122111-03-9) 
Gemcitabine (Fig 2.2) is a pyrimidine analogue with a molecular weight of 263.2. The 
molecular formula of Gemcitabine is C9H11F2N3O4 and its IUPAC name is                   
4-amino-1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidine-2(IH)-on  
(http://pubchem.ncbi.nlm.nih.gov). According to the IARC classification gemcitabine is 
under Group 3 (not classified as carcinogen to humans) but is a known mutagenic and 
teratogenic compound. Gemcitabine is formulated as its hydrochloride salt and is 
soluble in water but insoluble in ethanol and slightly soluble in methanol 
(http://pubchem.ncbi.nlm.nih.gov). Any accidental spill must be handled according to 
the local procedure for handling cytotoxic drugs. If the powdered form of drug is spilled 
it can result in dust generation, hence respiratory masks may be worn while cleaning up 
such spills. On thermal decomposition it may result in the formation of toxic fumes. 
Aquatic toxicity of gemcitabine has been recorded and it shows 96-hour median lethal 
 54 
 
concentration of more than 1043 mg L-1 on rainbow trout and 1014 mg L-1 on fathead 
minnow. Microbial toxicity studies show MIC of more than 1000 mg L-1 on mould, and 
800 mg L-1 on blue green algae. The biodegradability studies show that it is unlikely to 
undergo any hydrolysis and has aerobic biodegradation half-life of 30% in 28 days 
(Gemcitabine, MSDS).   
 
Figure 2.2: Chemical structure of gemcitabine 
Gemcitabine is either supplied as white to off white powder for solution or colourless to 
slightly yellow concentrate for solution for infusion. There are no special storage 
conditions for this drug. It is administered via IV infusion after dilution with normal 
saline and used in a wide range of conditions such as metastatic bladder cancer, 
adenocarcinoma of pancreas, non-small cell lung cancer, epithelial ovarian carcinoma 
and metastatic breast cancer (www.emc.medicines.org.uk). Due to its wide applications 
and frequent use gemcitabine is an ideal marker drug for this study. 
2.2.2 Chemicals and reagents 
Drugs and consumables used for the study were used from the authorised stock used 
within Derriford Pharmacy Manufacturing Unit (DPMU) and all chemicals and reagents 
used were of analytical or HPLC grade as appropriate. Drugs and chemicals used for the 
study were: MTX (batch T024411AA, exp: 01/08/09), obtained from Mayne pharma 
plc; epirubicin (batch: DT34B, exp: 01/07/2011), obtained from Pharmacia Ltd; 5-FU 
(batch: W022675AB, exp: 01/08/2011), gemcitabine (batch: Y0189424C, exp: 1/11/12; 
X018942AB, exp: 1/10/11) and oxaliplatin (batch: Y015358AA, exp: 1/10/12, 
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U015359AAX, exp: 01/11/10), supplied by Hospira UK Ltd; Cisplatin (batch: 
07M10NA, exp: 01/08/10) and carboplatin (batch 10C050C, exp: 01/03/2012, batch 
10C050C, exp: 1/3/12) were obtained from Teva UK Ltd; Cisplatin (batch: 96589704, 
exp: 1/10/12) was also obtained from Ebewe Ltd and oxaliplatin (batch: D9C665, exp: 
01/04/11) was  obtained from Sanofi.  
Di-sodium hydrogen orthophosphate, sodium dihydrogen orthophosphate, acetonitrile 
and methanol were purchased from Fisher Scientific UK Ltd. Potassium permanganate, 
orthophosphoric acid and sodium hydroxide 1N were obtained from BDH Chemicals 
Ltd. Hydrogen peroxide 30% was from Sigma Chemical Co, USA. Acetic acid 33% 
B.P. was from JM Loveridge Ltd and hydrochloric acid 1N was from Merck, Germany. 
Water used for the HPLC analysis was “sterile water for irrigation” BP purchased from 
Baxter healthcare SA and “water for injection” (WFI) used to saturate Klerwipes was 
obtained from Fannin Pharma UK. Purified water (18M ohm cm-1) was obtained from 
an Elga primar system (Buckinghamshire, UK). Hydrochloric acid (HCl) (37%) and 
nitric acid (HNO3) (65%) were trace analysis grade and were obtained from Fisher 
Scientific UK Ltd, and were used for sample digestion and sample stabilisation. Two 
percent HNO3 used for diluting digested residues was prepared by diluting HNO3 with 
purified water. The platinum standards used for calibration were prepared by diluting 
the 10,000 mg L-1 platinum solution obtained from Johnson Matthey Chemicals, UK 
into 2% HNO3. The 
193Ir (iridium) standard was 10,000 mg L-1 and was also obtained 
from Johnson Matthey Chemicals, UK. The above stock solution was diluted to           
10 mg L-1 with purified water and added to all samples to give a final concentration of           
10 μg L-1.  
Centrifuge tubes (50 mL) were obtained from Sterilin Ltd. Klercide-CR sterile filtered 
biocide B and Klerwipe sterile low particulate dry wipes (18×20.5cm) were purchased 
from Shield Medicare, UK. Cotton wool pads (5 cm diameter) were purchased from 
Asda Stores Ltd. The Spiriclens sterile spray (denatured ethanol 70% in water for 
injection) and hypochlorite solution used for cleaning the sampling bottles were used 
from quality controlled stock of the DPMU. Luer-Lok plastipak syringes and BD 
microlance 3 syringe needles were from BD Franklin Lakes, USA. Solid phase 
extraction cartridges and HPLC column were purchased from Phenomenex. Tevadaptor 
devices, vial adaptor (batch M0606H9), syringe adaptor (batch M0609H9), luer lock 
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adaptor (batch M0375H9) and spike port adaptor (batch M0560G9) were provided 
gratis by Teva Medical Ltd. Cytostatic protection gowns and cytostatic workmats were 
from Berner International, Germany. Nitrile gloves were from Ansell Ltd and 
Alcowipes were from Seton Healthcare. 
2.2.4 Tevadaptor 
Tevadaptor is a closed system drug transfer device used for reconstitution as well as 
administration of hazardous drugs (cytotoxic drugs). It is manufactured by Teva 
Medical Ltd at Migada (Israel). It has been available for use since 2006 and is approved 
by the FDA and is CE marked. As reviewed in Chapter 1, CSTDs have been proved to 
reduce surface contamination. However, most of the published data are based on 
PhaSeal device. The first phase of this project is to evaluate Tevadaptor device in its 
claims to be a safe system for compounding and administration of cytotoxic drugs by 
minimising the risk of aerosol formation during the compounding process and 
eliminating the risk of needle stick injuries. This device contains a 0.2 micron filter, 
which acts as an air filter rather than the drug filter, which helps in equalising the 
pressure in vials (vials are packed under negative pressure) and maintaining sterility of 
the contents. Tevadaptor is sterilized using ethylene oxide and supplied in separate 
packaging suitable to be wiped and sprayed in clean rooms. It can be used to compound 
all cytotoxic drugs except amsacrine, busulfan and drugs diluted with N,N-
dimethylacetamide (www.tevadaptor.com). The major components of Tevadaptor are, 
vial adapter, syringe adapter, connecting set, luer lock adaptor, spike port adapter and 
infusion set. 
 
Figure 2.3: Vial adaptor 
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The vial adaptor (Fig 2.3) is used to mount on the drug vial to allow drug transfer. It is 
available in 20 mm and 28 mm size which fits most of vials in the UK. It also has a 13 
mm convertor ring for smaller sized vials. It contains an active charcoal filter and is 
made up of acrylonitrile-butadiene-styrene (ABS) (www.tevadaptor.com).  
 
Figure 2.4: Syringe adaptor 
The syringe adaptor (Fig 2.4) is used to fit on standard luer lock syringes which can 
then be connected to vial adaptor, connecting set, spike ort adaptor, infusion set or luer 
lock adaptor to convert the Tevadaptor system into a closed system. It is made up of 
polyacetal and polycarbonate material with a stainless steel needle sheathed in septa 
made of polyisoprene (www.tevadaptor.com). 
 
 
Figure 2.5: Connecting set 
Tevadaptor connecting sets (Fig 2.5) fit most of the commonly used IV infusion bags 
and bottles. The connecting set has a port which can be attached to the syringe adaptor 
to transfer drug from the syringe into the bag and the other end could be attached to an 
IV administration set. The spike of the connecting set is made up of ABS and 
polyisoprene, the tubing is non-DEHP (di-ethyl-hexyl phthalate) PVC (polyvinyl 
chloride) material, the luer lock connection is made of clear ABS and the slide clamp is 
made of polypropylene (www.tevadaptor.com). 
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Figure 2.6: Spike port adaptor 
A spike port adaptor is required when IV administration is via a pump set. The spike 
port adaptor (Fig 2.6) also has a dedicated Tevadaptor connection for addition of drugs 
via syringes attached to a Tevadaptor syringe adaptor and it also a spike port which may 
be used to attach any available IV administration set. The spike of the adaptor is made 
of ABS, tubing is of non-DEHP PVC and slide clamp is made of polypropylene 
(www.tevadaptor.com). 
 
 
Figure 2.7:  Luer-lock adaptor 
The luer-lock adaptor (Fig 2.7) is attached to a patient’s IV line to convert standard luer-
lock connection to a closed Tevadaptor connection. It helps in preventing spills and 
unnecessary exposure. It is made up of ABS material (www.tevadaptor.com). 
 
Figure 2.8: Infusion set 180 cm 
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The Tevadaptor infusion set (Fig 2.8) can be used to compound and administer 
cytotoxic infusions. The spike port is used to spike an IV bag and drug can be added to 
the bad via the adaptor. The set can be primed in pharmacy aseptic units and sent to 
wards for administration using the attached infusion set. Its spike is also made of ABS 
and polyisoprene and the tubing is non-DEHP PVC (www.tevadaptor.com). 
2.3 Health and safety procedures 
A health and safety risk assessment of the project was carried out according to 
procedures of Derriford Hospital pharmacy QA department. All handling of cytotoxic 
drugs as well as other hazardous chemicals was assessed according to these procedures 
(DPMU SOP CH9). The operators taking part in the study were required to follow the 
above safety procedures as well as guidelines on the safe handling of chemotherapy 
drugs. The analysis and method validation was undertaken in the Derriford Hospital 
pharmacy QC lab which was fully equipped to handle cytotoxic drug spills. The 
operators were trained in the use of cytotoxic spill kits. The disposal of all drugs as well 
as contaminated material was also performed according to the pharmacy procedures 
which reflect the recommendations outlined in Section 1.6.5.3 (Chapter 1). All 
cytotoxic drug waste that could not be disposed in “Cyto-bins” was neutralized with 
12% bleach solution for a minimum of 24 hours before disposal. All marker drugs were 
COSHH-assessed according to the Derriford Hospital procedures. See Appendix 1 for 
all relevant COSHH assessment forms.  
2.4 Instrumentation 
During the course of this project the major analytical techniques used to quantify the 
marker drugs were high performance liquid chromatography (HPLC) and inductively 
coupled plasma-mass spectroscopy (ICP-MS). The pH of the solutions was measured 
using an Acorn pH 6 meter (Fisher Scientific Ltd) and conductivity of waste-water 
samples was measured using YSI 85 handheld dissolved oxygen/conductivity (Fisher 
Scientific Ltd) meter. A brief description of HPLC and ICP-MS is provided below. 
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2.4.1 High performance liquid chromatography 
High performance liquid chromatography was originally described as high pressure 
liquid chromatography and one of the first instruments was used by Csaba Horvath of 
Yale University (Moffat et al., 2004). The main features of HPLC are: 
 High resolution power 
 High speed of separation 
 Accurate quantitative measurements 
 Repetitive and reproducible analysis using the same column 
 Ability to automate analytical procedure and data handling 
Even though the HPLC systems were available from 1960s it took the pharmaceutical 
industry several years to accept the system and by 1990s the HPLC was the most 
popular analytical method based on the volume of sales (Mendham et al., 2009). The 
major uses of HPLC are: 
 Purification of synthetic and natural products 
 Characterisation of metabolites of various drugs 
 Quantitative assay of active ingredients, impurities and degradation products  
 Therapeutic drug level monitoring 
HPLC is a separation technique that involves injection of a small volume of liquid 
sample into a “column” packed with small particles (3 to 5 μm in diameter) known as 
the “stationary phase”. The sample is then moved along the column with a liquid 
“mobile phase” pumped under pressure through the column. Each component in the 
sample may interact with the stationary phase depending on its solubility in phases 
and/or molecular size, therefore different components of a sample move at different 
speeds through the column resulting in their separation. The separated components exit 
the column at different times and are passed through a detector to measure their 
quantity. The main components of the HPLC system are the pump, injector, column, 
detector and data recorder as represented in Figure 2.9.  
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Figure 2.9: Schematic representation of HPLC system copied from www.waters.com 
The HPLC system used for analysis of MTX, epirubicin and 5-FU consisted of HPLC 
360 autosampler (Kontran Intruments), LDC analytical isocratic constametric 3200 
pump, Jasco 875-UV UV-VIS detector, Jasco 821-FP spectrofluorometer and Chromjet 
integrator (Thermoseparation). 5-FU and gemcitabine were also analysed using a HPLC 
system which consisted of Thermoseparation spectra system AS 3000 autosampler, 
Thermoseparation P2000 isocratic pump and UV 6000LP UV-VIS detector.  Peaks 
were integrated using Chromoquest 2.51.  
2.4.2 Inductively coupled plasma-mass spectrometry  
Inductively coupled plasma-mass spectrometry (ICP-MS) is an analytical technique 
which can be used for determination of most of the elements in the periodic table. It is a 
combination of an ICP source and a mass spectrometer and has found use in various 
scientific disciplines including, environmental sciences, biological sciences, earth 
sciences, medical sciences and chemical sciences. ICP-MS technique was originally 
introduced in 1980s and has major advantages over other elemental determination 
techniques (Mendham et al., 2009, PerkinElmer, 2001); 
 Limit of detection (LOD) obtained by ICP-MS for most elements is equal to or 
better than graphite furnace atomic absorption (GFAA) 
 Both simple and complex matrices can be analysed using ICP-MS with 
minimum interference due to high temperature 
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 LOD of ICP-MS is better than that of inductively coupled plasma optical 
emission spectrometry (ICP-OES) 
 It can differentiate between isotopes of an element 
The basic principle of ICP-MS is that the sample (generally in liquid form) is 
introduced into the base of plasma as an aerosol. As the plasma is heated up to a 
temperature of 6000-7000 K the sample is ionized and is introduced to a mass 
spectrometer for detection. 
The major components of the ICP-MS system (Fig 2.10) are as follows: 
 Samples introduction system 
 ICP torch 
 Interface 
 Vacuum system 
 Lens 
 Mass spectrometer (Quadrupole) 
 Detector 
 Data handling and System controller 
 
Figure 2.10: Schematic representation of ICP-MS reproduced from 
http://www.webapps.cee.vt.edu/ewr/environmental/teach/smprimer/icpms/icpms.htm 
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Table 2.1: Operational parameters of the Thermoelemental ICP-MS (X-Series 2) 
Operational parameters of ICP-MS 
Forward Power 1.4kW 
Coolant gas flow 15L min-1 
Auxiliary gas flow 0.7L min-1 
Nebuliser gas flow 0.8L min-1 
Nebuliser type V-groove 
Spray chamber type Sturman-masters 
Dwell time  10ms 
Sweeps 50 
Collision cell gas 7%  hydrogen in helium 
Flow rate 3.5 mL min-1 
The platinum-based drugs (cisplatin, carboplatin and oxaliplatin) were analysed for the 
platinum content using an XSERIES 2 ICP-MS supplied by Thermo Scientific. It 
consists of “Protective Ion Extraction and Infinity II ion optics”, based upon a hexapole 
design with chicane ion deflector, and a peltier-cooled chamber.  Samples are 
introduced via a split flow turbo pump and high performance glass concentric nebulizer. 
The instrument is controlled by Plasma lab software, version 2.5.22.321. A summary of 
operational parameters of ICP-MS used during this project is provided in Table 2.1. The 
isotope used for the calculation of platinum concentration was 195Pt. 
2.4.3 Calibration 
Calibration of the HPLC system was performed by system suitability runs. A minimum 
of 5 injections of the same standard were made at the start of each HPLC session. The 
system was deemed suitable for sample analysis when a relative standard deviation 
(RSD) of ≤ 2% was obtained for the five consecutive injections. Each HPLC sample 
was injected twice (100 μL) and an external standard, with bracketed injections, was 
used.  
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Calibration of the ICP-MS was performed at the start of each session. The instrument 
was calibrated externally using a blank and five standards (up to 50 μg L-1) prepared by 
serial dilution of a 1 mg mL-1 platinum plasma emission standard in 0.1 M HCl, and 
internally by the addition of 50 μg L-1 of 193Ir to all samples and standards. A standard 
was analysed as a check after every ten samples and the five samples either side of any 
check that deviated by more than 10% of its true value were reanalysed. 
2.4.4 Precision  
Inter-day and intra-day precision was measured using the standards runs used during 
recovery validations for each drug. Relative standard deviation (RSD) was used as a 
measure of precision and acceptance was set at 5% RSD for intra-day precision and 
assay calibrations, 10% RSD for inter-day runs and due to the nature of the study a 20% 
RSD was accepted for recovery validations. A minimum of six sample runs were used 
to calculate inter and intra-day precision values. The limits of precision were set using 
the previously reported levels in a review article by Turci et al. (2003). 
2.4.5 Sensitivity 
In this study it was highly important to have methods with sufficient sensitivity to be 
able to estimate accurately the levels of contamination by the marker drugs. For the 
analytical methods used during this study the acceptable limit of detection (LOD) was 
three times the noise signal and limit of quantification (LOQ) was ten times the noise 
signal (ICH, 1996). The background noise level in the analytical methods was 
determined using multiple injections of blank samples. The LOD was then calculated 
using multiple measurements of the lowest concentration that produced a signal and 
LOQ was calculated by multiple measurements of the lowest standard concentration. 
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Chapter 3:  Tevadaptor isolator study 
3.1 Introduction 
Chemotherapy is widely used in the treatment of most forms of malignant disease and is 
frequently combined with surgical and radiotherapy modalities. It is now proven beyond 
doubt that many anticancer drugs present a risk to occupational health. The evidence of 
occupational risks of handling anti-cancer drugs and the steps taken to reduce such risks 
are discussed in detail in Chapter 1. One such measure is to reduce contamination of 
work surfaces by anti-cancer drugs with the use of CSTDs while compounding anti-
cancer drug infusions in pharmacy units. The present study evaluates the effectiveness 
of Tevadaptor in conjunction with pharmaceutical isolators in reducing surface 
contamination under standard working conditions in a specialist UK hospital pharmacy 
unit. Tevadaptor is a closed system drug transfer device used for reconstitution of 
hazardous drugs as well as for drug administration. See Chapter 2 Section 2.2.4 for 
detailed description of Tevadaptor and its components. If used according to the 
manufacturer’s instructions Tevadaptor device prevents overpressure in vials and 
eliminates the formation of aerosols. It is also a needle free system providing an added 
benefit of eliminating needle stick injuries to pharmacy and nursing staff.  
MTX, epirubicin, 5-FU, carboplatin, cisplatin and oxaliplatin were selected as marker 
drugs for this study on the basis of their frequency of usage in the pharmacy 
reconstitution unit. The marker drugs also represented different classes of anticancer 
drugs such as alkylating agents (cisplatin, carboplatin and oxaliplatin), antimetabolites 
(methotrexate and 5-FU) and antitumour antibiotics (epirubicin).  
This was a comparative study conducted over a period of three weeks, where 
contamination caused by current working practices was compared against the 
contamination caused while preparing cytotoxic IV infusions with the use of Tevadaptor 
(see Figure 3.1 for a flow diagram of the study design). All marker drug infusions were 
prepared in a pharmaceutical isolator reserved for this study. Throughout the study, the 
standard isolator cleaning procedure was followed: at the start of each week interior 
surfaces of the isolator were sprayed with Klercide B and left for 5 minutes. Surfaces 
were then wiped with low lint wipe and then sprayed with 70% denatured ethanol. After 
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every work-session (1.5 hours) the isolator was cleaned with sterile neutral detergent, 
wiped with low lint wipe and then sprayed with 70% denatured ethanol. During the 
study two sessions of work were carried out each day.  The study was conducted by 
taking wipe samples from pre-defined areas in the isolator as well as the outer surface of 
prepared IV infusion bags and syringes. The wipe samples were taken both at the start 
as well as at the end of working session prior to the cleaning of the isolator according to 
the above procedure. The drugs were than eluted and analysed using validated methods 
and the results for the baseline and intervention period were then compared to evaluate 
the effectiveness of the Tevadaptor device in reducing contamination caused by the 
anticancer drugs. The results of this study also provided a measure of effectiveness of 
standard cleaning regimens used in pharmacy manufacturing unit.    
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Figure 3.1: Flow diagram of the Tevadaptor isolator study design. 
3.2 Methods 
3.2.1 Study setting  
The study was conducted at Derriford Hospital Pharmacy Manufacturing Unit (DPMU). 
DPMU has two purpose-built aseptic suites with five pharmaceutical isolators dedicated 
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to chemotherapy preparation. At the time of the study MTX, epirubicin and 5-FU were 
manufactured as pre-filled syringes in batches ranging from 4 to 50 units per batch 
under “specials” license governed by the MHRA. On the contrary cisplatin, carboplatin 
and oxaliplatin were prepared as patient specific infusions under Section 10 of 
Medicines Act 1968 (Applebe and Wingfield, 1997).  
3.2.2 Pharmaceutical isolator used for the study 
 A two gloves rigid negative pressure isolator (Envair CDC-‘E’ 2GD) (Fig 3.2) was 
used for this study. The down-flow HEPA filter provides full laminar air flow over the 
work zone which is maintained at EU GMP Grade A and the suite provides a 
background environment classed as EU GMP Grade C. The air leaving the work zone is 
returned to the down-flow fan system via main HEPA filters located underneath the 
work tray and residual air is exhausted externally via an additional HEPA filter (for 
detailed design specifications of pharmaceutical isolators see Chapter 1 Section 1.6.4.) 
The products are introduced or removed from the isolator through air-flushed 
interlocking transfer chambers on each side of the isolator. During the study period this 
isolator was reserved for the preparation of infusions of marker drugs. 
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Figure 3.2: Photograph of the pharmaceutical isolator used for the study and areas 
sampled. 
3.2.3 Method development 
The marker drugs selected for this study were MTX, 5-FU, epirubicin, cisplatin, 
carboplatin and oxaliplatin. As this was a comparative study highly sensitive and 
selective methods of analysis for the marker drugs were required. The final drug assays 
were based on published methods and were re-validated in-house.  
3.2.3.1 Wipe material 
A variety of wipe tissues are available on the market but to be able to use them for such 
studies material used should be sterile, low linting, free from contamination, should be 
uniform in size and weight, stable to desorbing solution and able to fit in a centrifuge 
Transfer hatch door Isolator sleeves Isolator surface 
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tube. Commercially available sterile wipes are either alcohol impregnated or dry. Table 
3.1 provides a description of the wipes considered for the study. 
Stericlean Prep Pads were the smallest of the wipes which were suitable for such a study 
as they were not in a folded state in centrifuge tubes during desorption phase. As part of 
the initial suitability study these pads were spiked with 1, 2, 5 and 10 ng of platinum (in 
terms of cisplatin, carboplatin and oxaliplatin). Each wipe sample was desorbed using 
10 mL 1% HCl and centrifuged for 30 minutes at 500 g followed by sonication for 30 
minutes. A 5 mL supernatant was then analysed by ICP-MS. However, alcohol from the 
prep-pads produced interference in the results hence impregnated wipes were not 
suitable for the assay of Pt-based drugs.  
Table 3.1: Description of the wipes considered for the study 
Brand Dimensions Material Manufacturer 
Alcowipe (Sterets) 18.5 cm×14 cm Rayon. 70% IPA Seton Healthcare 
Stericlean Prep Pad 3.2 cm×6.7 cm Rayon/ 
Polypropylene 
mix. 70% IPA 
Helapet 
Stericlean Dry 
Wipes 
23 cm×23 cm polyester cellulose 
non-woven 
Helapet 
Klerwipe 18 cm×20.5 cm Cellulose Polyester 
blend 
Shield Medicare 
As the wipes needed for the study had to be sterile the choice of dry wipes was limited. 
There were just two commercially sterile dry wipes available (Stericlean Dry Wipe and 
Klerwipe). To test the above wipes for their suitability in the platinum assay, they were 
validated against cisplatin and carboplatin. Stock solutions of both drugs were prepared 
by diluting them with “sterile water for irrigation”. The stericlean tissues were spiked 
with 0.4 mL of the stock solutions and desorbed with 40 mL of 1% HCl whereas, 
Klerwipe tissues were spiked with 0.3 mL of stock solutions desorbed with 30 mL of 
1% HCl.  The samples were stored in 50 mL centrifuge tubes and centrifuged for 30 
minutes at 500g followed by sonication for 30 minutes. The final concentrations were 
0.1, 0.25 and 0.5 ng mL-1. A 5 mL supernatant from each solution was analysed using 
ICP-MS. Both dry wipes showed similar recovery profiles (see Table 3.2) and did not 
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show any interference with ICP-MS. However, due to their larger size and extra volume 
required to wet them the Stericlean Dry Wipes were not suitable. The final wipe tissue 
used for the study were Klerwipes as they were individually wrapped and were also 
smaller in size making them easier to fit in the centrifuge tubes. On further validation 
Klerwipes did not show any interference with HPLC methods used for epirubicin, MTX 
and 5-FU analysis.  
Table 3.2: Percent recovery and range (errors represent one standard deviation about the 
mean) of desorbed cisplatin and carboplatin (in terms of platinum) from dry wipes 
(Klerwipe and Stericlean) spiked with known amounts of cisplatin and carboplatin 
solutions 
 Cisplatin   Carboplatin   
Concentration (ng 
mL-1) 
0.1  0.25  0.5  0.1 0.25 0.5 
Klerwipe % 
recovery 
99±10 76±8 78.2±8 88.5±3 82.6±7 81.7±6 
Stericlean % 
recovery 
67.5±11 80.4±2 82.5±17 94.5±7 92.2±10 92.7±3 
3.2.3.2 Wetting agent  
As dry tissues were used for sampling, a wetting agent was required to assist in picking 
up maximum contamination from test surfaces. Choice of agents was limited to sterile 
liquids as non-sterile products cannot be introduced into the aseptic environment of the 
pharmaceutical isolator and thus, water for injections (WFI) was the logical choice. All 
the marker drugs used in the study were supplied as solutions for injection and all 
contained WFI as an excipient, therefore it was compatible with all marker drugs and, as 
WFI is used in reconstitution of various other drugs it is acceptable to be used in the 
pharmaceutical isolator. Furthermore, it is unlikely to introduce any contamination to 
the analytical system. On further validation WFI showed sufficient ability to recover 
marker drugs from various test surfaces (see Table 3.3 and 3.4).  
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3.2.3.3 Sampling technique 
Studies to evaluate work surface contamination by anticancer drugs tend to use either 
wipe sampling or immersion technique. Wipe sampling involves wiping the surface of 
interest with a suitable material and then removing the drug from that material into a 
desorbing solution, whereas in the immersion technique contaminated materials such as 
gloves are immersed in the desorbing solution. Desorption of the drug into the solution 
is usually achieved by vortexing, shaking and centrifugation. For the purposes of this 
study, wipe sampling techniques followed by centrifugation and sonication were used 
for the isolator, IV bag and syringe surfaces, whereas the immersion technique was used 
for operator gloves. 
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Table 3.3: Validation parameters for the analytical methods of MTX, epirubicin and 5-
FU. LOD, LOQ, mean recovery, range (approximate) and precision of recovery and 
analytical methods are shown (errors represent one standard deviation about the mean). 
Recovery of marker drugs from test surfaces was established using Klerwipe tissues 
 MTX Epirubicin 5-FU 
Limit of detection (LOD, ng mL-1) 5 0.3 5 
Limit of quantification (LOQ, ng mL-1) 10 1 10 
Average Recovery 
(%) (n = 3) 
Wipe tissue 80.4±4 34.6±2 94.3±2 
IV Bag 80.6±5 37.2±2 90.4±4 
Syringe 77.6±15 40.4±3 91.8±2 
Isolator surface 82.8±5 19.4±5 90.2±2 
 Gloves - 118±5 108±2 
 Chemo-Mats - 48.3±12 74±9 
Precision of recovery (RSD%) 
(n = 3) 
Wipe tissue 2.7 5.3 1.6 
IV Bag 5.0 5.5 4.1 
Syringe 17.1 7.3 2.2 
Isolator surface 5.7 16.6 1.7 
 Gloves - 3.6 1.7 
 Chemo-mats - 20.5 10.8 
Precision of analysis (RSD%) 
*(n = 6) 
Inter day 3.6 3.22 3.79 
Intraday 0.5 1.62 1.85 
  * Precision of MTX was measured at 100ng mL-1, EPI at 20ng mL-1 and 5-FU at 80ng mL-1.  
 -  Not performed 
Number of samples used to validate recovery was three and number of samples used to calculate 
precision of analysis was six 
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Table 3.4: Validation parameters for the analytical method of platinum.LOD, LOQ, 
mean recovery and range (approximate) and precision of recovery and analytical 
methods are shown (errors represent one standard deviation about the mean). Recovery 
of marker drugs from test surfaces was established using Klerwipe tissues 
 Cisplatin Carboplatin Oxaliplatin 
Limit of detection*(LOD, ng mL-1) 0.01 0.01 0.01 
Limit of quantification*(LOQ, ng mL-1) 0.1 0.1 0.1 
Average Recovery 
(%) (n = 3) 
Wipe tissue 83.5±3 95.6±11 80.6±7 
IV Bag 68.3±5 77.4±5 90.8±12 
Syringe 106.1±5 93.8±3 102.4±8 
Isolator 
surface 
103.3±8 92.7±8 86.4±12 
 Gloves 103.6±7 99.5±11 94.5±10 
 Chemo mats 98±2 96.3±4 93.5±15 
Precision of recovery 
(RSD%) (n = 3)   
Wipe tissue 6.1 11.6 2.9 
IV Bag 3.6 4.6 15.9 
Syringe 1.6 2.1 4.7 
Isolator 
surface 
3.4 8.5 14.8 
 Gloves 5.7 12.1 9.9 
 Chemo mats 1.4 3.8 17.3 
Precision of analysis 
(RSD%) (n = 6) ** 
Interday 9.6 9.6 9.6 
Intraday 1.8 1.8 1.8 
*LOD/LOQ for cisplatin, carboplatin and oxaliplatin is in terms of platinum metal. 
  ** Precision of platinum was measured at 0.5ng mL-1 
Number of samples used to validate recovery was three and number of samples used to calculate 
precision of analysis was six 
3.2.3.4 Collection vessel 
Wipe samples were centrifuged at 500 g and ultrasonicated for 30 minutes, respectively 
to obtain maximum desorption. The times for centrifugation and sonication were based 
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on previously validated data by Roberts (2008). Thus the samples were required to be 
collected in centrifuge tubes. These tubes were also stored at a temperature of -22oC, 
hence they were required to withstand such temperatures. The material of centrifuge 
tubes should also be chemically inert to prevent drug binding to its surface and also to 
prevent contaminating the samples. Commonly available centrifuge tubes are made of 
polypropylene which is compatible with the marker drugs and can be stored at a 
temperature of -22oC, hence they were used as collection vessels. The choice of 
polypropylene tubes was also beneficial as epirubicin may bind to glass or polyethylene 
materials (Allwood et al., 2002). The selected centrifuge tubes were available in 15 mL 
or 50 mL size but the selected wipe tissue was too big to fit in 15 mL tubes hence 50 
mL polypropylene tubes were used as collection vessel. 
Gloves and chemo-resistant mats used by pharmacy operators during preparation of 
chemotherapy infusions were also collected during the study. However, they were too 
big to fit in 50 mL centrifuge tubes therefore 1 L high density polyethylene (HDPE) 
bottles were used while desorbing drug off the used gloves and mats.    
3.2.3.5 Desorbing solution 
This is the solution required to desorb marker drugs from the wipe samples for further 
analysis. This solution should be compatible with marker drugs, not interfere with 
analysis and be able to remove the drug from the tissue. Brouwers et al. (2007) 
evaluated 1% HNO3, 5% HNO3 and 1% HCl as desorbing solutions for platinum-based 
drugs and concluded that 1% HCl was the most effective. This was further validated for 
this study as desorbing solution not only for platinum but also for other marker drugs 
(MTX, 5-FU and epirubicin) used in the study. The wipe tissues and test surfaces were 
spiked with known quantities of marker drugs and desorbed with 30 mL 1% HCl (see 
Tables 3.3 and 3.4 for recovery from various test surfaces). The volume of 30 mL was 
selected as this was the minimum volume visually observed to effectively wet the wipe 
tissue and a volume of 100 mL was used to desorb drugs from gloves and mats.   
 76 
 
3.2.4 Analytical methods for marker drugs 
3.2.4.1 Analytical method for MTX 
HPLC-UV is one of the most common methods used to analyse MTX in previously 
reported studies. Floridia et al. (1999) used HPLC-UV coupled with solid phase 
extraction (SPE) to measure surface contamination with MTX in hospital departments. 
However, the above method achieved a LOQ of 50 ng mL-1. A method using HPLC-UV 
was developed to assay MTX. In this method Techsphere ODS 5 μm, 250×4.6 μm 
column was used; the mobile phase was mixture of citric acid and phosphate buffer (1 
mmol) and acetonitrile (10%) and methanol (5%). The detection wavelength was set at 
210 nm and the limit of quantification with this method was 1 μg mL-1 which was not 
sufficient for this study.  
The final method used to analyse MTX in the present project was based on that 
described by Meras et al. (2005). They determined MTX in urine using fluorimetric 
detection by oxidising MTX samples with potassium permanganate for 35 minutes 
which was then neutralized with hydrogen peroxide. The separation was achieved on a 
150 × 4.6 mm stainless steel column packed with C18 (5 µm particle size) using a 
mobile phase of Tris-NaCl buffer (pH 6.8) at a flow rate of 1 mL min-1. The detection 
was by fluorometry, excitation wavelength (λex) 280 nm and emission wavelength (λem) 
was 444 nm. In this method potassium permanganate was used as the oxidising agent 
and hydrogen peroxide to quench the oxidation reaction. The resulting derivative 2,4-
diaminopteridine-6-carboxylic acid is fluorescent and is detected using a 
spectrofluorometer.  
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Figure 3.3: Oxidation reaction of MTX [diagram as reproduced from Roberts (2008)]. 
The final reaction (Fig 3.3) used for the assay was 0.4 mL MTX solution, 0.8 mL of 
potassium permanganate (0.01 M) in presence of acetate buffer (acetic acid + sodium 
acetate adjusted pH to 5.0) was left for 45 minutes at room temperature, and to the 
above mixture 0.24 mL of 30% hydrogen peroxide was added and then diluted with 2 
mL of mobile phase. This mixture was centrifuged for 10 minutes at 500 g and 100 μl 
supernatant liquid was injected in the HPLC system. In the case of recovered samples 
1% HCl was neutralized with 0.1 mL 1 M sodium hydroxide.  
MTX was detected using a Columbus 150 × 4.6 mm stainless steel column packed with 
C18 (5 µm particle size). The mobile phase was phosphate buffer (disodium hydrogen 
phosphate; 0.01 M, pH 6.2 adjusted with orthophosphoric acid) with 5% acetonitrile 
(v/v). Excitation was carried out at 380 nm, and emission at 458 nm using a 
fluorescence detector. MTX was eluted at a retention time of 2.43 minutes. The final 
injection volume was 100 μl.  The autosampler injection needle was flushed with          
2 × 500 µL of acetonitrile:water (50:50) v/v after each injection. Each sample run was 
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followed by flushing of column with acetonitrile injection. Limits of detection and 
quantification with this method were set at 5 ng mL-1 and 10 ng mL-1, respectively. An 
example of an HPLC chromatogram is provided in Appendix 2.  
 3.2.4.2 Analytical method for epirubicin 
Epirubicin has an inherent fluorescent property and this property is utilized to detect and 
quantify it in pharmacokinetic studies. The assay for epirubicin in this study was also 
based on its detection using HPLC-FL (fluorescence detection). Camaggi et al. (1988) 
detected epirubicin and doxorubicin in biological fluids using HPLC-FL. The separation 
was achieved on a cyanopropyl column (250 × 4.6 mm, 5 µm particle size) using a 
mobile phase of phosphate buffer (pH 4.3) with acetonitrile 24.4% (v/v) at a flow rate of 
1.5 mL min-1. The detection was by fluorescence detection (λex 470 nm and λem 580 
nm). Rudolphi et al. (1995) also utilized the natural fluorescence of epirubicin to detect 
it in biological samples. The method used coupled C4- alky-diol pre-column (20×4 mm, 
25 μm particle size) and LiChrospher RP select B analytical column (250 × 4 mm, 5 µm 
particle size) for separation. The mobile phase was 0.1% triethylamine (pH 2.0) with 
30% acetonitrile at a flow rate of 1 mL min-1. The detection was by fluorescence 
detector (λex 445 nm and λem 560 nm). The LOQ achieved from above methods was 0.5 
ng mL-1.  
Epirubicin in this study was analysed using a Luna CN (5 µm particle size) 250 × 4.6 
mm stainless steel column. The mobile phase was phosphate buffer (sodium dihydrogen 
orthophosphate; 0.05 M, pH 4.0, adjusted with orthophosphoric acid) with 35% 
acetonitrile (v/v). Due to a global shortage in supplies of acetonitrile at the time of 
analysis, reduced amounts of acetonitrile were trialled but it resulted in low signal 
strength. Excitation was carried out at either 254 or 480 nm and emission at 560 nm 
using a fluorescence detector. However, excitation at 254 nm resulted in high baseline 
noise therefore 480 nm was used as excitation wavelength in the final method and 
epirubicin eluted at a retention time of 4.7 minutes. The autosampler injection needle 
was flushed with 2 × 500 µL acetonitrile: water (50:50) v/v after each injection. The 
injection volume was 100 μL. On recovery from the wipe samples another peak eluted 
at 3.6 minutes, which was attributed to the presence of HCl from the desorbing solution. 
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Limits of detection and quantification were 0.3 ng mL-1 and 1 ng mL-1, respectively. An 
example of HPLC chromatogram is provided in Appendix 2.  
3.2.4.3 Analytical method for 5-FU 
5-FU is generally detected by HPLC-UV method in biological fluids. The method used 
was adopted from a published method used to determine 5-FU in human plasma. 
Compagnan et al. (1996) describe a method for detection of 5-FU in human plasma 
using cation-exchange resin column (300×7.8 mm). The mobile phase was 0.005 M 
sulphuric acid and detection was at 265 nm. However, the LOQ was 25 ng mL-1. 
Another method by Ciccolini et al. (2004) to detect 5-FU in plasma was more sensitive 
with a LOQ of 5 ng mL-1. The separation was achieved on a RP-18 X-Terra column (25 
cm, 5 μm particle size). The mobile phase was phosphate buffer (0.05 M) at                
0.5 mL min-1 flow rate and detection was at 254 nm.    
5-FU in this study was analysed using Luna C18 (5μm particle size) 250×4.6 mm 
stainless steel column. The mobile phase was 2% methanol with water. Increase in 
organic phase concentration resulted in flattening of peaks. Detection wavelength was 
set at 266 nm and 5-FU elutes at 6.2 minutes. The autosampler injection needle was 
flushed with 2 × 500 µL methanol:water (50:50) v/v after each injection of 100 μL. 
During analyses the baseline tended to shift upwards which may be due to residue in the 
column, hence after each run the column was washed with a methanol injection. Limits 
of detection and quantification were 5 ng mL-1 and 10 ng mL-1, respectively. An 
example of an HPLC chromatogram is provided in Appendix 2. 
3.2.4.4 Analytical method for platinum-based drugs (cisplatin, carboplatin and 
oxaliplatin) 
Researchers have used various analytical techniques to detect platinum-based drugs 
(Raghavan et al., 2000; Bettinelli, 2005; Le´Sniewska et al., 2006; Brouwers et al., 
2007; Bosch et al., 2008). These methods include UV-VIS spectrophotometry, 
phosphorescence, atomic absorption spectrometry (AAS), HPLC, voltammetry and 
ICP-MS. Raghavan et al. (2000) used HPLC-UV to detect cisplatin in water samples in 
the range of 20-200 ng mL-1. Although cisplatin does not have a chromophore it was 
derivatized using diethyldithiocarbamate forming a complex which was detected at 340 
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nm. The HPLC method is limited in scope as it can only detect one platinum-based drug 
at a time. Therefore in environmental monitoring studies methods measuring total 
platinum are preferred which can provide contamination levels of all three combined 
platinum-based drugs. Schmaus et al. (2002) used voltammetry to detect total platinum 
in wipe samples taken from surfaces in a pharmacy manufacturing unit. The samples 
were dissolved in 0.5 N HCl and digested with UV radiation and then analysed using 
voltammetry. The LOQ was 0.04 ng per sample. Brouwers et al. (2007) used ICP-MS to 
detect platinum levels in surface wipe samples taken in hospital pharmacies. Platinum 
was desorbed from wipe samples using 1% HCl before analysis.  
The method for detection of platinum in the present study was based on the method by 
Brouwers et al. (2007) and platinum was detected using ICP-MS. Spiking solutions of 
10, 20, 50 and 100 ng mL-1 of the platinum-based drugs  were prepared in terms of 
platinum content. The wipe tissue was then spiked with 0.3 ml of the above solutions in 
duplicate. Thirty mL of 1% HCl was added to the tissue samples and platinum content 
from the spiked wipes was desorbed by centrifugation at 500 g and ultrasonication for 
30 minutes, respectively, resulting in final concentrations of 0.1, 0.2, 0.5 and 1 ng mL-1. 
Supernatant (5 mL) from each sample was then analysed using ICP-MS. Blanks were 
also prepared by adding 30 mL, 1% HCl to unspiked tissues and subjecting them to 
centrifugation and ultrasonication. Limits of detection and quantification (in terms of 
total platinum) were 0.01 ng mL-1 and 0.1 ng mL-1, respectively.  
3.2.5 Method validation 
The methods of analysis of marker drugs used in this study were validated for various 
parameters including, precisions, sensitivity, specificity and recovery of drugs from test 
surfaces. The attained experimental values for each parameter are presented in Tables 
3.3 and 3.4. The above validation parameters compare well to the parameters described 
for method validation by Minoia and Turci (2012). 
3.2.5.1 Linearity of response 
A six point calibration line was plotted for MTX, EPI and 5-FU and regression analysis 
used to determine the linearity of the response. For the platinum assay a calibration line 
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was plotted at the start of each session and response was linear between a concentration 
range of 0 to 1000 ng mL-1. 
 
Figure 3.4: Calibration line of MTX showing its linear range and regression coefficient 
(R2) between 10 ng mL-1 to 1000 ng mL-1 as validated using the HPLC assay for the 
study. Each sample point represents an average of six readings and the percent error (as 
relative standard deviation) is less than 2%. 
 
 
Figure 3.5: Calibration line of epirubicin showing its linear range and regression 
coefficient (R2) between 5 ng mL-1 to 50 ng mL-1 as validated using the HPLC assay for 
the study. Each sample point represents an average of six readings and the percent error 
(as relative standard deviation) is less than 2%.  
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Figure 3.6: Calibration line of 5-FU showing its linear range and regression coefficient 
(R2) between 10 ng mL-1 to 100 ng mL-1 as validated using the HPLC assay for the 
study. Each sample point represents an average of six readings and the percent error (as 
relative standard deviation) is less than 2%.  
3.2.5.2 Recovery validation 
To validate drug recovery from surfaces selected for the study, test surfaces were spiked 
with known concentrations of drug. The test surfaces were selected based on their 
similarity to sampling surface materials or in the case of gloves and mats the same 
material used in pharmaceutical isolators was chosen. The surfaces selected were the 
steel of a class II biological safety cabinet, PVC and polyolefin IV infusions bags (100 
mL), gloves, syringes and chemo mats. For the purpose of validation 20 ml BD 
Plastipak syringes were cut into small flat pieces with metal scissors. Klerwipe tissues 
were also evaluated to ensure that acceptable quantities of spiked drug could be 
recovered from them and also that the tissues themselves did not contribute to sample 
signals.  
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Figure 3.7: Motion for wiping test surfaces. 
The steel base of class II BSC placed in Derriford Pharmacy QC laboratory was selected 
as a surrogate for steel surfaces of the isolator. The samples of the isolator gloves and 
chemo preparation mats used in the preparation of anti-cancer IV infusions were 
obtained and tested for drug recovery. Prior to and in-between validation runs the BSC 
surfaces were cleaned with hypochlorite solution followed by detergent, water and IMS 
to remove any traces of anti-cancer drugs and prevent any cross-contamination. 
Each test surface was spiked with a known amount of each marker drug. The amounts 
used on BSC surface, IV bag surface and syringe surfaces were 3000 ng  MTX, 600 ng  
epirubicin, 2400 ng  5-FU and 15 ng of the each individual platinum-based drug (in 
terms of platinum). The amounts of marker drugs used to spike gloves and chemo-mats 
were higher as the volume of desorbing solution was 100 mL as compared to 30 mL in 
case of surface samples. The gloves and chemo preparation mats were spiked with      
10 μg of MTX, 2 μg of epirubicin, 8 μg of 5-FU and 50 ng of the each platinum-based 
drug (in terms of platinum). Each test surface, gloves and chemo-mats were spiked in 
triplicate by dropping a known volume (0.1 mL) of the drug solutions using a pipette 
and then the surfaces were allowed to dry visually. The marker drugs were recovered by 
wiping them with tissues (Klerwipe) saturated with 5 mL WFI and desorbed with        
30 mL of 1% HCl after centrifugation and sonication as described previously in Section 
3.2.3.4. The flat surfaces including bags were wiped in the motion as illustrated in 
Figure 3.7 and syringe surfaces were wiped in a spiral motion. The glove samples were 
immersed in 100 mL of 1% HCl in 1 L HDPE bottles and shaken manually for two 
minutes. The chemo-mats, however, were too big to fit in the 1 L bottles; therefore, they 
were cut into 16 square pieces and placed in four separate bottles (four pieces in each 
bottle) and desorbed with 100 mL of 1% HCl by shaking manually for two minutes. The 
expected concentration of each marker drug in the supernatant (assuming 100% drug 
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recovery) was 100 ng mL-1 MTX, 20 ng mL-1  epirubicin, 80 ng mL-1  5-FU and          
0.5 ng mL-1 of the each platinum-based drug (in terms of platinum).An aliquot from 
each sample was then analysed in duplicate by HPLC or scanned in triplicate by      
ICP-MS. The validation results are presented in Table 3.3 and 3.4. Recovery of the 
marker drugs from the tested surfaces was sufficiently high (> 70%) and was also 
consistent with precision of recovery being < 15% RSD.  However, the recovery of 
epirubicin was consistently low across surfaces in the range of 19.4% (isolator surface) 
to 40.4% (syringe surface), except for the recovery of epirubicin from the glove material 
which was 118%. The difference in recovery of epirubicin from work surfaces was 
attributed to its propensity to adsorb on to selective surfaces (Allwood et al., 2002).    
3.2.5.3 Stability 
The samples were stored at -22oC in a temperature monitored freezer. During the 
storage of samples no temperature deviations were reported. All marker drugs were 
expected to be stable at this temperature. Standard solutions used during analysis were 
diluted in 1% HCl and stability was established for a minimum of 24 hours at room 
temperature. Assay development and stability studies (Li et al., 2007, Sewell et al., 
2003, Sinha et al., 2009) performed on the marker drugs for clinical usage also confirm 
the stability of the drugs. The samples for HPLC methods were desorbed and analysed 
within 24 hours. Although the samples for ICP-MS were desorbed and stored at 2 to 
8oC for a maximum of three days prior to analysis, the stability of platinum-based drugs 
in HCl was established for a minimum of 3 weeks by Brouwers et al. (2007).    
3.2.5.4 Effects of other marker drugs on analyte recovery 
This study was required to rule out the interference in the analysis of marker drugs by 
any other drugs. To perform this validation three Klerwipe tissues were spiked with a 
standard concentration of a marker drug individually and then those samples were 
spiked with three different concentrations of other marker drugs in the study with 
concentrations of 50, 100 and 200 ng mL-1 per drug.  
The wipes were then subjected to recovery as per Section 3.2.3.4 and samples analysed 
for each drug as per developed methods. None of the drugs showed any effect arising 
from the presence of other drugs (Fig 3.8, 3.9, 3.10, 3.11) except 5-FU. In the case of  
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5-FU there was a consistent increase in signal strength with all samples showing a 
percentage recovery of 112.9% on average. However, no data correction factor was 
applied according to the procedures of Derriford pharmacy QC laboratory for samples at 
low concentrations (< μg L-1) a variation of ± 15% in the results from the expected is 
considered acceptable (DPMU, SOP, QCG 7).   
 
Figure 3.8: Effect of the presence and concentration of other drugs on recovery of 100 
ng mL-1 of MTX. RSD is the overall relative standard deviation of all results (each 
sample point represents average of three values). Error bars represent ±7% error about 
the mean value.  
 
Figure 3.9: Effect of the presence and concentration of other drugs on recovery of 20 ng 
mL-1 of epirubicin. RSD is the overall relative standard deviation of all results (each 
sample point represents average of three values). Error bars represent ±5% error about 
the mean value.  
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Figure 3.10: Effect of the presence and concentration of other drugs on recovery of 50 
ng mL-1 of 5-FU. RSD is the overall relative standard deviation of all results (each 
sample point represents average of three values). Error bars represent ±4% error about 
the mean value.  
 
Figure 3.11: Effect of the presence and concentration of other drugs on recovery of 0.5 
ng mL-1 of platinum in terms of platinum based drugs. RSD is the overall relative 
standard deviation of all results per drug (each sample point represents average of three 
values). Error bars represent ±8% error about the mean value.  
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3.2.5.5 Pilot study into contamination levels in isolator samples 
To ensure the adequacy of analytical techniques developed for the study four test 
samples were taken from the isolator floor surface after a session of platinum-based 
drugs and an epirubicin batch, respectively. The contamination levels of platinum were 
found to be in the range of 0.0175 to 4.84 ng cm-2. The results from epirubicin samples 
were in the range of 0.2 to 3.1 ng cm-2.  
3.2.5.6 Microbiological validation of Tevadaptor   
According to the manufacturer’s claim the Tevadaptor device is compatible with all 
chemotherapy drugs except amsacrine and busulfan and is also capable of maintaining 
sterility in the syringes and IV infusion bags compounded and stored according to the 
storage requirements for the particular drug with the device in-situ. However, according 
to the licensing requirements of the Derriford pharmacy aseptic manufacturing unit, 
Tevadaptor was required to be validated to maintain sterility in the syringes and IV 
infusions bags prepared using the device for the period of drug shelf lives (maximum of 
84 days for 5-FU and epirubicin syringes and 7 days for platinum-based drug infusions). 
The validation was carried out according to the procedures of Derriford Hospital 
pharmacy QC department. See Appendix 3 for the details of the validation process. The 
results showed that Tevadaptor was able to maintain sterility in the syringes and IV 
infusion bags for the period of maximum shelf life assigned to marker drugs.     
3.2.6 Sampling method and schedule 
The sampling method and schedule was clearly defined and validated prior to the 
commencement of the study. The areas to be sampled were the insides of both hatch 
doors, left, centre and right areas from isolator floor and both left and right sleeve (Fig 
3.3). Each location was marked with sterile ink marker and numbered one to seven 
starting from right hatch door to left hatch door in the order of sampling. The area 
wiped from each location was approximately 400 cm2. Each set of samples was taken at 
the start of the work session (when isolator surfaces were presumed to be clean) and 
then again just before the isolator was cleaned at the end of work session in the defined 
order using a fresh tissue for each surface. Wipe samples were also taken from the 
surface of prepared IV bags and syringes using one fresh tissue for each IV bag and one 
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tissue to wipe four syringes. All prepared IV bags were wiped and a minimum of 10% 
of syringes from each batch were wiped. The areas were wiped using a sterile dry wipe 
(Klerwipe, Shield Medicare, 18×20.5 cm2) saturated with 10 mL water for injection. 
The wipe samples were taken in accordance with defined and validated protocols, 
giving detailed instructions on the frequency and direction of wipe-sampling and 
indicating when wipes should be turned to expose a fresh surface. The isolator surfaces 
and IV bags were wiped from top to bottom and then back once, in a sweeping motion 
(Fig 3.7) whereas syringes were wiped in a spiral motion.  
3.2.7 Sampling staff 
Voluntary participation from staff was requested for this study. Out of the two qualified 
pharmacy technicians with several years of experience of pharmaceutical isolators using 
the open system working system, one technician was assigned the lead role and other 
was designated as back up. Training sessions for the pharmacy technicians involved in 
the study were arranged and were undertaken by a technician from Teva UK. The 
pharmacy technicians achieved observed competency in using the Tevadaptor device 
before the study commenced. At the same time training was also arranged for the 
nursing staff who would receive chemotherapy infusions with the Tevadaptor infusion 
administration device fitted by pharmacy. The technicians were also trained and 
competency-assessed in taking wipe samples from the designated areas and recording 
any spillages during the study. This part of the training and assessment was undertaken 
by Derriford Hospital pharmacy quality control laboratory. The above training took 
place in the class II BSC placed in the pharmacy QC lab. 
3.2.8 Collection of samples 
Wipe samples were taken as defined in Section 3.2.5. For the baseline and intervention 
phases of the study, two batches each of MTX, epirubicin and 5-FU syringes were 
prepared, and in the case of platinum-based drugs 15 and 13 individual infusion bags 
were prepared during baseline and intervention phases, respectively. The study was 
originally planned to be undertaken in three consecutive weeks but owing  to staffing 
and operational constraints it was performed in one week blocks over a period of three 
months. The isolator remained reserved for the study for the entire period of three 
months. In week 1 the marker drug infusions were prepared with conventional practice 
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of using needles and syringes and wipe samples were taken from work surfaces as well 
as prepared syringes and bags (baseline samples) according to a pre-defined sampling 
schedule (see above). In week 2 the infusions were prepared using the Tevadaptor 
device but no samples were taken (familiarisation week). In the 3rd and final week, 
preparation was again undertaken with the Tevadaptor device, but samples were taken 
and surface contamination of marker drugs was measured (intervention samples). After 
sampling, tissues were placed in 50 mL polypropylene centrifuge tubes. The gloves and 
chemotherapy preparation mats used for each session were also collected. All collected 
samples were stored at -22oC.  Prior to analysis the samples were allowed to reach room 
temperature and marker drugs were eluted and analysed as per methods described in 
Section 3.2.3. 
3.3 Results 
The contamination levels of all marker drugs from the tested surfaces are provided in 
Tables 3.5, 3.6, 3.7 and 3.8. MTX was the only marker drug which remained undetected 
in all samples. This may have been due to the fact that at the time of the sampling MTX 
pre-filled syringes were bought-in from a commercial supplier rather that prepared in 
DPMU. For the purpose of this study two test batches of eight MTX syringes (20 mg in 
0.8 mL) were prepared during both baseline and intervention phases. However, the 
numbers prepared were comparatively less if all of MTX syringes were prepared         
in-house as expected at the start of the study. The above reason could have led to the 
reduced contamination of MTX than expected, resulting in contamination in the wipe 
samples below LOD. 
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Table 3.5: Levels of epirubicin and 5-FU detected on the isolator surfaces (ng cm-2), 
presumed to be contaminated at both the baseline and the Tevadaptor interventions. 
Samples were taken at the end of production run prior to the cleaning of the isolator  
 Baseline Tevadaptor 
Location Epirubicin 5-FU Epirubicin 5-FU 
 Batch 
1 
Batch 
2  
Batch 
1 
Batch 
2 
Batch 
1 
Batch 
2  
Batch 
1 
Batch 
2 
 n =30 n = 44    n =38  n = 32 n =40  n = 40  n =52  n =54  
Right door ND 0.05 0.74 2.74 ND ND ND ND 
Right Floor ND 0.04 ND 1.27 ND ND ND ND 
Right 
Sleeve 
0.9 0.09 2.1 3.58 ND ND ND ND 
Centre 
Floor 
ND 0.04 0.59 1.17 ND ND ND ND 
Left sleeve 0.03 0.05 0.39 2.93 ND ND ND ND 
Left floor 0.02 0.34 ND 0.77 ND ND ND ND 
Left door ND 0.04 ND 0.70 ND ND ND ND 
Mean 0.11   1.21 ND  ND  
Range ND-
0.9 
 ND-
3.58 
 ND  ND  
ND- Not detected 
n is number of syringes  prepared per batch 
*each location represents single wipe sample per batch and surface area of each location is approximately 
400 cm2 
** mean and range of contamination from the samples pooled from both batches made per drug during 
both phases 
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Table 3.6: Amounts of epirubicin and 5-FU on gloves, syringe surfaces (total, mean, 
range and percentage contaminated) and chemo mats (μg) at baseline and Tevadaptor 
intervention 
        Baseline Tevadaptor 
 Epirubicin 5-FU Epirubicin 5-FU 
Location Batch 
1 
Batch 
2  
Batch 
1 
Batch 
2  
Batch 
1 
Batch 
2 
Batch 
1  
Batch 
2 
aGloves
/pair  
 3.16 72.5 0.85 13.8 1.15 9.70 ND ND 
 Mean 39.4  7.33  6  ND  
aChemo 
mat  
 44.7 38.0 770 773 50.5 4.67 0.51 ND 
 Mean 41.4  772  27.6  0.26  
Syringe 
surface  
bTotal 0.11  101  ND  0.62  
 bMean 0.01  3.59  0  0.02  
 bRange 0.01-
0.05   
 0.19-
50.3 
 0  0-
0.62 
 
c% contaminated 
(N)   
57.1 
(28) 
 71.4 
(28) 
 0 (32)  3.1 
(32) 
 
ND-Not detected 
aThe values for glove and preparation mats are total amounts of drug recovered (μg) from entire item 
(number of glove pairs and mats collected per batch n = 4) 
bTotal contamination (μg) recovered from samples pooled from both batches (mean contamination per 
glove pair, chemo mat and syringe sampled, μg)    
c% of syringes sampled with contamination >LOD (number of syringes in sample) 
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Table 3.7: Levels of platinum detected on the isolator surfaces (ng cm-2), presumed to 
be contaminated at both the baseline and the Tevadaptor interventions. Samples were 
taken at the end of production run prior to cleaning of the isolator.  
Platinum 
Location*           Baseline  Tevadaptor 
 Batch 
1 
Batch 
2 
Batch 
3 
Batch 
4 
Batch 
1 
Batch 
2 
Batch 
3 
Batch 
4 
 n = 4  n = 4 n = 4 n = 3 n = 3 n = 3  n = 3 n = 4 
Right door 0.86 0.18 0.36 0.11 0.09 0.01 0.01 0.01 
Right Floor 0.23 0.26 0.25 0.92 0.05 0.01 0.01 0.01 
Right 
Sleeve 
0.50 0.26 0.27 0.70 0.06 0.01 0.01 0.01 
Centre 
Floor 
0.16 0.09 0.08 0.09 0.04 0.01 0.01 ND 
Left sleeve 0.25 0.47 0.17 0.09 0.08 0.01 0.01 0.01 
Left floor 0.07 0.54 0.05 0.20 0.03 0.01 0.01 0.01 
Left door 0.05 0.14 0.06 0.23 0.02 0.01 ND 0.01 
Mean** 0.27    0.02    
Range** 0.05-
0.92 
   ND-
0.09 
   
ND- Not detected 
n is number of IV infusion bags  prepared per batch 
*each location represents single wipe sample per batch and surface area of each location is approximately 
400 cm2 
** mean and range of contamination from the samples pooled from all four batches made per drug during 
both phases 
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Table 3.8: Amount of platinum (ng) on gloves, chemo mats and bag surfaces (total, 
mean and range) at baseline and Tevadaptor intervention  
                                                             Platinum  
Location           Baseline  Tevadaptor 
 Batch 
1 
Batch 
2 
Batch 
3 
Batch 
4 
Batch 
1 
Batch 
2 
Batch 
3 
Batch 
4 
aGlove/pair  9.63 5.18 3.25 12.84 0.21 0.28 1.8 0.54 
 bMean 7.73    0.71    
aChemo mat 82.2 5.36 2291 265.12 0.35 0.67 2.63 5.01 
 bMean 661    2.17    
IV bag 
surface  
(4 
batches) 
 
bTotal 11013 1016 
bMean 734 78.1 
bRange 27-2904 3-747 
aThe values for glove and preparation mats are total amounts of drug recovered (ng) from entire item 
(number of glove pairs and mats collected per batch n = 4) 
bTotal contamination (ng) recovered from samples pooled from all four batches (mean contamination per 
glove pair, chemo mat and bags sampled, ng)    
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3.3.1 Surface contamination in the isolator  
In the case of epirubicin and 5-FU, a total of 14 wipe samples were taken from isolator 
surfaces during both baseline and intervention periods. During the baseline period, the 
percentage of samples found to be contaminated with epirubicin and 5-FU (i.e. above 
the LOD) was 71.4% and 78.5%, respectively. The detected levels of contamination 
ranged from undetected to 0.9 ng cm-2 (epirubicin) and undetected to 3.58 ng cm-2          
(5-FU) (see Table 3.5). The mean surface contamination during the baseline phase was 
0.11 ng cm-2 (epirubicin) and 1.21 ng cm-2 (5-FU). However, during the intervention 
period, all wipe samples taken from isolator surfaces were free of contamination (below 
LOD) for both epirubicin and 5-FU (Table 3.5). The Tevadaptor device was clearly 
effective in reducing surface contamination by epirubicin and 5-FU in pharmaceutical 
isolators. 
The analytical method employed to detect the presence of platinum was highly sensitive 
which, in turn, resulted in a higher frequency of surface contamination measured for the 
platinum-based drugs. The LOD was established at 0.01 ng mL-1, which meant 100% of 
the 28 baseline samples and 64% of 28 intervention phase samples taken from the 
isolator surfaces showed detectable levels of platinum (Table 3.7). The detected range 
was 0.05-0.92 ng cm-2 during the baseline phase and 0.002-0.09 ng cm-2 during the 
intervention phase (Table 3.7). The mean surface contamination was 0.27 ng cm-2 
during baseline and 0.02 ng cm-2 during intervention.  These results show a reduction in 
mean surface contamination by a factor of 13.5 in the intervention samples as compared 
to the baseline samples. 
 3.3.2 Surface contamination on prepared IV infusion bags and syringes 
Surface samples were also taken from prepared syringes and IV infusion bags. Both 
epirubicin and 5-FU are presented as solutions for injections in glass vials. This solution 
is then drawn out aseptically and pre-filled syringes are sent to the clinic ready for 
administration to patients. The syringes used were BD Plastipak syringes and both drugs 
have been demonstrated to be compatible with the syringe material (Allwood et al., 
2002). A minimum of 12 syringes or 20% of the batch were sampled in each case. As 
the number of syringes prepared per batch was more than 30, it was decided to wipe 
four syringes using each to pick up contamination from the maximum possible number 
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of syringes. A total of 74 (batch 1 = 30, batch 2 = 44), epirubicin and 70 (batch 1 = 38, 
batch 2 = 32), 5-FU syringes were prepared during the baseline period. In each case a 
total of seven wipes were used to sample the surface of prefilled syringes. As one wipe 
sample was used to sample four syringes, the number of syringes sampled per drug was 
28. Out of the seven samples taken per drug, five (71.4%) samples of 5-FU and four 
samples (57.1%) of epirubicin were found to be contaminated and the total 
contamination was in the range of 12-45 ng/sample (epirubicin), 196-50,300 ng/sample 
(5-FU). During the intervention phase, 80 (batch 1 = 40, batch 2 = 40), epirubicin 
syringes and 106 (batch 1 = 52, batch 2 = 54), 5-FU syringes were prepared and 8 wipe 
samples were taken for each drug. There was no detectable contamination for epirubicin 
but with 5-FU one sample was positive (620 ng), which was comparatively lower than 
the contamination level from the baseline phase (Table 3.6). The mean surface 
contamination per syringe was 0.01 ng (epirubicin) and 3.59 ng (5-FU) during the 
baseline phase and during the intervention phase no contamination was detected by 
epirubicin and mean 5-FU detected per syringe was 0.02 ng, resulting in a reduction of 
contamination by a factor of 180.    
Due to the highly sensitive detection method for platinum all wipe samples from the 
infusion bag surfaces prepared during both baseline and intervention showed detectable 
levels of platinum. The detected ranges were 27-2,900 ng/bag (baseline phase) and      
3-700 ng/bag (intervention phase). There was a reduction of approximately 10 fold in 
the total platinum levels detected during the intervention phase (1,015 ng) as compared 
to the total platinum levels of the baseline phase (11,013 ng) (see Table 3.8). The mean 
surface contamination by platinum per IV bag also showed similar reduction by a factor 
of 9.4 during the intervention phase (78 ng per bag) as compared to the baseline phase 
(734 ng per bag).    
3.3.3 Contamination on gloves and chemo mats 
The gloves and chemo mats used during the preparation of marker drugs were also 
collected during both baseline and intervention phases. The amounts recovered from 
baseline glove samples were 1,100-6,100 ng/glove (epirubicin), 300-8,100 ng/glove   
(5-FU) and 1-6 ng/glove (platinum). At the same time the contamination on chemo-mats 
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was in the range of 38,000-44,600 ng/mat (epirubicin), 772,000-769,000 ng/mat (5-FU) 
and 5-2,200 ng/mat (platinum). 
The marker drugs were detected in comparatively lower amount after the introduction of 
Tevadaptor device. The amounts detected in gloves were 400-600 ng/glove (epirubicin) 
and undetected to 1 ng/glove (platinum). 5-FU remained undetected in all glove samples 
collected during the intervention phase. The contamination on chemo-mats was      
4,600-5,010 ng/mat (epirubicin), undetected to500 ng/mat (5-FU) and undetected to      
5 ng/mat (platinum).   
The mean contamination per glove pair during the baseline phase was 39,400 ng 
(epirubicin), 73,300 ng (5-FU) and 7.73 ng (platinum). The mean contamination in the 
intervention phase glove samples was 6,000 ng (epirubicin), 0.71 ng (platinum) and 
below detected levels for 5-FU. The reduction in contamination was by a factor of 6 in 
case of epirubicin and by a factor of 11 in the case of platinum. 
The mean contamination per chemo preparation mat during the baseline phase was 
41,400 ng (epirubicin), 772,000 ng (5-FU) and 661,000 ng (platinum). The mean 
contamination in the intervention phase glove samples was 27,600 ng (epirubicin),     
620 ng (5-FU) and 2,170 ng (platinum). The reduction in contamination was by a factor 
of 1.5 (epirubicin), >1000 (5-FU) and > 300 (platinum). 
3.3.4 Effectiveness of cleaning methods 
During both baseline and intervention phases of the study samples were collected from 
the same areas of the isolator after it was cleaned as per local procedures. The results 
are presented in Table 3.9 and 3.10. Table 3.9 shows the levels of 5-FU and epirubicin 
detected in the post-clean samples during both baseline and intervention phases. The 
range detected of 5-FU was ND to 1.69 ng cm-2 (baseline phase) and undetected in all 
intervention phase samples. Epirubicin remained undetected in post-clean samples from 
both phases.  
Table 3.10 shows, platinum levels detected in the post-clean samples during both 
baseline and intervention phases. The range was ND to 0.95 ng cm-2 (baseline phase), 
with one sample at 5.14 ng cm-2 and 0.002-0.042 ng cm-2 (intervention phase).  
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Table 3.9: Levels of epirubicin and 5-FU detected on the isolator surfaces (ng cm-2), 
cleaned using standard procedures at both the baseline and the Tevadaptor interventions. 
Samples were taken at the start of production run. 
 Baseline Tevadaptor 
Location* Epirubicin 5-FU Epirubicin 5-FU 
 Batch 
1 
Batch 
2 
Batch 
1 
Batch 
2 
Batch 
1 
Batch 
2 
Batch 
1 
Batch 
2 
 n =30 n = 44    n =38  n = 32 n =40  n = 40  n =52  n =54  
Right door ND ND ND 1.66 ND ND ND ND 
Right Floor ND ND ND 1.51 ND ND ND ND 
Right 
Sleeve 
ND ND ND 0.59 ND ND ND ND 
Centre 
Floor 
ND ND ND 1.69 ND ND ND ND 
Left sleeve ND ND ND 0.89 ND ND ND ND 
Left floor ND ND ND 0.73 ND ND ND ND 
Left door ND ND ND 1.23 ND ND ND ND 
Mean** ND  0.59  ND  ND  
Range** ND  ND-
1.69 
 ND  ND  
ND- Not detected 
n is number of syringes  prepared per batch  
*each location represents single wipe sample per batch and surface area of each location is approximately 
400 cm2 
** mean and range of contamination representative of two batches made per drug during both phases 
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Table 3.10: Level of platinum detected on the isolator surfaces (ng cm-2) cleaned using 
standard procedures at both the baseline and the Tevadaptor interventions. Samples 
were taken at the start of production run.  
Platinum 
Location*           Baseline  Tevadaptor 
 Batch 
1 
Batch 
2 
Batch 
3 
Batch 
4 
Batch 
1 
Batch 
2 
Batch 
3 
Batch 
4 
 n = 4  n = 4 n = 4 n = 3 n = 3 n = 3  n = 3 n = 4 
Right door ND 5.145 0.135 0.007 0.022 0.008 0.007 0.014 
Right Floor ND 0.952 0.052 0.015 0.002 0.011 0.007 0.021 
Right 
Sleeve 
0.001 0.607 0.022 0.007 0.003 0.010 0.007 0.029 
Centre 
Floor 
0.001 0.345 0.030 0.015 0.002 0.042 0.007 0.012 
Left sleeve ND 0.405 0.015 0.015 0.004 0.010 0.007 0.013 
Left floor ND 0.622 0.052 0.030 0.003 0.015 0.006 0.013 
Left door ND 0.180 0.007 0.007 0.002 0.006 0.005 0.008 
Mean 0.309    0.011    
Range ND-
5.145 
   0.002-
0.042 
   
ND- Not detected 
n is number of IV infusion bags prepared per batch 
* each location represents single wipe sample per batch 
** mean and range of contamination representative of four batches made during both phases 
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3.4 Discussion 
3.4.1 Comparison of baseline results with other studies 
This is the first study in the UK on the effect of using closed-system transfer devices in 
pharmaceutical isolators under actual practice conditions. As in previous studies 
(Crauste-Manciet et al., 2005, Roberts et al., 2006) contamination levels on the inside of 
the isolator were found to be considerable (Tables 3.5 and 3.7), particularly under 
baseline (conventional syringe and needle transfer) conditions. This was not surprising 
because essentially, the isolator is a containment device. Turci et al. (2003) have 
reviewed most of the published studies reporting contamination by anticancer drugs on 
work surfaces. Briefly, Sessink et al. (1997) and Connor et al. (1999) reported 5-FU in 
wipe and glove samples collected from pharmacy units in the range of                      
0.72-208.6 ng cm-2 and 21×103-620×103 ng/pair, respectively. Minoia et al. (1999) 
reported platinum in the range of 0.55-92.3 ng cm-2 and 20-193 ng/pair from wipe and 
glove samples. Most of above data are taken from pharmacy units using open-fronted 
laminar flow cabinets. The contamination levels reported in the baseline phase of the 
current study are comparable to the earlier studies.  
Some recent studies have reported contamination in pharmaceutical isolators and the 
contamination range on isolator surfaces were platinum 0.0005-0.013 ng cm-2, MTX 
0.0002-0.0674 ng cm-2, and 5-FU 9.73-87.6 ng cm-2 (Crauste-Manciet et al., 2005, 
Mason et al., 2005). The results from the previous studies also show the LOD and LOQ 
for the marker drugs used in this study were sufficient to measure the contamination 
levels expected to be observed in hospital pharmacy units. The importance of sensitive 
analytical techniques can be clearly observed in this study. As stated earlier, LOD for 
MTX was highest among the marker drugs used in this study therefore it could not be 
included. On the other hand platinum was detected in all samples even though the total 
amount detected was lower than epirubicin and 5-FU. This can be explained by the fact 
that the LOD for platinum was much lower than other drugs used in this study. Clearly, 
any comparison of measures of contamination frequency between different studies must 
be treated with caution given the high dependency of positive results on the LOD and 
LOQ of the analytical method used. 
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3.4.2 Comparison with other CSTDs 
There are other closed system devices present in the market such as PhaSeal and Codon 
along with the Tevadaptor device. A comparison study of the effectiveness of these 
devices was conducted using titanium tetrachloride and fluorescein which showed 
PhaSeal was the only air tight and leak proof device (Jorgenson et al., 2008). The results 
of the present study question the relevance of evaluating closed system devices using 
measures such as titanium tetrachloride and fluorescein. Recent studies have evaluated 
PhaSeal device and have reported reduction in surface contamination with anticancer 
drugs such as cyclophosphamide, ifosfamide and 5-FU on using the device for a period 
of six months (Wick et al., 2003) two weeks (Yoshida et al., 2009), 24 weeks (Connor 
et al., 2002) and 36 weeks (Harrison et al., 2006). Most of these studies are conducted 
where the closed system device is used in a biological safety cabinet as recommended 
by NIOSH. The current study is the only one where a closed system device is evaluated 
in a pharmaceutical isolator and the results showed a marked reduction in surface 
contamination within two weeks of using this device. There is much debate as to what 
constitutes a genuine “closed system” device. The Tevadaptor device used in this study 
utilises a carbon venting filter (to absorb the anti-cancer drug vapours which may 
become saturated with use and possibly leak) and would not be considered a “closed 
system” under ISOPP guidelines (ISOPP, 2007). It is possible therefore that a fully 
closed system device (e.g. PhaSeal) could result in further reduction of isolator 
contamination. 
3.4.3 Effectiveness of cleaning regimen  
The isolators are cleaned at the end of each session but the results from the post-clean 
wipe sample (see Tables 3.9 and 3.10) show that the existing cleaning procedures are 
not effective in chemically degrading the anticancer drugs and therefore the 
contamination in isolators may persist. These results are consistent with a previous 
study where  5-FU, cyclophosphamide and doxorubicin were used as marker drugs to 
evaluate the effect of detergents and vaporised hydrogen peroxide (VHP) to degrade 
cytotoxic drugs on work surfaces (Roberts et al., 2006). The results indicated that 5-FU 
and cyclophosphamide were chemically resistant to both VHP and detergents and to 
effectively remove traces of cytotoxic drug contamination from work surfaces they 
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should be cleaned with water, followed by detergents of high and low pH  and then 
denatured ethanol and VHP.  A further limitation of using VHP to chemically degrade 
anti-cancer drugs is that it may produce highly active cytotoxic degradation products. 
Further work is required to assess the degradation products of anti-cancer drugs when 
cleaned with VHP.   
3.4.4 Analysis of present results 
Data for contamination by 5-FU and epirubicin on the isolator surfaces as well as gloves 
and chemotherapy preparation mats used by the operator for each session are also 
represented in Tables 3.5 and 3.6. The total amount of 5-FU and epirubicin recovered 
from isolator surfaces during the baseline phase was 6.78×106 ng and 0.66×106 ng, 
respectively. On the contrary the isolator surface contamination was below the LOD in 
all samples for 5-FU and epirubicin during the intervention phase, proving that 
Tevadaptor device was highly effective in reducing isolator surface contamination.    
Under normal working practice, operators wear thin nitrile inner gloves and thicker 
outer gloves which are attached to the isolator sleeves. These gloves are likely to be 
contaminated as they come in direct contact with drug vials, the surfaces of which have 
been proved to be contaminated with cytotoxic residues (Connor et al., 2005, Mason et 
al., 2003, Nygren et al., 2002). Operators also use chemotherapy preparation mats 
which are spread on the surface of pharmaceutical isolators. These mats may capture 
any aerosols and droplets sprayed while manipulating anticancer drugs and will come 
into contact with the contaminated surfaces of drug vials. Table 3.6 shows that the total 
amount of epirubicin and 5-FU recovered from gloves and chemotherapy preparation 
mats was considerably reduced by the use of Tevadaptor. The presence of some residual 
contamination of chemotherapy preparation mats and isolator gloves was anticipated in 
view of the well-documented surface contamination on the vials themselves (Connor et 
al., 2005, Mason et al., 2003, Nygren et al., 2002). This also explains why Tevadaptor 
or any other CSTD is unlikely to completely eliminate contamination on isolator gloves 
since contamination from vial surfaces will occur irrespective of the transfer system 
employed. 
The total amount of platinum recovered from isolator surfaces, chemotherapy 
preparation mats and infusion bag surfaces all showed marked reduction with the 
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Tevadaptor. One particular chemo prep mat used during preparation of Batch 2 of the 
baseline phase showed considerably higher contamination than other samples. Even 
though no spillage was recorded during the preparation of this batch the spike in 
contamination is possibly due to increased generation of aerosols and shows that despite 
using best practice there is still a high risk of surface contamination and risk of 
occupational exposure during the preparation of chemotherapy infusions.   
The results from the current study also show the contamination of the external surfaces 
of pre-filled syringes and IV infusion bags. This study shows that the external surface of 
potentially half the pre-filled syringes and IV infusion bags sent to wards for patient use 
could be contaminated with measurable levels of anticancer drugs. This may have 
serious implications for healthcare staff involved in administration of anticancer drugs 
to the patients. Staff touching contaminated bags without gloves may get exposed to 
anticancer drugs. The current UK practice does not, in theory, allow any staff to 
administer anticancer drugs without gloves therefore the risk of dermal exposure should 
be minimal. Studies (e.g. Gross and Groce, 1998) have evaluated glove material and 
have concluded that the nitrile gloves do not allow permeation of anticancer drugs in 
normal practice but staff should be aware of good practice and should regularly check 
gloves for any holes which would allow exposure to anticancer drugs and in the case of 
pharmacy operators responsible for preparation of chemotherapy infusions gloves 
should be changed  at least every 30 minutes (Crauste-Manciet, 2007, NIOSH, 2004). 
Various factors may affect the amount of contamination arising from each individual 
drug, for example the tendency of the formulation to produce aerosols and the seal of 
the vial septum around the needle used for fluid transfer. It would be simplistic to 
expect any direct relationship of these to the contamination levels obtained. One factor 
that may be more relevant is the amount of drug in the infusions or pre-filled syringes 
prepared in the work area, and while direct correlations would seem unlikely it is 
reasonable to expect that the frequency and amount of contamination recovered would 
increase as the amount of drug manipulated in the isolator increases. 
With this in mind, the amount of contamination recovered was normalised for the 
amount of each drugs prepared (Table 3.11). This also provides a more realistic 
comparison between the base-line and intervention (Tevadaptor) arms of the study by 
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reducing bias related to the quantity of infusions prepared. Normalised values, 
expressed as percent of drug amount of drug prepared recovered as contamination, also 
show a marked reduction, typically >10-fold, in contamination of combined surfaces 
when the Tevadaptor was used.  
Table 3.11: Total amounts of marker drugs used (mg) in test preparations and recovered 
from each surface sampled (μg) during baseline and intervention periods, and residue of 
each drug recovered (as μg g-1 drug used) 
 
NA - Not applicable 
ND- Not detected  
a Denotes total drug recovered (μg) from all surfaces per g of drug used (or per g platinum-based 
drugs) in both baseline and intervention phase of the study 
A closed system device used in a pharmaceutical isolator will prevent the formation of 
aerosols and spillages while preparation of IV infusions and thus reduce the 
contamination in the isolators. The other advantages of a closed system device are it 
eliminates needle stick injuries, eliminates risk of exposure to staff involved in 
administration of IV chemotherapy associated with spiking and priming the IV bags and 
in some case may also compensate for poor technique of the operators; however, use of 
 Epirubicin 5-FU  Platinum 
 Baseline Tevadaptor Baseline Tevadaptor Baseline Tevadaptor 
Amount 
used (mg) 
4000 2200 11400 32400 2202 1280 
Amount 
from 
isolator 
(μg) 
660 ND 6780 ND 3050 
 
210 
Syringe 
(μg) 
0.11 ND 101 0.62 NA NA 
Bag (μg) NA NA NA NA 11.0 1.02 
Gloves + 
Mats (μg) 
93 11.8 1558 0.51 2.67 0.10 
aDrug 
recovered  
(μg g-1) 
188 5.4 740 0.04 7.60 0.96 
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closed system devices is likely to add extra cost in the healthcare system. In the view of 
numerous studies proving the levels of contamination noticed in healthcare setting by 
anticancer drugs and the absence of conclusive evidence on safe levels of exposure, due 
consideration should be given to the incorporation of closed system devices into routine 
practice. 
3.5 Conclusion 
This study has demonstrated that the current work practices in UK hospital pharmacies 
using isolators for cytotoxic preparation results in cytotoxic contamination of isolator 
gloves and work surfaces as well as prepared IV infusion bags and syringes. This 
contamination of the workplace may expose healthcare staff to anticancer drugs which 
present a serious occupational health risk. The use of a closed system device 
(Tevadaptor) in conjunction with good working practices considerably reduced such 
contamination, often to below the LOD of the assay methods used in this study. This 
clearly suggests that there is a strong case for more routine and widespread use of 
closed system devices in preparation of chemotherapy infusions in pharmaceutical 
isolators. 
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Chapter 4: Tevadaptor ward study 
4.1 Introduction 
In previous chapters the applications of anti-cancer drugs in treating various cancers as 
well as the risks posed by exposure to the occupational health of healthcare 
professionals working with anti-cancer drugs were discussed in detail. The healthcare 
professionals working in oncology departments are most at risk of exposure to anti-
cancer drugs via the dermal route which occurs by touching contaminated work surfaces 
or contaminated surfaces of IV infusion bags or syringes. Although the contamination 
levels on ward surfaces are likely to be low the adverse effects of prolonged exposure to 
a mixture of low levels of anti-cancer drugs cannot be ignored. In Chapter 3 the effect 
of a CSTD (Tevadaptor) on surface contamination by anti-cancer drugs in a pharmacy 
manufacturing unit was evaluated and the results indicate a reduction of more than 10 
fold in the surface contamination by anti-cancer drugs after the introduction of 
Tevadaptor. Other similar studies provide evidence of the effectiveness of CSTD in 
reducing contamination in pharmacy manufacturing units (Harrison et al., 2006, Wick et 
al., 2003, Connor et al., 2002, Spivey and Connor, 2003, Yoshida et al., 2009, Siderov 
et al., 2010). However, the data are limited on contamination levels of clinical ward 
surfaces and there are no studies on the effect of CSTDs on ward surface contamination 
by anticancer drugs. Accordingly, this chapter reports the extent of contamination on an 
oncology out-patients ward surfaces by anti-cancer drugs and also the effect of using the 
Tevadaptor during preparation and administration of marker drug infusions. This study 
also aims to gather information on the user friendliness of the Tevadaptor device from 
both the pharmacy and nursing staff. 
The marker drugs used for this study were gemcitabine, carboplatin, cisplatin and 
oxaliplatin. The drugs were selected for this study on the basis of their frequency of 
usage in the pharmacy reconstitution unit and the different classes of anticancer drugs 
they represented such as alkylating agents (cisplatin, carboplatin and oxaliplatin) and 
antimetabolites (gemcitabine).  
The study was conducted by taking wipe samples from pre-defined areas from a busy 
oncology out-patients department of Derriford Hospital. Gloves used by nursing staff 
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during  assembling and administration of marker drug infusions were also collected 
during both phases of the study (see Figure 4.1 for a flow diagram of Tevadaptor ward 
study design). The samples were then analysed for marker drugs using validated 
analytical methods. At the end of the study a questionnaire was distributed among the 
staff members who had used the Tevadaptor device, either during the preparation or 
administration of anti-cancer IV infusions. The results from the analysis of the wipe 
samples, and the questionnaire provide a measure of out-patients ward surface 
contamination as well as the effectiveness of Tevadaptor in reducing such 
contamination and the overall usability of the device.    
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Figure 4.1: Flow diagram of Tevadaptor ward study design 
4.2 Methods 
4.2.1 Study setting  
In this study wipe samples were taken from oncology out-patients department of 
Derriford Hospital, which is located in a purpose-built unit and consists of consulting 
rooms, an examination area, a treatment room and a counselling room as well as 
Study Protocol
Method 
development and 
validation
Tevadaptor clinic 
study
Week 2 
familiarization 
phase
Sample analysis
Results
Week 1 Baseline 
phase
Week 3 
Intervention phase
Samples collected 
once/day
Samples collected 
once/day
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collective and individual drug administration rooms. On average, 30 to 40 patients are 
administered chemotherapy infusion in the department per day. All individual 
chemotherapy infusions for patients are prepared in a hospital pharmacy manufacturing 
unit. Prior to the administration to patients, the chemotherapy infusions are stored in the 
treatment room in oncology outpatients department in one of the two fridges and the 
bench areas of the same room are used to assemble IV infusions on clean plastic trays. 
The infusions are then transported to the administration area on a trolley and are raised 
using a metal (steel) hanger.  
4.2.2 Method development 
The drugs for this study were selected on the basis of their overall usage. MTX, 5-FU 
and epirubicin used in the previous study could not be used as marker drugs during this 
study as they were not compounded in DPMU in batches and were bought from 
commercial suppliers. However, platinum-based drugs were still compounded in DPMU 
as individual infusion bags, therefore these drugs were included as marker drugs for this 
study. Gemcitabine was also selected as its use has increased over the last few years. 
During this study one wipe sample was used to pick up all marker drugs used in the 
study. Therefore the analytical methods were revalidated to ensure sufficient sensitivity 
and specificity as the overall contamination was likely to be lower than pharmacy 
surfaces and there were more interfering agents likely to be present on the out-patients 
ward surfaces. 
 4.2.2.1 Wipe material 
Klerwipe sterile low particulate dry wipes (18×20.5 cm2) were successfully used in the 
Tevadaptor isolator study. Therefore, it was decided to use the same wipes for the 
present study. However, during validation of gemcitabine assay it was discovered that 
Klerwipes produced an interfering signal with the gemcitabine signal which made them 
unsuitable for this study. As the sampling was performed in a clinical area the wipe 
material need not be sterile, a number of low linting wipes were tested. The selection 
was then narrowed down to various cosmetic cotton wool pads (5 cm diameter). Even 
though cotton pads were likely to be linting they were most suitable as all other wipes 
produced high background noise in the gemcitabine assay. On further validation cotton 
pads were also compatible with the ICP-MS assay used for platinum-based drugs. 
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Owing to above reasons the cotton wool pads (5 cm diameter) bought from ASDA 
Stores Ltd were used as wipe material in the Tevadaptor ward study. 
4.2.2.2 Wetting agent 
A wetting agent was required to assist in picking up maximum contamination from test 
surfaces. WFI was used in the previous study and proved to be able to pick up 
contamination from surfaces. Considering the need for a neutral wetting agent due to the 
test surface being in clinical areas WFI was used again. On further validation it showed 
sufficient ability to recover marker drugs for this study (see Table 4.1). 
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Table 4.1: Validation parameters for the analytical methods of gemcitabine (HPLC) and 
platinum-based drugs (ICP-MS). LOD, LOQ, mean recovery and range (approximate) 
and precision of recovery and analytical methods are shown (errors represent one 
standard deviation about the mean). Recovery of marker drugs from test surfaces was 
established using cotton wool pads. 
 Gemcitabine Cisplatin Carboplatin Oxaliplatin 
Limit of 
detection*(LOD, 
ng mL-1) 
 1 0.01 0.01 0.01 
Limit of 
quantification*   
(LOQ,  ng mL-1) 
 3 0.1 0.1 0.1 
Mean Recovery 
(%) (n = 3) 
Wipe 
tissue 
99.6±5 85.7±10 106.7±5 107.4±5 
 Surface 85.1±10 76.4±10 109.5±10 102.7±6 
 Gloves 108.4±10 103.6±7 99.5±10 94.5±7 
Precision of 
recovery 
(RSD%) (n = 3) 
Wipe 
tissue 
2.5 7.5 2.2 3.3 
 Surface 10 12.2 8.5 8.5 
 Gloves 4.7 5.7 12.1 9.9 
Precision of 
analysis 
(RSD%)**       
(n = 6) 
Inter-
day 
4.5 7.2 7.2 7.2 
Intraday 1.37 4.4 4.4 4.4 
*LOD/LOQ for cisplatin, carboplatin and oxaliplatin is in terms of platinum metal. 
  ** Precision of gemcitabine was measured at 40 ng mL-1 and platinum at 0.5 ng mL-1 
Number of samples used to validate recovery was three and number of samples used to calculate 
precision of analysis was six 
4.2.2.3 Sampling technique 
The sampling was performed by taking wipe samples from selected surfaces using the 
pre-validated method from the previous study and glove samples were analysed using 
the immersion technique.  
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4.2.2.4 Collection vessel and drug stability 
The wipe samples were collected and stored at -22oC in a temperature monitored freezer 
in 50 mL polypropylene centrifuge tubes, whereas gloves were stored in the same 
freezer in polyethylene bags. At the time of drug recovery gloves were transferred into 1 
L HDPE bottles and recovered by shaking them for 2 minutes. The stability of 
platinum-based drugs was demonstrated in Tevadaptor isolator study and the stability of 
gemcitabine has been established in water, normal saline and 5% glucose for up to 35 
days (Xu  et al., 1999). 
4.2.2.5 Desorbing solution 
In this study single wipe samples were used to recover all marker drugs at the same 
time. Therefore the desorbing solution was required to be compatible with gemcitabine 
and platinum-based drugs and be able to recover sufficient quantities from the test 
surfaces as well as the wipe tissues. HCl (1%) was used in the Tevadaptor isolator 
study. Therefore, it was trialled again as a desorption agent for the Tevadaptor ward 
study. However, HCl was not compatible with the SPE method used for gemcitabine 
assay, hence was not suitable for further validations. The final desorbing solution was 
WFI which was compatible with both gemcitabine and platinum assays. The volumes 
used for desorption were 15 mL for wipe samples and 20 mL for glove samples. In each 
case supernatants were taken for analysis. A minimum of 5 mL was needed for each 
assay. The volumes for desorption were the minimum required to wet the wipe tissues 
effectively as observed visually, whereas the recovery of gemcitabine from gloves was 
validated with 15, 20 and 30 mL of water. The glove samples were spiked with 0.3 mL, 
0.4 mL and 0.6 mL of gemcitabine (4 μg mL-1) and then desorbed using 15, 20 and 30 
mL “water for irrigation” such that the final concentration was 80 ng mL-1 in all samples 
and all three volumes showed approximately 100% drug recovery. A final volume of 20 
mL was used to desorb marker drugs from gloves as this was the minimum volume 
which effectively recovered drug and produced enough supernatant for both drug 
assays. The recovery validation results with water are presented in Table 4.1. 
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4.2.3 Analytical methods for marker drugs 
4.2.3.1 Analytical method for gemcitabine 
Analytical methods to detect and assay gemcitabine in pharmaceutical dosage forms and 
environmental samples are based on HPLC-UV or HPLC-MS. Murlikrishna et al. 
(2011) describe a method for assay of gemcitabine using HPLC-UV. The separation 
was achieved on a 150×4.6 (5 μm particle size) column packed with ODS (octadecyl 
silane) bounded silica. The mobile phase was 40% acetonitrile with water and detection 
was at 270 nm. The method was linear between the range of 80-120 μg mL-1. Another 
stability indication method (Rao et al., 2010) was also based on HPLC-UV. A C18 
column (25×4.6, 5 μm particle size) was used for separation and the mobile phase was 
40% methanol with phosphate buffer (pH 3.5) flowing at 1 mL min-1   . The detection 
was at 270 nm and the LOD of the method was 60 ng mL-1. Even though the above 
methods were simple and robust but they were not sensitive enough for this study. 
Sottani et al. (2007) used HPLC-MS to detect gemcitabine in wipe samples taken from 
pharmacy work surfaces. Solid phase extraction (SPE) was used for sample clean up 
and concentration. A propyl column (150×4.6, 5μm particle size) was used for 
separation and hydrophilic-lipophilic balance SPE cartridges were used for sample 
concentration. A gradient flow mobile phase consisting of 0.1% acetic acid with a 
mixture of acetonitrile and water was used. The detection was attained by mass 
spectrometry and a LOQ of 1 ng mL-1 was achieved. The final method for detection of 
gemcitabine was based on HPLC-UV with sample concentration by SPE.         
Gemcitabine samples were subjected to SPE prior to HPLC analysis. The final SPE 
method used Strata x-cw (weak cationic) 60 mg 3 mL-1 cartridges. The cartridges were 
activated with 3 mL of methanol and then washed with 3 mL of water. A 3 mL sample 
was then loaded and washed with 2 mL of 0.025 M ammonium acetate and eluted with 
two aliquots of 0.5 mL of 15% methanol in acetate buffer (0.05 M, pH 5.0). The 
recovery from SPE cartridge was approximately 55 to 60%. The eluent was then 
analysed by HPLC using a Luna C18 stainless steel column (250×4.6 mm, 5 μm particle 
size), using a mobile phase of 10% methanol with 0.05 M acetate buffer (pH 5.0 
adjusted with 33% acetic acid) flowing at 1 mL min-1 with UV detection at 277 nm. The 
retention time was 8.8 minutes. The autosampler injection needle was flushed with 
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2×500 µL methanol: water (50:50) v/v after each injection and the injection volume was 
100 μL.  Each HPLC sample was injected twice and an external standard with bracketed 
injections was used. The limit of detection and quantification were 1 and 3 ng mL-1, 
respectively. An example of an HPLC chromatogram is provided in Appendix 2. 
4.2.3.2. Analytical method for platinum-based drugs (cisplatin, carboplatin and 
oxaliplatin) 
The platinum-based drugs, cisplatin, carboplatin and oxaliplatin, were eluted into “water 
for irrigation” and were analysed in triplicate by ICP-MS (see Chapter 3, Section 3.2.3.9 
for method details). 
4.2.4 Method validation  
The methods of analysis of marker drugs used in this study were validated for 
parameters including, precision, sensitivity, specificity and recovery of drugs from test 
surfaces. Due to the nature and variety of test surfaces it was not feasible to test each 
surface, therefore a simulation validation study was set up in class II BSC. The steel 
surface of the BSC and gloves were contaminated with known quantities of each drug 
individually and also as a part of a mixture. The contaminated surfaces were then left to 
dry and then wiped using the described technique. Following elution the supernatant 
was subjected to assay validation.  
4.2.4.1 Linearity of response 
Gemcitabine assay calibration (Fig 4.2) was performed by using standard solution in 
seven concentration points ranging from 5 to 100 ng mL-1. Each concentration was 
prepared in triplicate and then injected in duplicate. The calibration plot was prepared 
using average of the values for each concentration. A seven point calibration line was 
plotted for gemcitabine and regression analysis was used to determine linearity. For the 
platinum assay a calibration line was plotted at the start of each session and response 
was linear between concentration ranges of 0 to 1000 ng mL-1. 
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Figure 4.2: Calibration line of gemcitabine showing its linear range and regression 
coefficient (R2) between 5 ng mL-1 to 100 ng mL-1 as validated using the HPLC assay 
for the study. Each sample point represents an average of six readings and the percent 
error (as relative standard deviation) is less than 2%. 
4.2.4.2 Recovery validation 
To validate drug recovery from surfaces selected for the study, test surfaces were spiked 
with known amounts of marker drugs. The surfaces selected for taking wipe samples 
from oncology out-patients ward were varied in nature (doors, bench surfaces, metal 
trolleys and IV infusion hangers). Therefore, it was not feasible to validate recovery 
from each type of surface. However, since the majority of samples were from the steel 
surfaces of drug trolleys and infusion hangers and gloves used by nursing staff, drug 
recovery from these surfaces was validated using a simulation study. Cotton wool pads 
were also evaluated to ensure that acceptable quantities of spiked drug could be 
recovered from them and also that the tissues themselves did not contribute to sample 
signals. 
The steel base of class II BSC placed in Derriford Pharmacy QC laboratory was selected 
as a surrogate for steel surfaces of door and fridge handles and metal drug trolleys. The 
samples of nitrile gloves used by nursing staff for the assembly and administration of 
marker drugs were obtained and tested for drug recovery.  Prior to and in-between 
validation runs the BSC surfaces were cleaned with hypochlorite solution followed by 
detergent, water and IMS to remove any traces of anti-cancer drugs and prevent any 
cross-contamination.   
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Each test surface was spiked with a known amount of each marker drug. The amounts 
used to spike the BSC surface were 1200 ng gemcitabine and 7.5 ng of the each 
platinum-based drugs (in terms of platinum) and gloves were spiked with 1600 ng 
gemcitabine and 10 ng of the each platinum-based drug (in terms of platinum). Each 
surface was spiked in triplicate by dropping a known volume (0.1 ml) of the drug 
solutions using a pipette and then the surfaces were allowed to dry visually. The marker 
drugs from BSC surface samples were recovered by wiping them with tissues saturated 
with 5 mL WFI and desorbed with 15 mL, water for irrigation after centrifugation and 
sonication as described previously in Chapter 3, Section 3.2.3.4. In the case of glove 
samples, a single glove was immersed in 20 ml water for irrigation in a 1 L HDPE 
bottle and drug desorbed by shaking the bottle manually for two minutes. The expected 
concentration of each marker drug in the supernatant (assuming 100% drug recovery) 
was 80 ng mL-1 gemcitabine and 0.5 ng mL-1 of the each platinum-based drugs (in terms 
of platinum). An aliquot from each sample was then analysed in duplicate by HPLC or 
scanned in triplicate by ICP-MS. The validation results are presented in Table 4.1. 
Recovery of the marker drugs from the tested surfaces was sufficiently high (> 80%) 
and was also consistent with precision of recovery being < 15% RSD.  
4.2.4.3 Effects of other marker drugs on analyte recovery 
This study was performed as per the protocol in Section 3.2.4.4. The results (Fig 4.3, 
4.4) show that there was no effect of the marker drugs on each other’s assay results and 
the drug recoveries were consistent with or without the presence of other marker drugs 
in the sample mixture.   
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Figure 4.3: Effect of the presence and concentration of other drugs on recovery of 40 ng 
mL-1 of gemcitabine. RSD is the overall relative standard deviation of all results (each 
sample point represents average of three values). Error bars represent ±5% error about 
the mean value.  
 
 
Figure 4.4: Effect of the presence and concentration of other drugs on recovery of 0.5 
ng mL-1 of platinum (as platinum based drugs). RSD is the overall relative standard 
deviation of all results per drug (each sample point represents average of three values). 
Error bars represent ±10% error about the mean value.  
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4.2.5 Sampling method and schedule 
Wipe samples were taken from various surfaces from the treatment room of the 
oncology out-patients department which were selected after consultation with the 
nursing staff as the areas most likely to be contaminated with the marker drugs for the 
study. The wiped surfaces were bench areas (sampled in four sections), both the front 
and back handles of the door to the treatment room, door handles of both drug storage 
fridges and the reception bench surface. Samples were also taken randomly at the end of 
each working day during the period of sampling from four drug trolleys and four 
hangers used for raising chemotherapy IV infusion bags. The surface area of each 
surface was measured and calculated. The approximate area of each surface was; 
hangers 141 cm2, fridge door 45 cm2, drug assembly bench 300 cm2 (each section), 
treatment room door 30 cm2, reception bench 60 cm2 and drug trolley 336 cm2.   
The above areas were wiped with a cotton wool pad (5 cm diameter) saturated with       
5 mL of “water for injections” and the area was wiped in accordance with defined and 
validated protocols by the same operator throughout the study. Samples were taken at 
the end of each working day and instructions were provided to nursing staff to place 
gloves used during administration of the marker drugs in the labelled bins. A single 
cotton wool pad was used for each individual surface. 
 4.2.6 Staff training 
Training was provided for both the pharmacy and nursing staff in the use of the 
Tevadaptor device in preparation and administration of chemotherapy infusions. 
Training sessions were undertaken by a pharmacy technician who had previously taken 
part in the Tevadaptor isolator study (Chapter 3). Sampling was performed by the single 
operator who had also validated the wiping motion in a class II BSC placed in the 
pharmacy QC laboratory. 
4.2.7 Sample collection 
The study was performed over a period of three weeks.  In week 1 the marker drug 
infusions were prepared with conventional practice of using needles and syringes and 
wipe samples were taken from the above surfaces (baseline samples) according to a  
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pre-defined sampling schedule. In week 2 a closed system drug transfer device 
(Tevadaptor) was introduced for the preparation and administration of chemotherapy 
infusions, but no samples were taken (familiarisation week). In week 3, preparation was 
undertaken with the Tevadaptor device, but samples were taken (intervention samples). 
The wiped cotton pads were placed individually in 50 mL polypropylene centrifuge 
tubes and the gloves used by nursing staff to assemble and administer marker drugs on 
each day were placed in individual mini-grip bags at the end of each day. All samples 
were stored in a temperature monitored freezer at -22oC prior to analysis for cisplatin, 
carboplatin, oxaliplatin and gemcitabine.  
4.2.8 Sample preparation 
Prior to sample preparation, polypropylene centrifuge tubes containing cotton pads were 
allowed to reach room temperature and then 15 mL of “water for irrigation” B.P was 
added to each tube. These tubes were then centrifuged (500 g for 30 minutes) and 
sonicated for further 30 minutes each. Glove samples were transferred to 1 L high 
density polyethylene (HDPE) bottles and were eluted into 20 mL water by shaking for 
60 seconds. In each case supernatants were taken for analysis as per validated methods. 
4.2.9 Staff questionnaire 
At the end of the three week sampling period a staff questionnaire was distributed 
among the participating nurses and pharmacy operators to assess the user friendliness of 
the Tevadaptor device and staff perception of working with anti-cancer drugs. An 
informal focus group consisting of a pharmacist and two pharmacy technicians was 
assembled to design the statements of the questionnaire. It was then presented to 
pharmacy staff at their weekly staff meeting and suggestions were asked for clarity and 
understanding of the questionnaire.   The questionnaire is reproduced below. 
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Operators’ Opinion on the Use of the Closed-System (Tevadaptor) Device 
Name of Operator …………………………………………..Date:……………. 
Q. How long have you been working with cytotoxic drugs? Describe experience 
…………………………………………………………………………………………. 
…………………………………………………………………………………………. 
Question Agree......................Disagree 
I am worried about working with cytotoxic drugs. 
 
1 2 3 4 5 N/A 
I feel current methods of handling cytotoxic drugs are 
adequately safe. 
1 2 3 4 5 N/A 
I was provided with adequate training prior to the use 
of this device. 
1 2 3 4 5 N/A 
The operator does not need extensive training to use 
this device. 
1 2 3 4 5 N/A 
The device is no more difficult to use than current 
methods. 
1 2 3 4 5 N/A 
The operators are protected from sharps and cytotoxic 
drugs at all times. 
1 2 3 4 5 N/A 
I was more careful while using this device 1 2 3 4 5 N/A 
This device may hinder work during normal practice 1 2 3 4 5 N/A 
This device is a better alternative to normal practice. 1 2 3 4 5 N/A 
Please add any comment 
.............................................................................................................................................
.......................................................................................................................................Sig
nature.................................................................................................Date.................. 
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4.3 Results 
4.3.1 Out-patients ward surface contamination 
A total of 248 surface wipe samples were collected during the course of the study. All 
samples were analysed for all the marker drugs used for the study. The percentage of 
surface samples with gemcitabine above LOD was 2.4% during both baseline and 
intervention phases. Similarly, the percentage of samples contaminated with platinum 
was 91.1% during both baseline and intervention phases. The levels of contamination 
during the baseline phase ranged from undetected to 4.97 ng cm-2 (gemcitabine) and 
undetected to 3.1 ng cm-2 (platinum). On the other hand, the contamination during the 
intervention phase ranged from undetected to 3.21 ng cm-2 (gemcitabine) and 
undetected to 2.69 ng cm-2 (platinum). 
Tables 4.2 and 4.3 present the range  of each marker drug determined on different test 
surfaces, these tables also present the frequency of samples detected above LOD from 
each test surface. The frequency of contaminated samples is the total number of times 
contamination was detected above the LOD in individual wipe samples from the 
particular surface over the three week study period. The recovered quantities were 
obtained by calculating the total drug in each wipe sample and dividing that by the 
surface area of the particular test surface. The results indicate that the contamination by 
marker drugs remained similar during both baseline and intervention phases. 
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Table 4.2: Range of gemcitabine residue determined on test surfaces (ng cm-2) at baseline and Tevadaptor intervention and frequency of samples 
above LOD 
Location  Baseline Tevadaptor 
 Surface 
area (cm2) 
Total 
Samples 
Number 
above 
LOD 
Recovered gemcitabine 
range (ng cm-2) 
Total 
Samples 
Number 
above 
LOD 
Recovered gemcitabine range 
(ng cm-2) 
Door handle 
(Front) 
30 5 0 ND 5 0 ND 
Door handle  
(Back) 
30 5 0 ND 5 0 ND 
Bench 1,200 20 1 ND-0.08 20 0 ND 
Reception 60 5 0 ND 5 0 ND 
Fridge 1 45 5 1 ND-4.97 5 0 ND 
Fridge 2 45 5 0 ND 5 0 ND 
Trolley 336 40 1 0.31 39 3 0.11-3.21 
Hanger  141 39 0 ND 40 0 ND 
ND-Not detected 
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Table 4.3: Range of platinum residue determined on test surfaces (ng cm-2) at baseline and Tevadaptor intervention and frequency of samples 
above LOD 
Location  Baseline Tevadaptor 
 Surface area 
(cm2) 
Total 
samples 
Number 
above 
LOD 
Recovered platinum 
range (ng cm-2)  
Total 
samples 
Number 
above 
LOD 
Recovered platinum range (ng 
cm-2) 
Door(Front) 30 5 5 7×10-5- 6×10-4 5 5 1×10-4-3×10-4 
Door (Back) 30 5 4 ND- 5×10-4 5 4 ND-4×10-4 
Bench 1,200 20 19 ND-4×10-3 20 18 ND-2×10-3 
Reception 60 5 5 7×10-5-0.22 5 5 1×10-4-3×10-4 
Fridge 1 45 5 5 1×10-4-3×10-4 5 4 ND-4×10-4 
Fridge 2 45 5 5 2×10-4-4×10-4 5 5 3×10-4-4×10-4 
Trolley 336 40 29 ND-3.05 39 37 ND-2.69   
Hanger  141 39 35 ND-9×10-2 40 35 ND-0.51  
ND-Not detected 
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4.3.2 Glove contamination 
A total of 103 pairs of gloves were collected during the course of the study. Total 
concentrations of the marker drugs detected on gloves are presented in Table 4.3 and 
4.4. During the baseline phase, 42% of gloves samples were contaminated with 
gemcitabine and 66% of glove samples were contaminated with platinum. The levels of 
contamination ranged from undetected to 1251 ng/glove (gemcitabine) and undetected 
to 405.4 ng/glove (platinum). On the other hand during the CSTD phase 13% of 
samples were contaminated with gemcitabine and 59% of gloves samples were 
contaminated with platinum. The levels of contamination ranged from undetected to 
9252 ng/glove (gemcitabine) and undetected to 1319 ng/glove (platinum). 
Table 4.4: Total amount of gemcitabine detected on gloves (ng) used by nursing staff 
and frequency of samples above LOD at baseline and Tevadaptor phase 
  Baseline  Tevadaptor 
 Total 
samples 
Number 
above 
LOD 
Gemcitabine  
(ng) 
Total 
samples 
Number 
above 
LOD 
Gemcitabine 
(ng) 
Gloves  26 11 5,809 16 2 11,816 
 
Table 4.5: Total amount of platinum detected on gloves (ng) used by nursing staff and 
frequency of samples above LOD at baseline and Tevadaptor phase 
  Baseline  Tevadaptor 
 Total 
samples 
Number 
above 
LOD 
Platinum 
(ng) 
Total 
samples 
Number 
above 
LOD 
Platinum 
(ng) 
Gloves  62  41 1,371 102 60 3,100 
4.3.3 Statistical analysis 
Due to the non-normal distribution of the data a non-parametric statistical test (Mann-
Whitney U test) was used to analyse the surface contamination data from baseline and 
intervention phases of this study. The results of individual wipe samples from the 
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baseline and intervention phases were compared against each other. The null hypothesis 
was that both sets of data were the same and a “p” value of less than 0.05 was required 
to reject the null hypothesis. The p-values for platinum contamination on each surface 
were 0.40 (trolleys), 0.09 (bench surfaces), 0.51 (hanger), 0.19 (gloves) and 0.61 (all 
combined surfaces). Contamination with platinum was also recorded on the reception 
area (n = 3) and treatment room door (n = 2) handle during the baseline phase. 
However, these areas were free from any contamination during the intervention phase 
therefore it was not possible to perform statistical analysis on these samples. The         
p-values for samples with gemcitabine contamination were 0.99 for out-patients ward 
surfaces and 0.11 for gloves used by nursing staff. As the calculated p-value for the 
above samples was above 0.05 the null hypothesis could not be rejected meaning there 
was no statistical difference between the samples from baseline and intervention phases. 
4.4 Discussion 
4.4.1 Comparison with other studies 
The concern regarding the occupational exposure of healthcare staff, particularly 
pharmacy and nursing, involved in preparation and administration of chemotherapy 
infusions, is very much evident from the large number of studies published that present 
not only the results of biological monitoring of staff but also levels of surface 
contamination observed in pharmacy manufacturing units and means of reducing this 
contamination by using measures such as CSTDs. However, there is a clear lack of data 
on the surface contamination by anticancer drugs in oncology ward areas. The present 
study appears to be the first attempt to detect the effects of a CSTD on the surface 
contamination in an oncology out-patients ward and at the same time examine the 
surface contamination in out-patients ward areas by collecting samples from a variety of 
out-patients ward surfaces. A literature search revealed just a single study aiming to 
detect surface contamination on oncology wards in a UK hospital (Ziegler et al., 2002). 
Ziegler et al. (2002) collected wipe samples from the handles and doors of the drug 
storage fridges, drug preparation benches and sluice rooms from two oncology wards 
and gloves of nursing staff involved in drug administration and other duties such as 
handling patients and taking observations.. The marker drugs were cyclophosphamide, 
ifosfamide, methotrexate and platinum-based drugs. Briefly, the levels of platinum 
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detected by Ziegler et al. (2002)  were 6 to 9 ng on the fridge door, <1 to 10 ng on 
bench in the preparation room, <1 to 259 ng in the sluice room and 0.4 to 36 ng on 
gloves. These levels are lower than those reported in the present study which may be 
due to the fact that oncology out-patients departments (sampled in the present study) 
tend to be lot busier and process greater quantities of the cytotoxic drugs than in-patient 
wards such as sampled by Zeigler et al. (2002).     
A review article by Turci et al. (2003) presented more data on the ward surface 
contamination by anti-cancer drugs. The authors included a study where wipe samples 
from drug administration areas and gloves from staff were collected. The marker drug 
was cyclophosphamide and levels reported were 0.01 to 96.6 ng cm-2 on the surface 
samples and 0.04 to 1.37 μg/pair on the glove samples. The surface contamination 
levels reported in the above review are comparable to the present study whereas glove 
contamination levels reported are comparatively higher to the present study.  
4.4.2 Analysis of present results 
Although the statistical analysis showed that there was no significant difference 
between the out-patients ward surface contamination caused by marker drugs during the 
baseline and intervention phases, the total amount recovered of each marker drug was 
markedly different. The total amount of gemcitabine recovered from various out-
patients ward surfaces during the intervention phase (1178 ng) was almost twice as high 
as the baseline phase (575 ng). On further breakdown of the results it was evident that 
the gemcitabine contamination was limited to drug trolleys during the intervention 
phase as compared to contamination on the treatment bench area, fridge and trolley 
during the baseline phase. Furthermore, out of the  three contaminated surface samples 
during the intervention period one sample collected on day 3 of intervention phase had 
unusually high levels of contamination (1079 ng) as compared to the other two samples 
which were in the range of 38-60 ng. On the other hand, the range of gemcitabine 
detected in surface samples (n = 3) during the baseline phase was 104 ng to 247 ng.  
A similar trend was observed in the amounts of gemcitabine recovered from the glove 
samples. The amount of recovered gemcitabine from gloves samples was almost double 
during intervention phase (11,816 ng) from the baseline phase (5,809 ng). The increase 
in detected gemcitabine during the intervention phase was despite the fact that the 
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number of contaminated glove samples was 5.5 times higher during the baseline phase 
(n = 11) as compared to intervention period (n = 2). It was also noted that both the 
contaminated glove samples from the intervention phase and the highly contaminated 
surface sample (from day 3) were collected on the same day. A possible explanation for 
a single contaminated surface sample and glove samples from same day could be 
spillage during administration of the IV infusion. If there was a recorded spillage of 
gemcitabine on day 3 than the results from day 3 may have been disregarded, resulting 
in a six fold reduction in the total contamination in surface samples from the 
intervention phase (99 ng) as compared to the total contamination in the baseline phase 
(575 ng). However, due to the lack of any recorded spillage such an assumption cannot 
be made. It should also be noted that as Tevadaptor device has an active carbon filter 
which may get saturated with use and possibly leak, further work is required to assess 
the loading capacity of this filter.   
The contamination due to platinum-based drugs was measured in terms of total 
platinum. The amount of platinum recovered from various out-patients ward surfaces 
showed a slight reduction during the intervention period (1,313 ng) as compared to the 
baseline phase (1,526 ng). Despite the reduction in total contamination, platinum was 
detected on all test surfaces during both baseline and intervention phases and the results 
from statistical analysis proved that there was no significant difference in contamination 
from all test surfaces between both baseline and intervention phases                              
[p =  0.40 (trolleys), 0.09 (bench surfaces), 0.51 (hanger)].  On the other hand, the total 
platinum recovery from the glove samples increased by more than two fold during the 
intervention period (3,100 ng) compared with the baseline phase (14,000 ng). The 
increase in total recovery of platinum occurred despite a decrease in percentage of 
contaminated glove samples during the intervention period, which may be due to the 
fact that during the intervention period the total number of glove samples collected was 
higher (n = 102 ) than the baseline period (n = 62). Therefore, platinum detected per 
glove was calculated and the values were 30.4 ng/ glove (intervention phase) and     
22.1 ng/glove (baseline phase). On further breakdown it was noticed that one glove 
sample from day 2 of the intervention phase showed platinum level of 1,319 ng 
accounting for 42.5% of total platinum recovered during the intervention phase. Such a 
high level of contamination on a single glove may occur due to spillage, possibly during 
attaching the IV administration set to the infusion bag.       
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Even though there was an increase in the total recovered amounts of both the marker 
drugs in wipe and glove samples after the use of CSTD, such a result was not entirely 
unexpected. Other studies have also reported an increase in surface contamination level 
at certain sampling sites after the use of a CSTD (Siderov et al., 2010, Sessink et al., 
2010). The study by Sessink et al. (2010) compared contamination on BSC surfaces of 
22 US hospitals following the preparation of cyclophosphamide, ifosfamide and 5-FU 
using a CSTD (PhaSeal). The overall results showed a reduction in surface 
contamination after the use of CSTD. However, at a sampling site there was an increase 
in contamination with ifosfamide from 0.18 to 0.72 ng cm-2, and at another site there 
was an increase in cyclophosphamide contamination from 0.30 to 1.84 ng cm-2. 
Similarly, the study by Siderov et al. (2010) compared contamination in two hospital 
sites using cyclophosphamide as marker drugs and PhaSeal as the CSTD. The data were 
collected over a period of 12 months. However, in one hospital there was an increase of 
contamination by cyclophosphamide on a BSC surface after five months from 0.13 (pre-
CSTD) to 0.30 ng cm-2 (post-CSTD). The increase in contamination in the above studies 
was attributed to the external contamination on the drug vials or residual contamination 
from pre-CSTD use.  
This increase in contamination in the present study may also be due to residual 
contamination from the baseline phase or contamination from external surfaces of anti-
cancer drug vials. The levels of contamination on the external surfaces of anti-cancer 
drug vials as supplied by manufacturers are well documented. CSTDs cannot prevent 
cross-contamination of external surfaces of infusion bags if the surfaces of vials 
themselves are contaminated. However in this study there is no evidence of carry over 
contamination as no drug vials are stored in the out-patients ward. Other possibilities of 
increase in contamination during the intervention phase could be poor design of 
Tevadaptor administration system or poor operator technique in attaching the 
administration set due to inadequate training. A one week familiarization period with 
the CSTD device was provided during the study but due to the number and shift pattern 
of nursing staff some staff members could have used Tevadaptor during the intervention 
period without any prior training. Unfamiliarity with the Tevadaptor device may have 
resulted in a faulty connection between the administration set and infusion bag causing 
a spillage of the marker drugs.  
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4.4.3 Inventory   
A further analysis was carried out into the relationship between recovered quantities of 
drugs from the out-patients ward surface and gloves with the amount of marker drugs 
administered each day. Figures 4.5a, 4.5b, 4.6a and 4.6b represent the amount of marker 
drugs administered daily in milligrams whereas the amount recovered is presented in 
nanograms; this was performed to facilitate the graphical representation of the data. 
Figures 4.5a and 4.5b show the amount of gemcitabine administered to patients and 
recovered from oncology out-patients ward surfaces and gloves during the baseline and 
intervention phases. No obvious relationship is identified between the amounts of drug 
administered and drug recovered. On day 1 of the baseline phase, gemcitabine was 
recovered from the fridge handle even though no drug was administered to the patients. 
This can be explained by the fact that the chemotherapy infusions are prepared in 
advance for the patients and are stored in the fridge at the chemotherapy unit. The wipe 
samples were taken at the end of the working day at which time prepared infusions were 
stored in the fridge and any surface contamination from the IV bags prepared using the 
conventional method of needle and syringes would have passed on to the fridge handle. 
The surface contamination on day 3 and 5 of the baseline week was from the drug 
trolley and assembly bench which is consistent with passing of contamination from bag 
surface to these areas. During the intervention phase all contaminated samples were 
from the same day and one surface sample (drug trolley) and a pair of gloves showed 
much higher levels of contamination than all other samples which, as discussed earlier, 
was possibly due to a faulty connection between the administration set and the infusion 
bag. 
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Table 4.6: Total amounts of marker drugs used (mg) in test preparations and recovered 
from each surface sampled (μg), during baseline and intervention periods, and residue 
of each drug recovered (as μg g-1 drug used).                  
  Gemcitabine  Platinum  
  Baseline Tevadaptor Baseline Tevadaptor 
Amount 
administered 
(mg) 
 19,800   48,500 6,660 6,799  
Amount 
recovered (μg) 
Surface 0.57 1.18 1.53 1.31 
Gloves 5.81 11.8 1.37 3.10 
Total Recovered 
(μg) 
 6.38 12.9 2.90 4.41 
aDrug  recovered 
(μg g-1) 
 0.32 0.26 0.44 0.65 
a Denotes total drug recovered (μg) from all surfaces per g of drug used (or per g platinum-based 
drugs) in both baseline and intervention phase of the study  
Table 4.6 presents the total amount of marker drugs administered as well as recovered 
during the study period. The amount of contamination recovered was normalised for the 
amount of each drug prepared during both the phases of the study. The results showed 
that the amount of gemcitabine recovered during the intervention phase was lower by a 
factor of 0.8 as compared to the baseline phase and the amount of platinum recovered 
during the intervention phase was higher by a factor of 1.5 as compared to the baseline 
phase. 
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Figure 4.5a: Amount of gemcitabine administered to the patients (mg) per day of the 
baseline week and the amount detected from the surface and glove samples (ng) from 
the corresponding day.  
 
Figure 4.5b: Amount of gemcitabine administered to the patients (mg) per day of the 
intervention week and the amount detected from the surface and glove samples (ng) 
from the corresponding day  
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Figure 4.6a: Amount of platinum (as platinum-based drugs) administered to the patients 
(mg) per day of the baseline week and the amount detected from the surface and glove 
samples (ng) from the corresponding day  
 
Figure 4.6b: Amount of platinum (as platinum-based drugs) administered to the patients 
(mg) per day of the intervention week and the amount detected from the surface and 
glove samples (ng) from the corresponding day 
Figures 4.6a and 4.6b represent the amount of platinum-based drugs administered to 
patients (represented in the terms of platinum) and recovered from oncology out-
patients ward surfaces per day during the baseline and intervention phases. The graph 
for baseline data (Fig 4.6a) does not show any obvious relationship between the amount 
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of platinum-based drugs administered per day and the amount of drug recovered from 
out-patients ward surfaces or gloves. However, the graph for the intervention phase  
(Fig 4.6b) shows that the increase in administered drug may result in increased surface 
contamination. The increase in the amount of drug administered also corresponded with 
an increase in number of patients resulting in more pressure on staff, which may have an 
impact on the efficacy of the device if the staff using it were not fully trained in its use. 
It is difficult to draw this inference from the data as the sampling phase with Tevadaptor 
was just five days. A study with longer sampling phase may be able to answer the 
questions raised in this study.  
4.4.4 Staff questionnaire 
A questionnaire was distributed at the end of study to all nursing and pharmacy staff 
regarding the use and suitability of Tevadaptor. The results of the three representative 
questions are presented in Fig. 4.7. 
 
Figure 4.7: Representation of questionnaire responses (n = 9) by nursing and pharmacy 
staff, designed to obtain staff perceptions regarding the use of CSTDs 
A total of nine members of staff with an experience of 1 to 12 years completed the 
questionnaires (five nursing staff and four pharmacy staff). Out of nine members of staff 
two did not think the CSTD was a better alternative to current practice, four members 
were neutral about the device and three thought that it was better than current practice. 
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On further breakdown of the data, three out of four pharmacy staff agreed the CSTD 
was better than current practice and one member was neutral, whereas three nurses were 
neutral about the device and two did not think it was better than current practice. In 
response to another question two members of staff were worried about working with 
cytotoxic drugs and the rest were either neutral or unconcerned about working with 
cytotoxic drugs. However, the staff who thought CSTD was better than current practice 
were either worried or neutral about working with cytotoxic drugs and staff who were 
not worried about working with cytotoxic drugs did not think the CSTD was better than 
current practice or were neutral towards risks of working with cytotoxic drugs. Despite 
being a small sample size the results of this questionnaire suggest that the perception of 
staff about CSTDs may depend on their perception of hazards associated with working 
with cytotoxic drugs. For future research a similar survey of staff perceptions regarding 
use of CSTDs may be conducted on a national/regional level which may support the 
results from present study. 
4.5 Conclusion 
The results of this study indicate that contamination of work surfaces with anticancer 
drugs is not only limited to pharmacy manufacturing units but is also prevalent in 
oncology out-patients ward areas such as drug trolleys, IV infusion hangers, treatment 
room surfaces, door handles and even reception desk.  Although the out-patients ward 
surface contamination found in this study was lower than the levels observed in 
pharmacy areas, the associated risk of occupational exposure of healthcare staff to 
anticancer drugs may be greater on the ward areas as ward environments are less well 
controlled than pharmacy manufacturing units. The results of this study showed that 
despite the use of CSTD (Tevadaptor) the contamination levels on ward surfaces with 
marker drugs remained statistically unchanged and highlighted the fact that despite best 
practice the risk of occupational exposure to anti-cancer drugs by nursing staff still 
remains. Even though the sample set was  small the results indicated that the staff 
perception of the usefulness of a CSTD may depend on their perception of the hazards 
associated with working with anticancer drugs, further work is required to support these 
results. In the absence of set safe levels of occupational exposure to anticancer drugs, 
effort must be made to keep work place contamination to ALARA (Weir et al., 2012). 
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One way of achieving ALARA would be the use of CSTD in preparation and 
administration of chemotherapy infusions. 
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Chapter 5: Drain study 
5.1 Introduction 
The presence of various pharmaceutical compounds in surface water bodies was first 
reported in the 1970s (Hignite and Aznaroff, 1977) and a number of studies have since 
reported on the more widespread presence of various pharmaceutical substances in the 
environment (Kosjek and Heath, 2011, Halling-Sorensen et al., 1998, Ashton et al., 
2004, Focazio et al., 2008, Stuart et al., 2012). Pharmaceutical drugs enter the 
environment via direct excretions from patients, waste discharges from the 
pharmaceutical industry, hospitals and agriculture and also from the disposal of unused 
pharmaceutical products (Jelic et al., 2012). The contamination of water bodies by 
pharmaceuticals may result in unexpected and undesired effects. For instance, Kidd et 
al. (2007) studied the effects of waste-water containing estrogenic substances (from 
urinary excretion of contraceptive pills) on fathead minnow fish and found that 
exposure to 17α-ethynylestradiol resulted in feminization of male fish via the 
production of vitellogenin mRNA and vitellogenin protein, which is synthesised by 
female fish during oocyte maturation; males exposed to 17α-ethynylestradiol produce 
vitellogenin protein and eggs in their testes. This phenomenon resulted in a near 
collapse of fathead minnow population in experimental lakes area (ELA) in Canada. 
Although drugs belonging to various therapeutic groups have been detected in waste 
waters (Jelic et al., 2012), the presence of anticancer drugs in water systems is of 
particular concern because they display mutagenic, teratogenic and carcinogenic 
properties (IARC, 1990) and are not readily biodegraded (Besse et al., 2012, Kosjek and 
Heath, 2011) or in some cases, such as cisplatin, degrade into active metabolites. As 
anticancer drugs are largely administered in hospitals, hospital waste water is an 
important source of these substances to the environment (Pauwels and Verstraete, 
2006). However, since chemotherapy infusions are often administered to out-patients, 
excretion into domestic sewage may also be significant.  
Kosjek and Heath (2011) reviewed published literature on the presence of the cytotoxic 
drugs as well as the parameters governing the behaviour of anti-cancer drugs in the 
environment. The parameters considered responsible for behaviour of cytotoxic drugs in 
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the environment were, dissociation, sorption, biodegradability, stability towards 
photolysis, volatility and transformation of cytotoxic drugs in the environment. As well 
as the above parameters Kosjek and Heath (2011) also provided data on the presence of 
cytotoxic drugs in the hospital waste water samples (e.g. presence of cyclophosphamide 
and ifosfamide in waste-water samples from a German hospital). The samples in the 
reviewed studies were taken from hospital drains and analysed using HPLC. The results 
for some of the commonly used anti-cancer drugs in hospital wastes are provided in 
Table 5.1. There are, however, no studies showing the presence of anti-cancer drugs in 
the waster-water of UK hospitals or cities.  
Table 5.1:  Reported environmental behaviour of specific anti-cancer drugs and their 
concentrations in hospital effluent. [adapted from data provided by Kosjek and Heath 
(2011)] 
Drug Biodegradable Adsorption 
to sludge 
Photolysis Hospital effluent 
concentration 
cyclophosphamide No No No 0.14-4.5 μg L-1 
Ifosfamide No No No 0.006-2 μg L-1 
doxorubicin No Yes - 0.1-1.35 μg L-1 
Epirubicin No Yes - 0.1-1.4 μg L-1 
gemcitabine Yes - - 0.009-0.038  μg L-1 
5-FU Yes No No 20-122 μg L-1 
Cisplatin No - - - 
- No data reported 
The Tevadaptor isolator (Chapter 3) and ward (Chapter 4) studies investigated 
contamination with anti-cancer drugs in pharmacy and hospital work surfaces. Once, 
administered to patients, the anti-cancer drugs are excreted by patients in hospital and 
domestic waste-water and have the potential to contaminate receiving river waters via 
the waster-water treatment plants. With this rationale in mind, the drain study was 
conducted. The present study is the first in the UK to report on the concentrations of 
platinum (as a measure of platinum-based anti-cancer drugs) in the waste-water from a 
UK tertiary care hospital (Derriford, Plymouth, UK). The marker drugs used for the 
present study were cisplatin, carboplatin and oxaliplatin. These drugs were selected 
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owing to their widespread use in the treatment of various cancers such as testicular, 
ovarian, bladder, squamous cell carcinoma of head and neck, small cell lung carcinoma, 
and metastatic colorectal cancer and all three drugs are primarily excreted via urine 
resulting in their discharge into waste water. According to the pharmacokinetics of 
platinum-based drugs, more than 90% of administered cisplatin is protein bound and 27 
to 45% of administered cisplatin is excreted via urine over 5 days, in the case of 
oxaliplatin up to 85% of administered drug is protein bound and up to 50% is excreted 
via urine over 2 days. However, the fraction of protein bound carboplatin post 
administration is 24% and 65 to 70% of carboplatin is excreted within 24 hours of 
administration and most of it is excreted in first six to eight hours of administration 
(http://www.medicines.org.uk; Schellens et al., 2005). The presence of these drugs in 
the waste water is of particular concern as they are cytotoxic in their unchanged form 
and also have tendency to form active metabolites which also have cytotoxic properties 
(see Equations 2.1 to 2.5, page 52-54). Cisplatin is widely studied and under 
physiological conditions forms monoaquacisplatin and diaquacisplatin (see Equations 
2.1 and 2.2, page 52) out of which monoaquaform is responsible for its cytotoxic action 
(Malinge et al., 1999).  Hann et al. (2003) measured the distribution of cisplatin and its 
active monoaquacisplatin form in the diluted urine of a cancer patient and simulated 
waste-water conditions. The samples of urine and waste-water were analysed using 
HPLC-ICP-MS and the results revealed that the percentage of monoaquacisplatin to 
cisplatin was up to 40% in the urine samples and up to 75% in the waste-water samples. 
Even though there is no data on behaviour or presence of carboplatin and oxaliplatin in 
sewage systems, the pharmacological properties of these drugs could be used to 
estimate their behaviour in environment. Carboplatin is a pro-drug of cisplatin and in 
physiological solutions and normal saline solution it converts into cisplatin in the 
presence of chloride ions (see Equations 2.3 and 2.4, page 53) which in turn forms 
active metabolites as revealed by Hann et al. (2003). Oxaliplatin also undergoes 
extensive biotransformation in the human body and results in formation of cytotoxic 
metabolites including the monochloro, dichloro- and diaquo-diaminocylohexane species 
(see Equation 2.5, page 54) (Martin et al., 2000) which are then excreted through urine 
but no data are available on the presence of these metabolites in the environment.  
The present study was conducted by taking daily samples for three consecutive weeks 
(to mimic a three week chemotherapy cycle) from two hospital drains collecting     
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waste-water from the oncology out-patients department (see Fig 5.1 for a flow diagram 
of drain study design). The samples were then treated according to validated methods 
and analysed for total platinum by ICP-MS. 
 
Figure 5.1: Flow diagram of drain study design 
5.2 Methods 
5.2.1 Study setting 
The waste-water samples were taken from drains of Derriford Hospital, which has two 
specialist in-patient wards, one each for oncology and haematology, and a 
Study Protocol
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chemotherapy outpatients department. For the purpose of this study the waste-water 
samples were collected from the outpatient department only, as the usage of platinum-
based anticancer drugs is minimal on the in-patient wards. The oncology building has 
two toilets specifically for patients as well as separate toilets for staff. On average,     
30-40 patients are administered chemotherapy infusion in the department per day. An 
extensive underground drainage system of the hospital collects waste-water from all 
sites of the hospital, which is then discharged into the municipal drainage system. To 
collect waste-water samples two drains were identified which were located immediately 
outside the oncology outpatients department and were labelled drain1 and 2 (See 
Appendix 4 for a diagram of the drains). Drain 1 carried waste from all toilets (both 
patient specific and staff) from the oncology building whereas, drain 2 contained waste 
from drain 1 and a section of the hospital comprising of non-oncology wards. The drain 
pipes were semi-circular in shape with a diameter of approximately 15 cm. According to 
the figures provided by the Estates Department of Derriford Hospital, the average flow 
rate from drain 2 was approximately 3.2 L sec-1 (273,970 L day-1). This was based on 
the assumption that 100,000 m3 water is discharged through drain 2 annually (no flow 
rate figures were available for drain 1).  
5.2.2 Method development and validation 
The marker drugs used for this study were cisplatin, carboplatin and oxaliplatin. The 
platinum-based drugs were selected for this study as these drugs are excreted by patients 
via urine and can be detected in a complex matrix of waste-water using ICP-MS. The IV 
infusions of platinum-based drugs are administered to patients in the oncology out-
patients unit and then patients are discharged on the same day. During this study 
samples were collected from two pre-identified drains and were then analysed for 
platinum content, pH and conductivity.  
5.2.2.1 Sampling 
Samples were collected between 12 noon and 1 pm on week days during June and July 
2012 over a 21 day period, thereby encompassing a three week chemotherapy cycle. 
Due to access restrictions to the drains it was not possible to siphon off waste-water into 
a collection vessel, therefore the samples were collected manually by placing a 1 L high 
density polyethylene bucket into the waste stream with the aid of a 4 m length of nylon 
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string. Once sufficient waste water had been collected, the bucket was carefully raised 
and a screw-capped 60 mL polyethylene centrifuge tube filled to the mark. The bucket 
was then rinsed successively with 0.1 M HNO3, hypochlorite disinfectant solution and 
distilled water before being stored in a plastic zip-lock bag until required for the next 
sampling.  
The sample from each drain was divided into two 50 mL aliquots and stored in 
polypropylene centrifuge tubes (Fisher Scientific). One aliquot was vacuum-filtered 
using a Sartorius vacuum filtration unit with vacuum resistant flask. The filtration unit 
was made of glass, except for a polytetrafluoroethylene (PTFE) ring containing the 
glass frit filter support. Whatman 542 hardened ashless filter papers (2.7 μm pore size) 
were used for the filtration. The filtered aliquot was stored in a 50 mL polypropylene 
centrifuge tube at -22oC pending analysis; the second aliquot was stored likewise but 
without filtration.  The filters containing solid residue were also stored in polypropylene 
tubes at -22oC. 
5.2.2.2 Sample preparation and analysis 
In the laboratory and as required, the frozen samples were allowed to defrost overnight 
at room temperature prior to analysis. The pH and conductivity of the defrosted samples 
were measured using an Acorn pH 6 meter (Fisher Scientific Ltd) and YSI 85 handheld 
dissolved oxygen/conductivity (Fisher Scientific Ltd) meter, respectively. The samples 
were then acidified using 1 mL concentrated HCl (trace metal grade). Total platinum 
was then measured in filtered and unfiltered aliquot as well as the solid residue from the 
filtered samples. The solid residue was analysed after the digestion of each filter 
according to a procedure described by Lenz et al. (2005). Each filter was placed in an 
acid cleaned, 50 mL glass beaker and was digested in a 12 mL solution of three parts 
concentrated HCl and 1 part concentrated HNO3, (Fisher trace metal grade) the beakers 
were then heated to 85oC on a hot plate under a watch glass for 30-60 minutes. The 
digested solution was then allowed to cool and diluted to 20 mL in a polypropylene tube 
(50 mL) with 2% HNO3 and then stored at room temperature and in the dark pending 
platinum analysis (see Sections, 2.4 and 3.2.3.9 for details of platinum analysis). For 
quality assurance purposes, 250 mg of a certified reference material was digested in 
triplicate likewise. The certified reference material was National Institute of Standards 
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and Technology (NIST) 2556, used auto catalyst pellets (697 μg g-1 platinum) and was 
obtained from Gaithersburg, USA. Total platinum in filtrates, unfiltered samples and 
digests was determined in triplicate by ICP-MS. The results from the reference 
materials digestion (n = 3) were in the range of 583-611 μg g-1 platinum with an 
average of 602 ± 9.5 μg g-1 platinum. This compares with a certified value of              
697 ± 2.3 μg g-1 platinum indicating on average 86% efficiency of the digestion process.  
5.3 Results 
The results of this study are provided in Table 5.2 and 5.3. The pH and conductivity of 
the samples was measured prior to the acidification of the samples. The conductivity of 
a solution is a measure of the concentration of ions and the pH is the logarithmic 
measure of hydrogen ion concentration of the solution and is used as measure of the 
acidic (pH < 7) or basic (pH > 7) nature of the solution. The range of pH in drain 1 
samples was 2.88 to 7.7 (median = 6.8) and in case of drain 2 the pH range was 5.15 to 
8.8 (median = 6.86). The conductivity values from both drains also showed a wide 
range.  The conductivity of drain 1 samples ranged from 143-630 S cm-1            
(median = 275 S cm-1) and in drain 2 the range was from 164-794 S cm-1          
(median = 417 S cm-1). The total platinum concentration was above the LOD in all of 
the samples from both drains. The range of the total platinum concentrations in the 
filtered solutions and on the filters of drain 1 samples was 0.02-141 μg L-1               
(median = 0.89 μg L-1) and the range of drain 2 samples was 0.01-95.6 μg L-1        
(median = 0.63 μg L-1).  
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Table 5.2: Platinum concentration (μg L-1) and aqueous fractionation, and pH and 
conductivity (S cm-1) of samples from drain 1 (median, min amd max values of the 
samples are in bold). 
Drain 1 
Sample pH Conductivity Aqueous 
platinuma 
Filter 
platinumb 
Total 
platinum 
% aqueous 
1 3.00 601 1.37 0.06 1.43 95.8 
2 6.80 282 0.48 ND 0.48 100 
3 6.80 630 39.1 2.12 41.2 94.9 
4 7.02 143 0.24 0.18 0.42 57.1 
5 7.70 275 5.17 ND 5.17 100 
6 6.56 225 0.29 ND 0.29 100 
7 7.10 280 138 2.52 141 97.9 
8 6.80 357 6.94 0.07 7.01 99 
9 6.91 278 1.42 0.37 1.79 79.3 
10 6.40 216 4.17 0.06 4.23 98.6 
11 6.48 175 0.29 ND 0.29 100 
12 2.88 621 0.02 ND 0.02 100 
13 5.98 175 0.14 ND 0.14 100 
14 7.07 272 0.11 0.10 0.21 52.3 
15 6.38 235 0.89 ND 0.89 100 
Median 6.80 275 0.89 0.06 0.89 99 
Min 2.88                                       143 0.02 ND 0.02 52.3 
Max 7.70 630 138 2.52 141 100 
ND- Not Detected 
a-Platinum content in the filtrate 
b-Platinum content in the solid content 
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Table 5.3: Platinum concentration (μg L-1) and aqueous fractionation, and pH and 
conductivity (S cm-1) of samples from drain 2 (median, min and max value of samples 
are in bold). 
Drain 2 
Sample pH Conductivity Aqueous 
platinuma 
Filter 
platinumb 
Total 
platinum 
% 
aqueous 
1 8.30 392 1.48 0.02 1.50 98.7 
2 7.24 214 0.26 0.06 0.32 81.3 
3 8.40 472 2.72 ND 2.72 100 
4 6.32 417 0.55 0.08 0.63 87.3 
5 8.80 438 0.39 9.54 9.93 3.92 
6 8.40 446 0.19 ND 0.19 100 
7 6.95 365 80.6 3.96 84.6 95.3 
8 6.70 234 1.69 ND 1.69 100 
9 7.06 494 1.61 ND 1.61 100 
10 6.86 352 95.1 0.48 95.6 99.5 
11 6.58 538 0.10 ND 0.06 100 
12 6.52 453 ND 0.01 0.01 0 
13 5.15 164 0.19 ND 0.19 100 
14 6.26 335 0.10 ND 0.06 100 
15 6.20 794 0.03 ND 0.03 100 
Median 6.86 417 0.39 0.08 0.63 100 
Minimum 5.15 164 ND ND 0.01 3.92 
Maximum 8.80 794 95.07 9.54 95.6 100 
ND- Not Detected 
a-Platinum content in the filtrate 
b-Platinum content in the solid content 
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The percentage of platinum in the aqueous phase of each sample, also shown in Tables 
5.2 and 5.3, was calculated using Equation 5.1:  
% platinum in aqueous phase = (aqueous platinum/ (aqueous platinum + filter    
platinum))×100%                                                                                 Eqn 5.1 
This value was used to provide a measure of binding of platinum to the suspended 
solids in the samples. Where platinum was not detected in the filters, the fraction in the 
aqueous phase was assumed to be 100%. The percentage of platinum in the aqueous 
phase ranged from 29.58 to 100% for drain 1 samples and 1.6 to 100% in case of drain 
2 samples. The median value of platinum in aqueous phase was 97.3% and 100% for 
drain 1 and drain 2, respectively.  
Tables 5.2 and 5.3 present the amount of platinum detected in samples from both drains 
from each day in the aqueous as well as well as the solid phase. The distribution of 
platinum in filtered aliquots and filters revealed that the amount of platinum was greater 
in 90% (n = 27, out of 30) of filtered samples but there was a measurable quantity of 
platinum in the solid phase of most of the samples. This finding is partly consistent with 
the known propensity of platinum to adsorb to suspended solids in a solution (Lenz et 
al., 2005, Curtis et al., 2010). Since in most samples the percentage of platinum in the 
aqueous phase is considerably higher than in the solid phase, it is possible that there was 
insufficient contact time to allow appreciable adsorption of platinum-based drugs to the 
solid phase. The rate of adsorption is dependent on the rate of aquation and the rate at 
which aquated species adsorb according to a first-order process which is a time 
dependent process (see Equations 2.1 to 2.5, page 52-54). However, the platinum 
content was higher in the solid phase of samples from day 4 and day 14 from drain 1 
and day 5 sample from drain 2. This was possibly due to high amount of organic matter 
in these samples resulting in the binding of platinum to the solid material. Dissolved 
platinum may bind to the sulphur present in the organic matter in the waste-water 
samples resulting in its precipitation which in turn may increase concentration of 
platinum in suspended solids (Lenz et al., 2005).  
Figure 5.2 shows a plot of conductivity against pH for all drain samples. The maximum 
conductivity of the samples from current study was 794 S cm-1 and pH of the same 
sample was 6.2 (see Table 5.3, sample 15); on the contrary the minimum conductivity 
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was 143 S cm-1 and the pH of this particular sample was 7.02 (see Table 5.2, sample 
4). These results do not show any correlation to each other because samples collected 
for the current study contained a complex matrix of various ions and acidities as shown 
by the results in Tables 5.2 and 5.3. 
 
Figure 5.2: Conductivity (μS cm-1) against pH as detected in the waste-water samples 
collected from drain 1 and 2.  
In Figures 5.3 and 5.4 dissolved platinum is represented against pH and conductivity, 
respectively. These graphs were plotted for  data from both drains. Even though the 
median pH value for both drains was 6.8, there was a greater variability in samples from 
drain 1 with samples from day 1 and 12 having a pH of 3 and 2.88, respectively. The 
normal pH of human urine ranges from 4.6 to 8.0. However, a study has demonstrated 
that consumption of Coca-Cola can result in urinary pH of as low as 2.54 (De Vries et 
al., 1986). The same study also showed consumption of yoghurt and orange juice can 
also result in acidic urine. It is possible that the collection of these samples coincided 
with excretion from patients who had consumed one of the above products. As the 
samples were from drain 1 which collected waste from the oncology building there was 
less probability of sample dilution as the flow rate in this drain was low. Although the 
combined range of pH from both drains was 2.88 to 8.8, the maximum number of 
samples (n = 22 out of 30) were within 6.2 to 7.7 which was the pH range the maximum 
platinum was also detected. Therefore, from these data it is not possible to assume that 
the pH of the samples had any obvious impact on or cause of the platinum 
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concentration. Similarly, there was no relation between the conductivity and platinum 
concentration of the samples.  
 
 
Figure 5.3: Dissolved platinum concentrations (μg L-1) in the waste-water samples from 
Drain 1 and 2 against pH as detected in those samples  
 
Figure 5.4: Dissolved platinum concentrations (μg L-1) in the waste-water samples from 
Drain 1 and 2 against conductivity (μS cm-1) in those samples 
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5.4 Discussion 
5.4.1 Comparison with other studies  
The major sources of platinum contamination in the environment are excretion of 
platinum-based drugs, emissions from catalytic converters of cars, and wastes from the 
electronics and jewellery industries (Kummerer et al., 1999). It is important to identify 
the sources of platinum as the toxicity profile of inorganic platinum is different from 
platinum species of chemotherapeutic agents. Kummerer et al. (1999) reported platinum 
levels in hospital effluent from five different European hospitals (one each from 
Germany, Belgium, Italy, Austria and Netherlands). A 1 L sample was taken every 2 
hours for a 24 hours period from the main drain of the each hospital and was analysed 
for platinum content. The reported platinum concentration was in the range of        
<0.01-0.601 μg L-1. Another study (Lenz et al., 2005) also reported platinum 
concentration in the effluent from an Austrian hospital. The samples were collected by 
rebuilding the sewerage system of the oncology ward in such a way that all waste water 
was collected in a collection tank over a period of 28 days. Samples were taken from the 
collection tank daily and analysed for total platinum content (solid and liquid phase) 
which ranged from 4.7 to 145 μg L-1. No data on the median values or number of 
samples were provided in both of the above studies. However, the range of platinum 
detected in the above studies is similar to the present study where platinum 
concentrations are in the range of 0.02-144 μg L-1. The similarity of the data from these 
studies to the present study is not unexpected as the platinum-based drugs are licensed 
and used throughout the EU for the treatment of various cancers. The dose of cancer 
chemotherapy is based on body surface area and as the demographic is similar in most 
EU countries the amount of platinum-based drugs administered per patient is likely to 
be similar. At the same time based on the pharmacokinetic profile of platinum-based 
drugs the elimination by patients in these studies should also be similar to each other. 
Therefore it may be assumed that the amounts of platinum-based drugs administered 
and eliminated per patient were similar in these studies. Furthermore, in the study by 
Kummerer et al. (1999) the sampling pattern was similar to the present study where 
samples were taken from constantly flowing hospital sewers every two hours. The 
above discussed reasons may cause the similarity of data in these studies.  
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5.4.2 Platinum concentrations in the drains 
This is the only UK study reporting data on concentrations of platinum as a measure of 
platinum-based anti-cancer drugs in the waste-water from a UK hospital. It is evident 
from the results that the distribution of platinum concentration of the samples is non-
normal, which is the reason for using median values to describe results of this study. 
The major reason for this variability was the sampling schedule. Owing to access issues 
to the drains the sampling was limited to once a day and only a 100 mL sample was 
collected from the constantly flowing drains which meant an inherent randomness to the 
sample concentrations was expected. Even though there was a constant flow of     
waste-water in the drains the platinum concentration in the waste-water spiked as and 
when a patient excreted platinum via urination. As the samples were only collected once 
a day, if the sample collection coincided with patient excretions high concentration of 
platinum was collected in those samples and none or negligible amount of platinum was 
collected in the rest of the samples, explaining the wide range of platinum concentration 
in the samples. Furthermore, the patients are administered their IV infusions in the    
out-patients unit and are discharged the same day, which provides a very narrow 
window of time (maximum of 8 hours) for the platinum to be excreted by the patients in 
the hospital. It should also be noted that samples were generally collected from drain 1 
followed by drain 2 and there was a time lag of few minutes between the collection of 
both samples. As drain 1 flowed into drain 2 the time lag between sampling may be 
responsible for the higher platinum concentrations in drain 2 samples from day 5 and 10 
(Fig. 5.5 shows platinum concentrations from both drains on a logarithmic scale each 
day of sampling) even though drain 1 samples were expected to have higher platinum 
concentrations, as this drain collected waste-water from only the oncology building. 
This can be explained by assuming a sample was collected from drain 1 followed by 
drain 2, in the time between closing drain 1 and collecting a sample from drain 2 a 
patient could urinate excreting platinum which is then collected in drain 2 resulting in 
higher concentration of platinum in drain 2 sample. The combined effect of the above 
factors resulted in the non-normal distribution of the platinum concentrations in the 
collected samples.  
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Figure 5.5: Platinum concentrations detected in drains 1 and 2 each day of sampling. 
The logarithmic values of platinum concentrations are represented in this graph.   
Figure 5.5 summarises platinum concentrations in the two drains on a log scale while 
Table 5.4 provides a breakdown of each marker drug administered during the study 
period. From Table 5.4 it is evident that no marker drugs were administered to the 
patients on day 5 and 11 but even on these days platinum was observed in drain samples 
(see Fig. 5.5). Platinum based drugs are generally used in conjunction with other 
chemotherapeutic agents for the treatment of various cancers (Schellens et al., 2005). 
For example a combination of cisplatin and gemcitabine are used in cases of bladder 
cancer where IV infusions of both drugs are administered on day 1 of treatment cycle 
and gemcitabine is administered again on day 8 (Tewari et al., 2004, 
www.macmillan.org.uk/cancerinformation/cancertreatment). The elimination of 
cisplatin may take up to 53 days (Schellens et al., 2005). It is possible that a patient on 
this regimen might have been treated with a second dose of gemcitabine on the day 5 or 
11 of sampling and this patient would still be excreting cisplatin. Similarly, a 
combination of carboplatin and etoposide is used for treatment of small cell lung cancer. 
In this regimen IV infusions of both drugs are administered on day 1 and etoposide is 
repeated on day 2 and 3 (www.macmillan.org.uk). Up to 70% of carboplatin is 
eliminated in first 24 hours of treatment (www.emc.medicines.org.uk). A patient 
coming in for second dose of etoposide of this regimen would still be excreting their 
carboplatin dose which may have been the source of platinum in either day 5 or 11 
samples for this study.          
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Table 5.4: Amount of marker drugs and equivalent platinum administered presented in 
brackets during the study period in mg. 
Day cisplatin       
(platinum) 
carboplatin 
(platinum) 
oxaliplatin 
(platinum) 
total 
platinum/day 
1 45 (29.25) 530 (280.9) 0 310.15 
2 0 0 440 (215.6) 215.6 
3 0 0 380 (186.2) 186.2 
4 149 (96.85) 250 (132.5) 0 229.35 
5 0 0 0 0 
6 45 (29.25) 470 (249.1) 0 278.35 
7 105 (68.25) 500 (265) 200 (98) 431.25 
8 0 0 560 (274.4) 274.4 
9 75 (48.75) 128 (67.84) 0 116.59 
10 105 (68.25) 0 200 (98) 166.25 
11 0 0 0 0 
12 110 (71.5) 950 (503.5) 260 (127.4) 702.4 
13 44 (28.6) 250 (132.5) 0 161.1 
14 0 750 (397.5) 620 (303.8) 701.3 
15 0 440 (233.2)  340 (166.6) 399.8 
Sum 678 (440.7) 4268 (2262.04) 3000 (1470) 4172.4 
5.4.3 Inventory 
From Table 5.4, during the study interval a total of 0.68 g cisplatin, 4.3 g carboplatin 
and 3 g of oxaliplatin were administered to the patients at Derriford Hospital. Based on 
the fact that one mole of each platinum-based drug contains a mole of platinum and 
using the molecular weight of each marker drug (cisplatin = 300 g mol-1, oxaliplatin = 
397.3 g mol-1, carboplatin = 371.2 g mol-1 and the molecular mass of platinum           
(195 g mol-1), the total platinum administered to the patients was calculated to be 4.2 g 
over the three week period. The platinum contribution arising from the use of each drug 
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was calculated by multiplying the amount of each drug used over three weeks with the 
platinum content in one mole of each drug. 
According to the pharmacokinetic profile of carboplatin (see Section 5.1), 65 to 70% of 
the administered dose is excreted within the first 6 to 24 hours of administration, 
therefore the maximum possible amount of carboplatin which could be excreted during 
the study interval would be approximately 2.98 g (70% of 4.3 g) which equates to     
1.56 g of platinum. On the other hand, cisplatin and oxaliplatin are excreted over a 
period ranging from 2 to 5 days (Schellens et al., 2005, Martin et al., 2000). Therefore, 
the majority of these drugs are likely to be excreted by patients at home. As all the 
marker drugs were administered to patients in the out-patients unit and they had a 
window of  8 hours to excrete these drugs, platinum as carboplatin (maximum 1.56 g) 
was expected to be recovered in hospital waste during the study interval and the 
platinum as cisplatin or oxaliplatin was expected to be discharged via the household 
waste-water. 
As discussed in Section 5.2.1 the average flow rate from drain 2 was approximately      
3 L second-1 (no flow rate data available for drain 1). Applying the median platinum 
concentration value of drain 2 (0.63 μg L-1) to its flow rate the total platinum discharged 
through this drain over 3 working weeks (127.5 hours) would be 0.86 g which was 55% 
of the expected amount (1.56 g) and 21% of the total platinum administered (4.2 g) to 
the patients during the study interval and is expected to be only from carboplatin. The 
remaining platinum (80%) is expected to be emitted in the household waste-water and 
will be from the excretions of mixture of carboplatin, cisplatin and oxaliplatin. 
However, the majority of platinum in household waste would be from cisplatin and 
oxaliplatin. 
5.4.4 Predicted species, environmental concentrations and fluxes in hospital waste-
water 
The findings of this study may also be used to estimate the total amount of platinum-
based drugs disposed via hospital and household waste-water in a year.  The average 
weekly usage of the three marker drugs during this study in terms of the total platinum 
was 1.39 g equating to 72.28 g of platinum over a year. On applying the results of the 
present study approximately 14.5 g (20% of the total platinum) of platinum (carboplatin 
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only) should be excreted via hospital waste-water and the rest 57.78 g (80% of the total 
platinum) (mixture of carboplatin, cisplatin and oxaliplatin) should be excreted via 
household waste-water. These results agree well with a study by Lenz et al., (2007) 
where the authors concluded that 28-34% of the total platinum administered to patients 
was emitted via hospital waste-water. In their study the wastewater from the hospital 
was fed into a membrane bioreactor system (MBR) and effect of adsorption of platinum 
onto activated sludge was studied. The platinum concentration of hospital waste-water 
influent to the MBR system and the treated effluent from the MBR system were 
detected and ranged from 3-250 μg L-1 in the influent and 2-150 μg L-1 in the effluent 
showing an elimination efficiency of 51-63% by removing suspended solids and 
platinum adsorbed on to the activated sludge. The platinum species were identified by 
HPLC-ICP-MS and it was revealed that most of the platinum in hospital wastewater 
originated from carboplatin. 
Lenz et al. (2005) also studied the adsorption of the three platinum-based drugs to 
activated sludge particles suspended in various waste waters at concentrations of about 
4 g L-1 and at pH 6-7. In order to allow for realistic speciation (i.e. aquation), the drugs 
underwent aging in NaCl solution ([Cl-1] = 61 mg L-1) for at least 48 h before being 
spiked into the suspensions. The results revealed average removals of 92%, 72% and 
78% for cisplatin, carboplatin and oxaliplatin, respectively, presumably through the 
adsorption of reactive, aquated products (see Equations 2.1 to 2.5, page 52-54) to 
suspended sludge particulates.  
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Figure 5.6: Schematic diagram of hospital and household waste water into receiving 
river waters  
By applying the results of Lenz et al. (2005) and Lenz et al. (2007) to the present study 
the amount of platinum-based drugs released into the environment over a specified 
period of time may be estimated. As per standard practice the waste-water from 
hospitals is treated in municipal sewage treatment plants along with household sewage. 
Treated sewage is then discharged to surface waters, and mainly rivers or estuaries (as 
conceptualised in Figure 5.6). According to the information provided by South West 
Water UK the sewage from Derriford Hospital is treated at Marsh Mills sewage 
treatment plant and rest of the sewage from Plymouth city is treated at Plymouth 
Central, Camels Head and Ernesettle sewage treatment works, where waste-water is 
treated with activated sludge. Therefore, the removal efficiency of activated sludge from 
Lenz et al. (2005) may be used to derive the amount of platinum released to the 
environment. This was calculated by multiplying the average weekly usage of platinum 
(1.4 g as estimated in the present study) by 52 and the platinum contribution of each 
drug and the percentage removal of each drug as described by Lenz et al. (2005) (92%, 
72% and 78% for cisplatin, carboplatin and oxaliplatin, respectively). This calculation 
revealed that 0.94 g of cisplatin, 20.71 g of carboplatin and 11.54 g of oxaliplatin as 
parent compound may be released into the environment per year, equating to the 
disposal of 17.19 g of platinum annually from the platinum based drugs administered 
from just one hospital in the UK out of which 3.44 g is expected to be in hospital waste 
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water (20% of emitted platinum) and 13.76 g is expected to be disposed via household 
waste (80% of emitted platinum) (see Table 5.5). Further information provided by 
South West Water UK revealed that the Plymouth Central and Marsh Mills treatment 
works receive sewage from 64% of  properties in Plymouth as well as waste-water from 
Derriford Hospital and the treated water is discharged into River Plym whereas, Camels 
Head and Ernesettle plants receive sewage from  the remaining 36% properties in 
Plymouth and the treated water is discharged into the Tamar and Hamoaze estuary. 
Assuming most patients treated at oncology outpatients unit of Derriford Hospital live 
in Plymouth city the total platinum discharged into the River Plym is 12.25 g per year 
[sum of platinum from hospital waste water (3.44 g) and platinum contribution from 
64% of properties in Plymouth (12.25 g)] and 4.95 g platinum per year is discharged 
into Tamar and Hamoaze estuaries [contribution from 36% of properties in Plymouth 
(4.95 g)] (see Table 5.6). 
Table 5.5: Estimated average use of platinum based drugs per year at Derriford Hospital 
and emissions of drugs and the total platinum on applying published removal efficiency 
of sewage treatment (units of drugs and platinum are in grams)   
 
 
Average 
usage per 
year 
Removal 
efficiency 
Amount 
emitted per 
year 
Hospital 
contribution 
(20% of 
total Pt 
emitted) 
Household 
contribution 
(80% of 
total Pt 
emitted) 
Cisplatin 
(Pt) 
11.75 (7.64) 92% 0.94 (0.61) - - 
Carboplatin 
(Pt) 
73.98 
(39.21) 
72% 20.71 (10.98) - - 
Oxaliplatin 
(Pt) 
52 (25.48) 78% 11.44 (5.61) - - 
Total Pt 72.33 - 17.19 3.44 13.76 
- No contribution 
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Table 5.6: Estimated amount of total platinum emitted (in grams) in river waters per 
year from waste water treatment plants in the study location 
 Amount of platinum 
release into river Plym 
per year   
Amount of platinum 
released in river Tamar 
and Hamoaze per year 
Hospital Contribution 3.44  - 
Platinum from 64% of total 
properties 
8.81 - 
Platinum from 36% of total 
properties 
- 4.95 
Total Pt 12.25 4.95 
- No contribution 
 
An assumption of such calculations is that all platinum based drugs are delivered to the 
treatment process continuously and in the aqueous phase. It should also be noted that 
the computed concentrations in receiving waters include all chemical and physical 
forms of each drug (i.e., the parent molecule and various metabolites in the dissolved, 
colloidal and adsorbed states).  
 
Figure 5.7: Predicted concentrations of platinum from cisplatin (Ptcis), carboplatin (Ptcar) 
and oxaliplatin (Ptoxa), as well as total platinum (Pttot), in waste-receiving surface water 
as a function of flow rate, based on administration figures for Derriford Hospital over 
the three week study period Diagram reproduced from Vyas et al. (2014).  
The removal efficiency of activated sludge as calculated by Lenz et al. (2005) (92%, 
72% and 78% for cisplatin, carboplatin and oxaliplatin, respectively) was applied to 
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each platinum-based drug to obtain the amount of each individual drug predicted to be 
discharged into receiving waters. This amount was then used to calculate the amount of 
platinum (in ng) from cisplatin, carboplatin and oxaliplatin emitted into river water per 
second. As the receiving waters are tidal rivers the flow rate may vary depending upon 
the tide and river water discharge. Therefore, the concentration of platinum in pg L-1 in 
receiving waters was calculated using ranges of river flows from 1 m3 sec-1 to            
100 m3 sec-1. The calculated platinum concentrations from cisplatin (Ptcis), carboplatin 
(Ptcar) and oxaliplatin (Ptox)), as well as the total platinum (Pttot), are plotted as a function 
of the flow rate of the receiving waters on a logarithmic scale in Figure 5.7. Clearly, 
concentrations increase with decreasing dilution or flow rate of receiving waters, and at 
the lowest flow rate modelled the predicted concentration of the total platinum is about 
540 pg L-1. The majority of platinum originates  from carboplatin and at the lowest flow 
rate considered its predicted concentration is about 350 pg L-1; this is equivalent to 
about 650 pg L-1 of carboplatin and is considerably lower than the 10 ng L-1 predicted 
environmental concentration for an individual drug that acts as a trigger for further 
environmental risk investigation (EMEA, 2006). At the location under study, waste-
water from Derriford Hospital and about 20% of the population of the city of Plymouth 
(or 11% of the population that the hospital serves) are processed at a sewage treatment 
plant that continuously discharges at a mean rate of 0.2 m3 sec-1 into a tidal river (River 
Plym). Given that the mean annual flow of the river is 2.60 m3 sec-1 but that mean 
monthly flow is regularly less than 1 m3 sec-1, the total platinum concentrations in 
excess of 100 pg L-1 could occur for periods around low water. 
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Table 5.7: Measured concentrations of dissolved platinum in river and estuarine waters. 
Environment  salinity
  
[Pttot], pg L-1  Reference 
Tama River, Tokyo 0.2 6100 Obata et al. (2006) 
Tama Estuary, Tokyo 3.2 6860  
 23.8 940  
Ara Estuary, Tokyo 5.1 2030  
   16 2650  
Lérez River, NW Spain <0.1 41 Cobelo-García et al. (2013) 
   0.5 8  
Lérez Estuary, NW Spain 3.0 12  
 6.7 35  
 27.4 96  
Duman River, E Russiaa - 35 Soyol-Erdene and Huh 
(2012) 
Lena River, NE Russiaa - 70  
River Indigirka, NE Russiaa - 99  
Huang He, N Chinaa - 123  
aSalinities not specified; median concentrations reported for multiple samples. 
For comparison, Table 5.7 shows the measured concentrations of total dissolved 
platinum (i.e. from all environmental sources of the metal) in various rivers and 
estuaries around the world. In surface waters draining heavily urbanised areas, platinum 
concentrations in excess of 1000 pg L-1 are reported, largely because of platinum from 
vehicular emissions. In pristine rivers-estuaries or those not directly impacted by 
urbanisation, concentrations of less than 100 pg L-1 are more typical, with a minimum 
reported concentration of 8 pg L-1. Estimates from Figure 5.7 suggest that platinum 
concentrations in surface waters arising from the excretion of platinum-based anticancer 
drugs could exceed concentrations resulting from natural inputs. However, the 
measurement of total platinum in river waters is not enough to differentiate between the 
platinum from platinum-based drugs and vehicular emissions (Lenz et al., 2007). 
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5.4.5 Environmental impacts of platinum-based drugs in surface water 
It is important to distinguish between the platinum sources as cisplatin is classed as a 
Group 2A compound by the IARC (probably carcinogenic to humans) (IARC, 1990), 
whereas carboplatin and oxaliplatin are not classified by the IARC. An important step in 
assessing the environmental impact of platinum-based drugs would be to evaluate their 
subsequent fate in the environment. The likely behaviour and impacts of the platinum-
based drugs in the surface water environment is dependent on its salinity (or, strictly, 
chlorinity). It should be noted that, carboplatin converts to cisplatin in presence of 
chloride and oxaliplatin converts into monochloro, dichloro and diaquo 
diaminocylohexane species (Martin et al., 2000) in the human body which are then 
excreted through urine (see Equations 2.3 to 2.5, page 52,53). Thus, where waste is 
discharged to fresh water a relatively high proportion of each drug is predicted to 
remain aquated and, therefore, reactive, with a propensity to interact with aquatic life. 
Although, with increasing salinity of recipient water, the proportion of reactive species 
is predicted to decline as aquated metabolites may slowly convert back to their 
relatively unreactive, chlorinated parent compounds (Curtis et al., 2010).  
In a recent study, Turner and Mascorda (2014) compared the adsorption of the three 
platinum-based drugs to estuarine sediment suspended in river water (salinity < 0.1;  
[Cl-] = 17.6 mg L-1) and estuarine water (salinity = 3.20; [Cl-] = 1800 mg L-1) after a  
24-hour period of incubation of the drugs in river water. The sediment-water 
distribution coefficients for cisplatin and carboplatin are about 770 mL g-1 and           
550 mL g-1, respectively, in river water, and about 170 mL g-1 and 90 mL g-1, 
respectively in estuarine water; coefficients for oxaliplatin are similar (about 70 mL g-1) 
in both media. The interaction of cisplatin has been studied with both the freshwater 
vascular plant, Lemna minor (Supalkova et al., 2008), and the estuarine-coastal 
macroalga, Ulva lactuca (Easton et al., 2011). Although platinum was measurably 
accumulated in both studies, no phytotoxicity (efficiency of photochemical energy 
conversion) was observed in U. lactuca up to a platinum concentration of 30 μg L-1 and 
the concentration for growth inhibition of L. minor (96 h EC50 platinum) was as high as 
1.4 mg L-1.  
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Despite these observations, and the inability to detect and differentiate platinum-based 
drugs and their metabolites at environmental concentrations, the presence of cytotoxic 
substances in surface waters should be a cause for concern. Clearly, more information is 
required on the toxicity of all three platinum-based drugs to a wider range of organisms 
and over a greater exposure period. Furthermore, it is predicted that the combined 
effects of these and other cytotoxic drugs on aquatic life are likely to be more harmful 
than their individual effects (Johnson et al., 2008). A further concern is the potential 
effect of low concentration of these drugs on foetal health (due to their teratogenic 
nature) in places where rivers are used as a source for drinking water (Collier, 2007).   
5.5 Conclusion 
This is the first study in the UK to report the presence of platinum as an indicator of 
platinum-based drugs in the UK hospital waste-water. The results from this study show 
the presence of platinum in Derriford Hospital waste-water in the range of 0.01 μg L-1 to 
144 μg L-1 and a median concentration of 0.63 μg L-1 which is comparable to other 
studies (Kummerer et al., 1999; Lenz et al., 2005). This study is a significant step in 
establishing the presence and concentrations of an important group of anticancer drugs 
in UK hospital effluents. As per NHS policy, most cancer patients now receive their 
chemotherapy infusions in either outpatients departments or in community clinics rather 
than hospital wards as in-patients, therefore the presence of anticancer drugs in 
household sewage is expected to be higher than hospital waste-water as estimated in this 
study (80% in household waste-water, 20% via hospital waste-water). The results from 
this study were also used to predict the environmental concentrations of platinum in 
tidal rivers around Plymouth, which receive the treated waste-water from the treatment 
plants. The predictions suggested that at the time of low water the total platinum 
concentrations may exceed 100 pg L-1. Even though the majority of platinum in most 
surface waters results from vehicular emissions, these forms are comparatively less 
reactive than platinum in anti-cancer drugs and their metabolites. This information on 
presence of concentrations of cytotoxic forms of platinum in river water could be used 
to assess safety of water for consumption in places where rivers are used as sources of 
drinking water, particularly in times of low water flow. With a growing concern over 
contamination of water systems with various drugs, these results may be used to tailor 
methods to remove the contaminating drugs from waste-water at the source itself. 
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Clearly, there is also a need for further studies to assess environmental concentrations 
and fate of various other anti-cancer drugs.  
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Chapter 6: Conclusions and recommendations 
6.1 Major findings of this study 
The studies conducted during the present project were designed to determine the levels 
of contamination with anti-cancer drugs in pharmacy and oncology out-patients ward 
surface areas as well as measures to reduce the above contamination. A further aim was 
to determine levels of anti-cancer drugs in hospital waste-water and provide an 
estimation of anti-cancer drugs which may be released in the environment on annual 
basis. The choice of marker drugs for each study was based on the frequency of the 
usage, different classes of the anti-cancer drugs and also the availability of sensitive and 
selective analytical methods. The choice of marker drugs based on the analytical 
method is important as there are close to 30 different anti-cancer drugs used regularly in 
the UK and all are potentially carcinogenic therefore, the methods used to detect marker 
drugs must be highly sensitive and selective to provide true levels of contamination 
caused by anti-cancer drugs.    
The baseline data from the Tevadaptor isolator study (Chapter 3) demonstrates that a 
substantial amount of contamination is caused by anti-cancer drugs on pharmaceutical 
isolator surfaces as well as on the outer surface of prepared IV bags and syringes and 
the gloves used by pharmacy operators during the compounding of these drugs. The 
baseline contamination data from Tevadaptor isolator study was undetected to            
0.9 ng cm-2 (epirubicin), undetected to 3.58 ng cm-2 (5-FU) and 0.05-0.92 ng cm-2 
(platinum) in the wipe samples from the pharmaceutical isolator surfaces and the 
amounts detected on glove samples were 1,100-6,100 ng/glove (epirubicin),             
300-8,100 ng/glove (5-FU) and 1-6 ng/glove (platinum). These levels were similar to  
previous studies confirming that the conventional practice of using needles and syringes 
to compound IV infusions will result in contamination of the work surfaces. The results 
from the Tevadaptor isolator study also indicate that the standard practice of cleaning 
the pharmaceutical isolators with detergents and IMS is ineffective in removing the 
residual contamination by anti-cancer drugs. The baseline samples collected post-clean 
showed detectable levels of contamination with marker drugs and concentration ranges 
for 5-FU were 0.59-1.65 ng cm-2 and platinum was 0.0006-0.95 ng cm-2. The use of a 
CSTD (Tevadaptor) in the intervention phase of this study was highly effective in 
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reducing the work-surface contamination by the marker drugs. The isolator surface 
contamination was below LOD in all samples for 5-FU and epirubicin during the 
intervention phase. Even though platinum was detected on the isolator surfaces during 
the intervention phase the levels were in the range of 0.002-0.09 ng cm-2 as compared to 
0.05-0.92 ng cm-2 during the baseline phase. Similarly, the use of Tevadaptor resulted in 
a reduction of contamination on external surfaces of prepared infusion bags and 
syringes as well as operator gloves by a factor of 10 or more for all marker drugs used 
in the study.  
The results from the Tevadaptor ward study presented evidence of contamination of 
ward surfaces with anti-cancer drugs. During the baseline phase the ward surface 
contamination ranged from undetected to 4.97 ng cm-2 (gemcitabine) and undetected to 
3.1 ng cm-2 (platinum). In case of gloves used by nursing staff during administration of 
IV drug infusions the levels of contamination ranged from undetected to 1,251 ng/glove 
(gemcitabine) and undetected to 405.4 ng/glove (platinum). Surprisingly, the use of the 
CSTD resulted in increased total contamination on ward surfaces even though there was 
a decrease in the frequency of contaminated samples. The contamination on ward 
surfaces during the intervention phase ranged from undetected to 3.21 ng cm-2 
(gemcitabine) and undetected to 2.69 ng cm-2 (platinum) and contamination levels on 
gloves ranged from undetected to 9,252 ng/glove (gemcitabine) and undetected to  
1,319 ng/glove (platinum). These results highlight the need for increased training to 
effectively use CSTDs. The questionnaire regarding the efficacy of Tevadaptor device 
highlighted the difference in the way different staff groups perceive risk of working 
with anti-cancer drugs. Even though the number of staff respondents to the 
questionnaire were limited, the results indicated that the pharmacy technicians were 
more likely to be worried about working with anti-cancer drugs than the nursing group 
which was surprising as a number of studies have proved increased risk of DNA 
damage in nurses working with anti-cancer drugs (Falck et al., 1979, Cornetta  et al., 
2008). 
The results from the drain study (Chapter 5) demonstrate levels of platinum in the 
hospital waste-water as an indicator of platinum-based anti-cancer drugs (cisplatin, 
carboplatin and oxaliplatin). The range of platinum in the waste-water (0.02-144 μg L-1) 
reported in the drain study is similar to other European studies. The results also 
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highlighted that the majority (up to 80%) of anti-cancer drugs are likely to be disposed 
via the household waste- water rather than the hospital and there is a potential for 
considerable amounts of anti-cancer drugs to be released into the aquatic environment. 
The data obtained from this study was used to predict concentrations of platinum (from 
platinum based drugs) in river waters receiving treated waste water. The model suggests 
that at times of lowest flow rate the concentration of carboplatin could be up to           
650 pg L-1, this should be a cause for concern as carboplatin may form highly active and 
cytotoxic aquated species.   
All of the above studies were the first of their kind in the UK . All published data on the 
efficiency of CSTDs in reducing work surface contamination with anti-cancer drugs is 
based on studies conducted in continental Europe or North America where the standard 
practice is to use open fronted LFCs to prepare IV infusions and the majority of these 
studies have tested the PhaSeal device (Connor et al., 2002; Sessink et al., 2010; Wick 
et al., 2003). In the UK, standard practice is to use pharmaceutical isolators which may 
make handling a CSTD comparatively restrictive to LFCs. The Tevadaptor isolator 
study proves that a CSTD, when used in conjunction with an isolator, is highly efficient 
in reducing surface contamination with anti-cancer drugs. The Tevadaptor ward study 
proves that despite the current best practice in preparation and administration of anti-
cancer drugs the contamination on ward surfaces still remains and even after the use of 
a CSTD the ward surface contamination remained unaffected. Nursing as well as 
healthcare staff should be educated about these results and the risks of occupational 
exposure to low levels of anti-cancer drugs and the use of PPE should be emphasised 
even during cleaning beds, chairs and equipment used by patients while being treated 
with anti-cancer drugs. The drain study was the first in the UK to report the presence of 
platinum as an indicator of platinum-based drugs in the UK hospital waste-water and 
predicted concentrations of anticancer drugs in the river waters and demonstrated the 
concentration levels as a function of river flow.            
6.2 Limitations of the work 
As with any study the present project also has its limitations. In the Tevadaptor isolator 
study (Chapter 3) MTX was used as one of the marker drugs, but due to commercial 
reasons the compounding of MTX syringes was outsourced at the time of sampling and 
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therefore, batch production of MTX was simulated for the purpose of the study. 
However, the batch size was smaller than a commercial batch, which may have resulted 
in reduced contamination in the isolator surfaces, as there is an established direct 
relation between the amount of drug processed and recovered from work surfaces. It 
should also be noted that the LOD for MTX was 5 ng mL-1, which is higher than all 
other marker drugs. These two factors may have been responsible for lack of detection 
of MTX in any of the samples.  
In the Tevadaptor ward study (Chapter 4) the results indicate that the use of CSTD 
increased ward surface contamination. This may have been either due to an unrecorded 
spill or lack of training of some of the nursing staff in the use of Tevadaptor. Even 
though training sessions were conducted in the use of CSTD and there was a 
familiarization week with CSTD prior to sampling it may not have been enough to train 
all members due to reasons such as shift pattern of the staff. A longer familiarization 
period may have provided adequate training to all nursing staff. It should also be noted 
that as the Tevadaptor device has an active carbon filter, which may get saturated with 
use and possibly cause leaks, further work is required to assess the loading capacity of 
this filter.  A repeat of the intervention phase for a longer period was considered but 
owing  to commercial reasons the preparation of marker drug infusions was outsourced, 
thus making it impossible to repeat the study.   
A questionnaire to assess the usefulness of the CSTD was distributed to all pharmacy 
and nursing staff who used the device either to prepare or administer chemotherapy 
infusions. As the study was conducted in one hospital the number of respondents was 
low (n = 9). For future research a similar survey of staff perceptions regarding use of 
CSTDs may be conducted on national/regional level which may support the results from 
present study. 
The major limitation of the drain study (Chapter 5) was the sampling pattern. Owing to 
limited access to the drains, samples could only be collected once per day. A more 
substantial measure to estimate the platinum concentration in the waste-water of 
hospital drains may have been to collect 24 hour samples in a holding tank. However, 
due to the design limitations of the existing drains and major work that would have 
required to redirect the waste-water into a holding tank, such an approach was not 
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feasible. In this study the individual drugs were also not identified and the effect of 
water treatment with activated sludge on removal of platinum species was also not 
conducted. These measures could have provided an accurate measure of each individual 
drug being released into the environment. However, estimates on the species of 
platinum-based drugs and amounts released were made using results from published 
studies. 
6.3 General discussion 
The overwhelming evidence presented by numerous studies has revealed the health 
risks to health care staff caused by occupational exposure to anti-cancer drugs (Falck et 
al., 1979, Harris et al., 1993, Clapp et al., 2007, Connor, 2006, Dabrowski and 
Dabrowska, 2007). The members of staff most at risk are pharmacy personnel 
(pharmacy technicians and assistant technical officers) involved in compounding of 
anti-cancer IV infusions in the pharmacy aseptic manufacturing units and the nursing 
staff responsible for administration of the above infusions to the patients either in out-
patient wards or in community. However, the risk of exposure to anti-cancer drugs is 
not just limited to hospital/clinic settings. A large number of patients are being treated 
in the community or being cared for at home by family members who are also at 
potential risk of suffering adverse health effects from the exposure to anti-cancer drugs. 
Researchers have also identified the risk to the environment from human 
pharmaceuticals including anti-cancers drugs (Jelic et al., 2012, Pauwels and Verstraete, 
2006). A major proportion of pharmaceuticals administered to patients are excreted in 
urine, which is then disposed of via municipal drainage system in the water sources. 
Even though the waste-water is treated prior to its release in the aquatic environment, 
studies have presented data on measurable quantities of pharmaceuticals including anti-
cancer drugs in the water systems (Besse et al., 2012, Jelic et al., 2012).       
Despite the irrefutable evidence presented by previously discussed studies (see Chapter 
1) on the levels of anti-cancer drug contamination in the work-place and subsequent 
DNA damage to staff members, there is no legal requirement for regular monitoring of 
the contamination by anti-cancer drugs in the work-place or occupational exposure 
monitoring of staff members. However, standardised monitoring of the workplace in 
UK hospitals has now been proposed by Quality Control North West (QCNW), a 
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quality control laboratory based in North West England (Weir et al., 2012). Thus, in an 
ongoing attempt to establish levels of contamination ALARA, customised surface wipe 
kits are used to sample the work place. Wipe samples are then returned to QCNW and 
analysed for various anti-cancer drugs using liquid chromatography/mass spectrometry 
(LC/MS). Levels are used as a guideline and if a sample exceeds ALARA the specific 
area is cleaned to reduce surface contamination. However, the guideline levels 
generated from such initiatives should not be perceived as safe minimum levels. There 
is also an opportunity for other laboratories with similar capabilities to provide a 
commercial monitoring service to pharmacy manufacturing units.     
6.4 Implications for current pharmacy aseptic practice 
The current project has several implications for practice which could make the work- 
environment safer for the staff. The results from the Tevadaptor isolator study clearly 
indicate that the current practice of using needles and syringes to prepare IV infusions 
leads to substantial work surface contamination and such practice should be reassessed 
and the use of CSTDs which reduce work surface contamination should be encouraged. 
The argument of cost implication of using closed devices should not get in the way of 
making practice safer for healthcare staff. The contamination levels on pharmacy work 
surfaces noticed during the baseline phase of this study may be used to highlight the 
potential health hazards to new pharmacy staff during training and may be used to 
emphasize good practice with regards to PPE.  
Although the contamination on oncology out-patients ward surfaces was found to be 
low, as compared to pharmacy work surfaces, nursing and other members of staff 
working on oncology units must be made aware of the potential risks. The emphasis 
should also be placed on effective use of PPE to reduce the risk of exposure to anti-
cancer drugs. The results also highlight the need for adequate training of staff in the use 
of CSTDs and  acceptance that the use of CSTDs does not completely eliminate the risk 
of occupational exposure to anti-cancer drugs.   
The results from the drain study may be used to estimate the amounts of anti-cancer 
drugs released to river waters from waste-water treatment plants and demonstrated that 
house-hold waste water is a bigger contributor of pharmaceutical compounds in the 
general environment as compared to hospital waste-water. These results also indicate 
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that if the treated waste-water is discharged into tidal rivers the levels of anti-cancer 
drugs may be up to 100 pg L-1, this information could be used to assess the safety of the 
water for bathing and general consumption.  
6.5 Future work 
The use of the Tevadaptor conclusively reduced the contamination with marker drugs in 
pharmacy areas.  Even though Tevadaptor was highly effective in reducing 
contamination caused by platinum-based drugs, epirubicin and 5-FU, more work should 
be undertaken to investigate its effectiveness in reducing contamination with other 
chemotherapeutic agents. There is a growing use of monoclonal antibodies in the 
treatment of cancer and these drugs are large proteins, CSTDs should also be tested in 
their effectiveness in reducing contamination with larger molecule drugs.  
In the current economic and political environment where great emphasis is placed on 
cost savings to be made by NHS, the cost implication of using CSTDs over the current 
practice of using needles and syringes is a major obstacle in their uptake by NHS 
hospitals. This reluctance in the widespread use of CSTDs can have major impact on the 
health of a number of health workers. The CSTD manufacturers have also realised this 
limitation of their product therefore, some CSTDs (PhaSeal) are now being promoted 
for multiple use of drug vials to reduce drug wastage and bring the cost of CSTD down. 
Work is still required to validate microbiological integrity and stability of drugs in vials 
with attached CSTD.  
Some studies have focussed on comparisons of various CSTDs in their efficacy. A 
study used titanium tetrachloride and fluorescein in which the above solutions were 
drawn out using devices such as PhaSeal, Tevadaptor, Codan and Chemo mini spike 
plus (Jorgenson et al., 2008).  The results indicated that PhaSeal was the most effective 
device. Another study used radioactive technetium isotope (99mTc) to detect leakage in 
Chemoclave, OnGaurd and PhaSeal devices (Lorena et al., 2013). The results indicated 
the least leakage was from PhaSeal devices. Such studies may provide a measure of 
efficacy of the CSTDs but do not provide evidence of the superiority of any device in 
real practice. Considering that all other devices except PhaSeal use active carbon filters 
to absorb anti-cancer drugs which upon saturation may affect their performance, a 
comparison study of the above devices in real practice using chemotherapy drugs 
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should therefore be conducted to provide customers a better indication of the superiority 
of any one device. Future work should also be conducted on the loading capacity of the 
active carbon filter present in CSTDs.       
The results from the Tevadaptor ward study did not provide any conclusive evidence of 
its effectiveness to reduce contamination from the ward surfaces as it was a short term 
study. Therefore, the effect of Tevadaptor must be studied on ward surface 
contamination over a longer period. For future research a survey of staff perceptions 
regarding use of CSTDs may be conducted on national/regional level.  
Future investigations should also be undertaken into the levels of anti-cancer drugs in 
municipal waste-water. Platinum-based drugs are the choice of drugs for such studies as 
platinum can be detected in a complex matrix using ICP-MS, although component drugs 
cannot be discriminated at environmental levels.  Future work should focus on 
differentiating platinum from the component drugs and also inorganic sources. Studies 
should also be conducted to detect environmental concentrations of other non-
biodegradable anti-cancer drugs and study their effect on aquatic life.  
6.6 Concluding remarks 
The results clearly show that when anti-cancer IV infusions are compounded in 
pharmaceutical isolators using current practice of needles and syringes the surfaces of 
pharmaceutical isolators as well as prepared bags and syringes are highly contaminated 
with anti-cancer drugs. It is clear that the use of CSTD (Tevadaptor) in preparing the 
above infusions reduces work surface contamination with anti-cancer drugs to levels 
below LOD in most cases. Despite this evidence, CSTDs are still not used in general 
practice in the UK which can only be due to the fact that using a CSTD adds cost to the 
process of aseptic compounding. In the light of evidence provided in this project as well 
as number of previously discussed studies the argument of increased cost must not be 
used over the safety of the staff.   
This study has also highlighted that the problem of surface contamination by anti-cancer 
drugs is not just limited to pharmacy manufacturing units but also to the ward surfaces 
as well as the general environment. Even though contamination by anti-cancer drugs on 
oncology out-patients ward surfaces was detected during baseline sampling, the effect 
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of using a CSTD on this contamination is still not clear and further work may be 
required to devise measures to reduce ward surface contamination. The results from this 
project have highlighted the potential of contamination of water bodies and general 
environment by anti-cancer drugs. These results are of particular interest owing to the 
potential of adverse effects on larger populations and the aquatic environment. Further 
research is required on the environmental fate and levels of pharmaceuticals.              
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Appendix 1: COSSH assessment of marker drugs 
Substance name: Methotrexate, Epirubicin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Oxaliplatin  
 
Reference Number: N/A 
Work Activity Assay development and validation.  
Compounding of IV infusions of anti-cancer drugs in pharmaceutical isolators placed in 
clean rooms.  
 
Comments N/A 
Supplier/Manufacturer Various Area of use Pharmacy Tech services 
Product Code Various Storage required Yes 
Maximum quantity in use No more than 1 L Duration of exposure 1-6 hours/day 
Maximum quantity in 
storage 
No more than 50 L Duration of exposure N/a 
Is substance decanted? No Frequency of Exposure Daily 
Size of second container N/A Data sheet attached Yes 
Completed by (Nitin Vyas)  
Date of Completion 8/7/08 
Date of Review 
Hazard Identification 
Priority Group (delete those not relevant) 
1 
High Risk 
Extensive Controls 
  
Category of Danger (from SDS & EH40)                  delete those that do not apply 
 
 
 
Very toxic 
Toxic Risk to 
Reproduction 
    Carcinogen Mutagenic  
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Workplace Exposure Limits (WELS) No defined limits 
Ingredients (chemical name) Hazard(s) associated with 
ingredient 
 
7 hour TWA 
ppm mg/m³ 
STEL 15 mins 
Ppm mg/m³ 
     
EXPOSURE ROUTES YES/NO FIRST AID MEASURES (if known) 
Inhalation Yes See individual MSDS (In file QC Lab) 
Skin contact Yes MSDS 
Eye contact Yes MSDS 
Ingestion Yes MSDS 
Inoculation Yes MSDS 
Alternative substance available No Alternative substance and reasons for not using 
 
 
THE WORK ACTIVITY AND CURRENT CONTROL MEASURES 
 YES/NO DESCRIPTION DETAILS 
Written safe system of work available Yes SOP 
CH1,CH3,CH7,CH8,CH9,H4,CH11,CH13,CH18,CH19CH20. 
Copies are in tech services procedures folder. 
Record of Information / instruction / training 
given 
Yes See individual staff competency files 
Local ventilation Yes Product prepared in pharmaceutical isolators or 
manipulated in class II BSC. Closed container used for 
HPLC and ICP-MS assay. 
Fume cupboard Yes Isolators and BSC  
Exposure monitoring No None required 
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Health surveillance No None required 
Appropriate PPE: 
Gloves, Lab Coat, Safety goggles, 
Respiratory protection, etc 
Yes Double gloves (outer layer chemo-resistant), chemo-
gown, chemo-mats and masks. 
Appropriate warning signs or labels Yes  
Spillage procedure Yes SOP H4, CH20. 
Disposal procedure Yes SOPG6 
Other   
Toxicity 
Cytotoxic injectables  (see MSDS for individual toxicity) 
Alternative substance available 
Alternative substance and reasons for not using 
Is a less hazardous substance available                                                NO 
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Appendix 2: HPLC chromatograms of marker drugs 
 
Figure A 2.1: Example of MTX (50 ng mL-1) HPLC chromatogram  
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Figure A 2.2: Example of epirubicin 10 ng mL-1 HPLC chromatogram.  
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Figure A 2.3: Example of 5-FU 40 ng mL-1 HPLC chromatogram 
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Figure A 2.4: Example of gemcitabine 40 ng mL-1 HPLC chromatogram.  
 
 
 
 
 
 
 
 
 
 
 
 
Minutes
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Detector 1-270nm
std 40 ng
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Appendix 3: Sterility validation of Tevadaptor 
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Appendix 4 – Schematic diagram of Derriford Hospital drainage 
system  
 
 
Diagram not to scale 
 
 
 
 
